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The capacity to blunder slightly is the real marvel of DNA. Without this special  
attribute, we would still be anaerobic bacteria and there would be no music. 
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Introduction 
Based on the article: Prediction of BRCA status 
Simon A Joosse and Juliane Hannemann 






The hallmarks of cancer 
 In humans, cell growth and development is a 
continuous process, which is strictly controlled 
by genes encoded by DNA of the cell nucleus. 
Two different types of genes regulate the mecha-
nism of cell proliferation, the first are called 
proto-oncogenes that are positive regulators of 
cell proliferation and promote cell division and 
cell growth, and the second are called tumor 
suppressors that negatively regulate cell prolif-
eration and suppress cell growth. Upon muta-
tion or loss of these genetic regulators, cells may 
keep on dividing beyond the body's normal 
needs and cause harm to other tissues and body 
functions. This is the hallmark of cancer, a 
malignant growth characterized by uncontrolled, 
unwanted, purposeless, damaging and continu-
ing growth of cells. These so called tumor cells 
differ functionally, structurally (anaplasia) and 
in behavior from the normal cells from which 
they develop; they have the potential for a 
limitless and uncontrolled replication independ-
ently from external stimulatory signals and 
uninhibited by antigrowth and apoptosis signals 
(1). Furthermore, not only is cancer dangerous 
for its direct surrounding tissue, it can be most 
harmful upon invasion of the body and estab-
lishment of metastasis in distant organs (2, 3). 
Metastasized cancer is the leading cause of death 
from cancer and is considered an incurable 
disease (4). In 2004, around 7.4 million people 
died of cancer - 13% of all deaths worldwide - of 
which breast cancer was the most common form 
of cancer in women (5). 
Causes of cancer 
 Most cancer arises from a single cell that has 
accumulated DNA damage and genetic muta-
tions to a number of key tumor suppressor genes 
and proto-oncogenes to escape programmed cell 
death and induce unlimited replication (1). 
These DNA mutations are sequentially acquired 
through time, which is why the likelihood for 
cancer increases with age. When a mutated pre-
disposition gene is inherited, the risk for cancer 
is already present at a much younger age. 
Damage to genes is caused by both exogenous 
and endogenous factors. The exogenous factors 
are mainly environmental DNA damaging 
agents, such as ionizing radiation, ultraviolet 
rays, air pollution, and inhaled cigarette smoke. 
The endogenous factors include reactive oxygen 
species produced from cellular metabolism and 
replication errors of several cellular processes, 
such as DNA duplication and meiotic recombi-
nation. Although the risk for cancer by endoge-
nous factors is difficult to control, over 30% of 
all cancer can be prevented by adopting a 
healthy life-style, i.e. not using tobacco, having a 
healthy diet, preventing infections that may 
cause cancer and being physically active (5, 6). 
CHAPTER 1    
 4 
Classification of cancer 
 Cancer is initially named after the site of the 
body from which it originates. Next, tumors are 
divided into groups based on the cell of origin; 
carcinomas are the largest group of solid tissue 
malignant tumors and are of epithelial origin, 
such as skin, colon or mammary ducts. For that 
reason, tumors growing in the breast are mainly 
classified as "breast carcinomas". Because cancer 
can arise from all organs and different cell types 
it is a complex disease consisting of many 
diverse entities that all have their own unique 
characteristics and behavior. Since the applica-
tion of radiotherapy and chemotherapy in the 
first half of the 20th century as anti-cancer 
treatment, it has become clear that different 
tumors can respond differently to different types 
of therapy (7). This has motivated researchers to 
find tumor markers that allow for the identifica-
tion of therapeutic groups to predict prognosis 
and adapt therapy to the clinical situation, a 
process which is called tumor classification. For 
many years now, the most important factors in 
tumor classification are site, degree of local and 
remote invasion (staging), histological type, cell 




 Breast cancer accounts for approximately 
one-forth of all cancers in women worldwide, 
making it the most common female malignancy. 
As a result of early detection and improved 
treatment, death rates from breast cancer have 
been steadily decreasing; however, breast cancer 
is still the leading cause of cancer-related death 
in women, closely followed by lung cancer. 
Figure 1 depicts the worldwide breast cancer 
prevalence; as can be seen, the incidence of 
breast cancer is the highest in economically 
developed countries, i.e., in Europe, Australia 
and North America, where it accounts for 
approximately half of all the breast cancer cases 
worldwide. The incidence of breast cancer in 
Africa or Asia is about six-fold lower than that. 
The disease is not common until after the age of 
40 and the incidence increases with age (Table 
1). The average age of women to be diagnosed 
with breast cancer is between 60-61 years (5, 9, 
10). Less than one percent of all breast cancers 
occur in men (11). 
 
Histological classification of 
breast cancer 
 A woman's breast consists of milk glands 
(lobules), tubes for transporting milk from the 
glands to the nipple (ducts), fatty and connective 
tissue, blood vessels, and lymph vessels (Figure 
2). Pathologically, breast cancer can be divided 
into two main and several uncommon types. The 
most common type is called ductal carcinoma 
Table 1. Breast cancer incidence per 100,000 women in Northern 
America, Northern and Western Europe and Australia/New 
Zealand. Data source: GLOBOCAN 2008, International Agency 
for Research on Cancer http://globocan.iarc.fr/ 
 













and is thought to be derived from the breast 
ducts; the second type is called lobular carci-
noma and is deemed to have arisen from the 
breast lobules at the end of the ducts. However, 
there is no true evidence for the site of origin 
(duct or lobules) and classification is made on 
histological parameters (12). Other, less com-
mon types of breast carcinoma are tubular, 
invasive cribriform, medullary, mucinous, 
invasive papillary, invasive micropapillary, 
apocrine, metaplastic, glycogen-rich clear cell, 
lipid-rich, adenoid cystic, acinic cell, Paget's 
disease of the nipple, and inflammatory carci-
noma. As long as a carcinoma is still growing 
within the ductulo-lobular system of the breast, 
it is called carcinoma in situ. Based on the 
histological properties, ductal carcinoma in situ 
(DCIS) or lobular carcinoma in situ (LCIS) can 
be distinguished. If the carcinoma shows evi-
dence of breaching the basement membrane and 
thereby infiltrating the adjacent stroma, the 
tumor is classified as invasive ductal carcinoma 
(IDC) or invasive lobular carcinoma (ILC). To 
be able to estimate prognosis of breast cancer, 
carcinomas are generally classified by the TNM 
classification system and by a grading system. In 
the TNM system, three different parameters are 
assessed (Table 2). The first parameter, desig-
nated T, is the size or extension of the primary 
tumor starting from 0 (no primary tumor) to 4 
(exceeding adjacent structures). The N parame-
ter concerns the rate of invasion of regional 
nodes scored from 0 (no metastasis) to 3 (inva-
sion beyond regional nodes). Last, the M com-
ponent describes the presence of metastasis 
where M0 classifies as no remote metastasis and 
M1 the presence of metastasis at distant site(s). 
Besides size, the primary tumor is graded as a 
 
Incidence Incidence Incidence 
1) Northern America 
2) Central America 




4) Northern and Western Europe 
5) Southern Europe 




7) Asia  
8) Africa  





Figure 1 - Breast cancer prevalence. Age-standardized breast cancer incidence per 100,000 women by world area in 2008 (crude rate 
statistic). Image and data source: GLOBOCAN 2008, International Agency for Research on Cancer http://globocan.iarc.fr/ 
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measure for its rate of growth and cell abnormal-
ity; the most used system for this is the Bloom-
Richardson-Elston grading system. By assessing 
tubule formation, nuclear polymorphism and 
mitotic rate, a carcinoma can be graded as grade 
1: well differentiated; grade 2: moderately 
differentiated; or grade 3: poorly differentiated 
(13). In the past decade, new methods have been 
developed to classify breast cancer based on 
molecular characteristics; this will be discussed 
further on. 
 
Detection of breast cancer 
 Breast cancer can be detected by breast self-
examination which, is best performed every 3 
months at the end of the menstrual stage. 
Because breast self-examination will only detect 
palpable breast cancer or breast cancer in 
advanced stage, it does not provide early diagno-
sis; consequently, breast self-examination has 
not proven to reduce mortality in women (14). 
Because breast cancer has no obvious symptoms 
at early stage in general, the first sign of breast 
cancer is often an abnormality detected on a 
mammogram. Mammography is currently the 
most widely used imaging technique for early 
detection of breast cancer. It has been demon-
strated that periodically screening by mammog-
raphy can decrease breast cancer death rates; 
however, this technique has its limitations and 
does not detect all breast cancers (15). After a 
suspicious abnormality has been detected by 
mammography, additional tests such as ultra 
sound are performed or a needle aspiration is 
taken. In the presence of a highly suggestive 
lesion, surgery immediately follows mammogra-
phy without any additional diagnostic tests. 
Needle biopsy is an invasive technique which 
can be used if needle aspiration results without a 
definitive diagnostic evaluation.  
It is taken using a wide-caliber needle and is 
followed by histological analysis of the biopsy, 
on which many different tumor markers can be 
examined, for the presence of tumor cells. 
Another imaging technique for breast cancer 
detection is magnetic resonance imaging (MRI) 
of which the sensitivity is much higher for 
infiltrating carcinomas and in situ lesions than 
mammography, but lacks high specificity. 
Therefore, it is suggested to use MRI in combi-
nation with mammography or ultrasound only 
(16). A technique that is fully under investiga-
tion is the detection of breast cancer by meas-
urement of blood markers. Measurement of 
circulating tumor markers in breast cancer 
patients is currently most established in ad-
vanced disease, aimed at the diagnosis of metas-





Figure 2 - Anatomy of a woman's breast. Reprinted by the 
permission of the American Cancer Society, Inc. All rights 




 The main treatment of primary breast cancer 
is surgery. The goals of surgery are to remove the 
cancerous tissue and to analyze the size, grade 
and other clinical factors that are important to 
determine sequential therapy. Removal of the 
tumor can be performed by lumpectomy, a 
partial removal of the breast which includes the 
tumor and some of the surrounding tissue. 
Lumpectomy is breast conserving surgery (BCS) 
and is also referred to as wide local excision. 
Mastectomy is the oldest known form of breast 
cancer treatment and means the complete 
removal of the breast which may include re-
moval of skin and muscle tissue (18). After 
breast cancer surgery, the tumor but also the 
removed surrounding breast tissue is macro-
scopically examined and sliced for further 
microscopic examination. For the preservation 
of cellular histological markers and long term 
storage, tissue blocks are prepared and are either 
formalin-fixed and paraffin-embedded (FFPE) 
or frozen in liquid nitrogen. From the paraffin 
blocks, slices of 3-5 μm are cut for staining with 
hematoxylin and eosin (H&E), and staining for 
estrogen receptor (ER), progesterone receptor 
(PR) and ERBB2 (human epidermal growth 
factor receptor 2). Based on the macro- and 
microscopic examinations, a pathologist will 
determine tumor type, histological grade, 
invasion, tumor size, pTNM stage and hormone 
receptor status of the breast tumor on which 
further treatment is based (19). Surgery might be 
followed by radiotherapy to destroy any remain-
ing tumor cells in the breast, axillary tissue or 
chest wall. Radiotherapy can be given externally 
by collimated beams of radiation or internally 
after lumpectomy where a small pellet of radio-
active material is given directly into the tumor 
bed (18). Next, treatment might be followed by 
systemic chemotherapy. The aim of adjuvant 
chemotherapy is to destroy or stop any tumor 
cells that have invaded the body. Chemotherapy 
interferes with the ability of rapidly growing cells 
to divide, including cancer cells but also cells 
present in the bone marrow, hair follicles and 
gastrointestinal tract. Different chemotherapeu-
tic drugs are listed in Box 1 (18). Estrogen 
receptor positive breast tumors are dependent 
on estrogen for growth and proliferation. 
Endocrine treatment aims at estrogen starvation 
of the tumor cells by blocking the production of 
estrogen or limiting estrogen in reaching the 
tumor cells (18).  Other targeted therapies aim at 
specific proliferative cell functions. These 
treatment options includes the targeting of 
ERBB2, EGFR, tyrosine kinases (IGF), and 
Table 2 - Cancer TNM classification table. 
 








Carcinoma in situ 
≤ 2 cm 
2-5 cm 
>5 cm 
Tumor of any size, 
extending though 







No lymph node metastasis 
Metastasis in movable ipsilateral axillary 
lymph nodes 
Metastasis in ipsilateral axillary lymph 
nodes or in internal mammary nodes 
Metastasis in axillary lymph nodes and in 
ipsilateral infraclavicular, supraclavicular, 
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angiogenesis (VEGF) (18, 20). Chemotherapy 
can also precede surgery and is then called neo-
adjuvant chemotherapy. Its goal is to reduce the 
size of the tumor to make radical treatment 




 Each year, approximately 130 per 100 000 
women are diagnosed with breast cancer in 
Northern America, Northern and Western 
Europe, Australia and New Zealand (9). Based 
on these data, it can be estimated that approxi-
mately one in nine women will develop breast 
cancer during a period of > 80 years, setting the 
cumulative lifetime risk of breast cancer at 11% 
in these regions. The risk for developing breast 
cancer seems to be much lower in Asia or Africa 
as is indicated by the incidence of the disease 
(Figure 1). The international variations seem to 
disappear when Asian or African natives immi-
grate to regions with high breast cancer inci-
dence (22-25). This has led to the conclusion 
that besides being a woman, significant risk of 
developing breast cancer lies in regional factors 
such as lifestyle and culture. The very first study 
to identify risk factors for breast cancer was 
performed by Janet Elizabeth Lane-Claypon and 
published in 1926 (26). Lane-Claypon identified 
that giving birth to a high number of children 
(>10) and giving birth to the first child at young 
age reduces the risk of breast cancer, women 
who have had no children at all, such as nuns, 
have a greater risk of breast cancer. These risk 
factors are examples of current cultural differ-
ences between the economically well and less 
developed countries. Besides reproductive 
behavior, other factors determined by lifestyle 
influence the risks for breast cancer; people in 
the western world tend to eat more animal 
products, eat less vegetable, have less physical 
activity and become older compared to people in 
other parts of the world. More factors that can 
influence the risk for breast cancer are birth 
weight, birth length, age at menarche, and age at 
menopause (27). Additional to the latter factors 
that are associated with the body's level of 
hormone exposure, one of the strongest risk 
factor for developing breast cancer is a family 
history of the disease (Box 2). 
 Surgery: lumpectomy, mastectomy. 
 Radiation: internal, external. 
 Chemotherapy: 
 CMF (cyclophosphamide, methotrexate, and 
fluorouracil), AC (cyclophosphamide and 
doxorubicin), CAF (cyclophosphamide, 
doxorubicin, and fluorouracil), CEF (cyclo-
phosphamide, epirubicin, and fluorouracil), TC 
(docetaxel and cyclophosphamide). 
 Hormonal therapy: aromatase inhibitors 
(anastrazole, exemestane, letrozole, fadrozole), 
selective estrogen receptor modulators (ta-
moxifen, raloxifene, toremifene), oophorec-
tomy. 
 Targeted therapy: ERBB2 (trastuzumab, 
lapatinib), angiogenesis inhibitor (bevacizu-
mab), EGFR inhibitor (gefitinib), tyrosine 
kinase inhibitor. 
 
Box 1 - Breast cancer treatment options  (18, 20). 
 
 Diet and diet-related factors 
 Ionizing radiation 
 Hormone and reproductive factors 
 Benign breast disease 
 Family history of breast cancer 
 




Hereditary breast cancer 
History 
 Families with three or more close relatives 
with breast cancer are commonly classified as 
"breast cancer families" (28).  In the past, segre-
gation analyses were performed in such families, 
showing an autosomal dominant mode of 
inheritance in most cases (29-31). By linkage 
analysis on a large group of families with early-
onset breast cancer, the locus of a high-
penetrance cancer susceptibility gene was 
mapped on chromosome 17q12-21 in 1990 (32). 
Not until 1994 a candidate gene was completely 
characterized and truncating mutations were 
linked to breast cancer (33). Because it was the 
first gene to be associated with hereditary breast 
cancer, it was called "breast cancer 1, early onset" 
or BRCA1. In the same year, the second major 
breast cancer susceptibility gene, BRCA2, could 
be localized on 13q12-13 and was cloned just 
one year later by Wooster and colleagues. The 
identification of loss of heterozygosity (LOH) at 
the BRCA2 locus and germline mutations of this 
gene in breast cancer demonstrated the role of 
BRCA2 as tumor suppressor gene (34, 35). After 
the discovery of the breast cancer susceptibility 
genes BRCA1 and BRCA2, major changes have 
been made in the care of women with inherited 
predisposition to breast cancer such as increased 
screening and surveillance and risk reduction 
options (36). Mutations in the BRCA1 and 
BRCA2 genes are responsible for the major part 
of the hereditary breast cancer syndrome; 
however, other genes have been correlated with 
different forms of hereditary breast cancer 
syndromes. These syndromes are: Cowden 
disease, caused by mutation in the PTEN gene 
(37); Li-Fraumeni syndrome, caused by muta-
tions in the TP53 gene (38); Peutz-Jeghers 
syndrome, caused by mutations in the STK11 
gene (39) and Ataxia Telangiectasia, caused by 
mutations in the ATM gene (40). Furthermore, a 
single mutation in CHEK2, 1100delC, has also 
been reported to be associated with hereditary 
breast cancer (41) (Table 3). Breast cancer 
caused by mutations in breast cancer susceptibil-
ity genes has several distinctive clinical features 
such as considerably younger age at diagnosis 
compared to sporadic cases, the prevalence of 
bilateral breast cancer is higher, and associated 
tumors (e.g., ovarian, colon, prostate, and 
pancreatic cancers, as well as male breast cancer) 
are seen in some families. 
Incidence and risk 
 Mutations in the BRCA1 and BRCA2 genes 
can be identified in approximately 80% of 
families with a high number of breast cancer 
cases (i.e., four or more) diagnosed before the 
age of 60 years. Germline mutations in BRCA1 
Table 3 - Gene associated life time risk of breast cancer in female carriers (42). 
 













2-5 fold elevated risk 
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have been detected in approximately half of 
familial breast cancer cases and in most cases of 
combined familial breast/ovarian cancers. 
BRCA2 mutations are found in about thirty 
percent of the hereditary breast cancers. Clini-
cally, carriers of a BRCA germline mutation 
present with a substantially higher risk of 
developing breast and ovarian cancer than the 
general population. By the age of 70 years, the 
breast cancer risk in BRCA1 mutation carriers is 
65% (95% CI 51-75%) and the ovarian cancer 
risk is 39% (95% CI 22-52%); in BRCA2 muta-
tion carriers, the corresponding risks are 45% 
(95% CI 33-54%) and 11% (95% CI 4-18%), 
respectively (43) (Table 3). The median age of 
diagnosis in mutation carriers is 42 years, 
approximately 20 years earlier than unselected 
breast cancer in the Western World and several 
years before mammographic screening is 
recommended in the general population (44). A 
small percentage of the hereditary breast cancer 
syndromes can be explained by other high- and 
low-penetrance breast cancer genes (45-48) 
(Table 3), but these will not be discussed further 
in this thesis. In total, it is estimated that 5-10% 
of all breast cancer cases are due to inherited 
mutations of which mutation in the BRCA1 and 
BRCA2 genes are the most frequent (49, 50). 
However, in an additional 15-20% of all breast 
cancer cases a positive family history of the 
disease is found; therefore, from all the families 
that are actually eligible and tested for BRCA 
germline mutations, only in approximately 25% 
a BRCA1 or BRCA2 mutation is diagnosed 
according to literature (51-54); in Dutch hospi-
tals the current percentages are around 7-14% 
(55). About 10-25% of the cases tested for BRCA 
predisposition is diagnosed with an unclassified 
variant (UV) (55-57), whereas for the remaining 
breast cancer families the genetic test result is 
uninformative/inconclusive. In literature, the 
latter families are referred to as 'non-BRCA1/2 
families' and it is likely that these people are 
carrier of mutations in other, still unknown, 
breast cancer susceptibility genes, which are 
collectively designated as BRCAX (58). 
The importance to determine 
BRCA status 
 As a mutation in the BRCA1 or BRCA2 gene 
is one of the greatest risk factors for developing 
breast and ovarian cancer, identification of such 
a mutation is of significant clinical value. 
Mutation carriers are offered special medical 
care to reduce the risk of cancer development 
and, ultimately, mortality. First of all, providing 
individuals general information about BRCA1/2 
mutations by genetic counseling has been shown 
to reduce worrying about breast cancer, reduce 
anxiety and depression, and increase the likeli-
hood of participating in genetic testing (59). 
Second, intensified screening for early detection 
of cancer by both mammography and magnetic 
resonance imaging (MRI) has been recom-
mended for women with BRCA mutations (60, 
61). Furthermore, women who have been 
identified with a germline mutation in BRCA1/2 
can opt for prophylactic surgery which includes 
prophylactic bilateral mastectomy (PBM) and 
prophylactic bilateral salpingo-oophorectomy 
(PBSO), to reduce the risk of breast and ovarian 
cancer by 85-100% (62-67). Lastly, women with 
an inherited predisposition to breast cancer can 
be offered chemopreventive agents such as oral 
contraceptives (68, 69) or tamoxifen, which has 
been found to reduce the incidence of breast 
cancer in healthy BRCA2 mutation carriers by 
62% (70). Poly(ADP-ribose) polymerase 1 
(PARP1) inhibitors, a novel class of drugs which 
is still under investigation, have shown to be 
highly effective against BRCA-/- pre-cancerous 
CHAPTER 1 
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cells and might become chemopreventive agents 
in the future (this will be discussed in more 
detail further on) (71). Although these interven-
tions might benefit women carrying a BRCA 
mutation, they should be avoided in non-carrier 
relatives (true negatives). 
 Recently, it has been shown in vitro that 
BRCA-deficient cell lines display increased 
sensitivity to agents causing double-strand DNA 
breaks such as cisplatin (72, 73). These findings 
may open the possibility that determination of 
BRCA status may also be used to guide therapy 
in the near future. However, because of the lack 
of prospective clinical validation, BRCA muta-
tion carriers are offered similar adjuvant therapy 
as non-hereditary breast cancer patients at the 
moment (74, 75).  
Eligibility for BRCA mutation 
testing 
 As a result of the large sizes of the BRCA1 
and BRCA2 genes, mutation screening is expen-
sive, complex and time-consuming. It would be 
inefficient to screen for inherited cancer suscep-
tibility in all women diagnosed with breast 
cancer and it is therefore necessary to preselect 
eligible families for mutation testing. Several 
referral guidelines have been developed based on 
family characteristics that have been associated 
with increased risk of germline mutations in 
BRCA1 or BRCA2 for further risk evaluation 
(76-82). These risk factors include breast cancer 
onset at young age, ovarian cancer, two breast 
cancer primaries, a combination of breast and 
ovarian cancer, male breast cancer, or a known 
BRCA mutation in the family, ethnic group, and 
family history of breast or ovarian cancer (Box 3) 
(51, 54, 56, 83). In addition to the risk factors, 
several models have been developed to accu-
rately evaluate the probability of a person 
carrying a BRCA mutation (84). Next, genetic 
counseling is performed with the subject and 
only those women with strong evidence for a 
germline mutation and with assumed sufficient 
benefit are recommended for further DNA 
diagnostics.  
Estimation of BRCA carrier 
probability 
 The most important factors that determine 
the individual likelihood of a deleterious BRCA 
mutation in affected or cancer-free women 
remain family history of breast or ovarian cancer 
and a known family mutation (85, 86). Several 
models have been developed to estimate the 
probability that an individual person or family is 
a carrier of a mutation in BRCA1 or BRCA2 
based on their family history of cancer (i.e., age 
of onset and type of cancer in first- and second-
 Diagnosis of breast cancer at early age  (<50 years) 
 Triple negative breast cancer (ER, PR, ERBB2) 
 Two breast cancer primaries (bilateral or ipsilat-
eral) 
 Both breast and ovarian cancer 
 Ovarian/fallopian tube/primary peritoneal cancer 
 One or more cases of breast and/or ovarian cancer 
in the family 
 Clustering of breast cancer with various other 
cancers such as thyroid or pancreatic cancer on the 
same side of the family 
 Presence of breast cancer in a male family member 
 Known BRCA1 or BRCA2 mutation in the family 
 Member of a population at risk (e.g., Ashkenazi 
Jewish) 
 
Box 3 - Family characteristics covering first-, second-, and third-
degree relatives that have been described to be risk factors for 
hereditary breast cancer (51, 54, 56, 83). Affected individuals with 
one or more risk factors might be eligible for further risk evaluation. 
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degree relatives), non-hereditary risk factors 
(e.g., age at menarche and age at birth of first 
child), but also on the population prevalence of 
mutations, age-specific penetrance, and ethnic 
ancestry (87). The application of these tools is to 
select or exclude people from genetic counseling 
and genetic testing in order to provide a cost-
efficient and clinically appropriate service. The 
currently available probability models include 
BRCAPRO (88-90), models from Myriad 
Genetic Laboratories (Salt Lake City, UT, USA) 
(56, 83, 91), the Couch model (also known as the 
Penn model) (54, 92), IBIS (International Breast 
Cancer Intervention Study) (93), and 
BOADICEA (Breast and Ovarian Analysis of 
Disease Incidence and Carrier Estimation 
Algorithm) (94, 95). Most models can calculate a 
BRCA mutation probability for affected as well 
as unaffected individuals. Table 4 describes 
seven of these models, noting on what their 
estimates are based and to whom they are 
applicable. The results of all of these tests should 
be interpreted with some caution, because each 
model bases its calculation of risk estimate on 
Table 4 - Models to calculate the likelihood of carrying a BRCA1 or BRCA2 mutation. References refer to original publication and 
electronic tool if available. 
 
Model Estimates based on Applications References 
BOADICEA 
(BRCA1 and BRCA2) 
Extensive information on family 
history of cancer, male breast 
cancer. 
Applicable for proband 




(BRCA1 and BRCA2) 
Extensive information on family 
history of cancer, age at diagnosis, 
presence of bilateral breast cancer, 
male breast cancer, Ashkenazi 
Jewish heritage. 
Applicable for individuals 





(BRCA1 and BRCA2) 
Breast/ovarian status, extensive 
information on family history of 
cancer, nonhereditary risk factors. 
Applicable for proband 





Bilateral breast cancer, ovarian 
cancer, age at diagnosis, Ashenzi 
Jewish ethnicity, and family history 
of cancer. 
Only applicable for proband 
affected by breast and/or 
ovarian cancer. Applicable to 
families with small numbers 
of affected members. 
(56) 
Myriad  II 
(BRCA1 and BRCA2) 
 
History of breast and ovarian 
cancer, Ashkenazi Jewish heritage, 
and family history of cancer. 
Only applicable for proband 
affected by breast cancer < 50 





Age at diagnosis, family history of 
cancer, Ashkenazi Jewish heritage. 
Applicable for proband with 




(BRCA1 and BRCA2) 
Ashkenazi Jewish heritage, family 
history of cancer. 
Applicable for proband with 
or without breast or ovarian 
cancer but with > 2 breast 




different parameters, which might mean that 
different results are generated for the same 
person (102-104). It should be well understood 
that these models calculate the probability of a 
BRCA mutation and not the true breast cancer 
risk, although some of them are able to do the 
latter. Other models that assess the risk of 
developing breast cancer include the Gail, Claus, 
Jonker, and extended Claus models (105-108). 
Additional models that have been developed to 
assist in selecting women for referral to genetic 
counseling include FHAT (Family History 
Assessment Tool), the Manchester scoring 
system, and RAGs (Risk Assessment in Genetics) 
(109-111). 
Genetic testing 
 Mutations in the BRCA1 and BRCA2 genes 
are found throughout all coding regions and at 
splice sites, with most of these mutations being 
small insertions or deletions causing frameshift 
mutations, nonsense mutations, or splice site 
alterations. In order to detect these specific 
genetic alterations, the entire BRCA1 and 
BRCA2 genes have to be examined, which is a 
complex procedure. Only known founder 
mutations can be detected relatively easy in some 
high-risk families from specific ethnic groups 
(112). The current gold standard to determine 
BRCA mutations is direct sequencing of genomic 
DNA; however, since this is an expensive and 
time-consuming technique, many laboratories 
prefer the use of pre-screening techniques to 
detect any genetic anomalies first. Pre-screening 
techniques include protein truncation test 
(PTT), denaturing gradient gel electrophoresis 
(DGGE), denaturing high-performance liquid 
chromatography (DHPLC), single-stranded 
conformational polymorphism (SSCP), two-
dimensional gene scanning (TDGS), fluorescent-
assisted mismatch analysis (FAMA), heterodu-
plex analysis, and fluorescent conformational 
sensitive gel electrophoresis (F-CSGE) (113, 
114). None of these techniques, including direct 
sequencing, is able to identify all cancer predis-
posing mutations in the BRCA1 or BRCA2 gene. 
Only by applying additional detection strategies 
for large deletions or duplications such as 
multiplex ligation dependent probe amplifica-
tion (MLPA), can an estimated detection rate of 
up to 95% be achieved (115). 
 If a gene mutation is found, sequential 
clinical steps can be undertaken. If no mutation 
is found in a family member of a known BRCA 
mutation-carrying family (a "true negative"), the 
individual's risk of breast cancer is equal to that 
of the general population and no additional 
preventive measures are required. However, 
difficulties arise when no pathogenic mutation is 
found but the hereditary risk of breast cancer 
cannot be ruled out for this individual or family. 
Such test result is called uninformative or 
inconclusive which is absence of identification of 
a deleterious mutation in an entire family or 
identification of an unclassified variant (UV), a 
sequence variant of which the clinical signifi-
cance is still unknown. 
BRCA mutations 
 To date of writing, 1647 and 1857 unique 
mutations are described in the BIC database for 
the BRCA1 and BRCA2 genes, respectively. The 
majority of the mutations found are frame-shift 
or nonsense mutations (Table 5) and about 10% 
of the mutations are large exonic deletions or 
insertions (116, 117). These mutations are 
described as pathogenic because they result in 
missing, truncated or not properly functioning 
protein products. Splice site alterations cause 
incorrect splicing and may result in unstable 
mRNA and thus reduced levels of protein (118). 
 If a mutation can be traced back to a com-
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Table 5 - Source: The Breast Cancer Information Core (BIC) Database. UV, unclassified variants. 
 








3-prime Untranslated Region (3'UTR) 2 0.1% 1 0.1% 0 0  
5-prime Untranslated Region (5'UTR) 3 0.2% 3 0.4% 10 0.5% 7 0.7% 
Frameshift (F) 542 32.9% 0 544 29.3% 3 0.3% 
In Frame Insertion (IFI) 1 0.1% 1 0.1% 4 0.2% 3 0.3% 
In Frame Deletion (IFD) 24 1.5% 24 3.2% 23 1.2% 23 2.2% 
Intervening Sequence (IVS) 264 16.0% 159 21.0% 173 9.3% 124 12.1% 
Missense (M) 570 34.6% 537 71.2% 847 45.6% 812 79.2% 
Nonsense (N) 194 11.8% 0 189 10.2% 1 0.1% 
Splice (S) 1 0.1% 1 0.1% 2 0.1% 0  
Synonymous (Syn) 46 2.8% 29 3.8% 65 3.5% 52 5.1% 
total 1647 755 1857 1025  
mon ancestor it is called a founder mutation. 
Such a mutation is often enriched in a certain 
ethnic group. The prevalence of a founder 
mutation can be strongly enriched among 
certain ethnic groups such as the Ashkenazi 
Jews, in which three founder mutations have 
been identified: the 187delAG and 5385insC in 
BRCA1, present in about 1.1 and 0.15% of the 
Ashkenazi Jews, and the 6174delT mutation in 
BRCA2, present in 1.5% of the Ashkenazi Jews. 
These three mutations account for a total BRCA 
mutation carrier frequency of 1 per 40 individu-
als of Ashkenazi Jewish descent, which is notably 
high (119-121). Another example is the founder 
mutation BRCA2 999del5 that accounts for 7-8% 
of female breast cancers and for 40% of male 
breast cancers in Iceland (122). More BRCA 
founder mutations are seen in other countries in 
which endogamy is a common practice among 
certain social or religious groups, including in 
the Netherlands (112, 123-125). 
Unclassified variants in BRCA 
 Besides the pathogenic mutations found in 
the BRCA1 and BRCA2 genes, more than half of 
the nucleotide changes in these genes occur 
rarely (<1%) and their clinical significance is 
unknown (116). These mutations are called 
unclassified variants (UVs) and are generally 
missense (M) or intervening sequence (IVS) 
variants that result in substitution or loss of a 
single amino acid (Table 5) (118). Clinically, the 
identification of an UV in an individual's 
germline DNA is a difficult situation and to 
prevent unnecessary surgery, it is important to 
determine whether the mutation adversely 
affects the functions of the protein. However, 
determining the pathogenicity remains difficult 
because of the limited knowledge about the 
functional outcomes of such nucleotide variant; 
therefore, much research is currently being 
performed to assess the pathogenicity of each 
UV. Multifactorial classification models base the 
risk associated with a UV on combined data 
from variant frequency, co-segregation with 
cancer, and features consistent with a real 
pathogenic gene mutation such as family history 
of cancer, co-occurrence (in trans) of another 
known pathogenic mutation, tumor histopathol-
ogy, loss of heterozygosity (LOH) of the wild-
type allele, evolutionary conservation, and 
evidence from functional assays (126, 127) 
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(Table 6). Because multifactorial classification 
models are limited by the amount of families 
carrying the UV, complementary approaches are 
often required, i.e., in vitro assays that make use 
of transcript and functional analyses or predic-
tion of splicing aberrations using bioinformatics 
(in silico) (128-132). Still, determining the 
pathogenicity of UVs remains difficult, laborious 
and time consuming and new techniques are 
being developed to preselect for variants with 
high pathogenic possibility. 
Non-BRCA1/2 families 
 Most of the women from breast cancer 
families do not carry a pathogenic mutation or 
unclassified variant in the BRCA1 or BRCA2 
gene (53, 55). Linkage analysis mapped a third 
breast cancer susceptibility gene on chromosome 
13q, distinct from BRCA2 and Rb, but this was 
opposed a few years later (133). It is now sus-
pected that an unknown number of low pene-
trance genes or a combination of common 
Table 6 - Types of evidence for UV classification (126, 130). 
 
Multifactorial classification 
Variant frequency Frequency of the variant occurring in cases and controls provides a direct estimate of 
associated cancer risk but studies would need to be prohibitively large because of the 
rarity of the variants. 




UVs, co-occurring with a deleterious mutation in the same gene (in trans), can be 
classified as neutral if homozygotes are assumed to be embryonically lethal. However, 
this method exhibits less power to show causality. 
Family history Personal and family history of cancer of the carriers of the UV usually can easily be 




Histopathological tumor features are a potential powerful predictor for BRCA1-
related tumors in which the pathological characteristics are quite distinct, however, 
for BRCA2-related tumors the prediction might be weak (discussed further on). 
LOH Occurrence of loss of heterozygosity in tumor DNA should be used as an adjunction 
to co-segregation results. 
Conservation The severity of the amino acid change and its conservation across species can be very 
predictive if enough evolutionary time sequence is available. Still, it is only indirectly 
related to disease risk. 
In vitro assays 
Functional analyses Functional analyses can evaluate the effect of the variant on the protein's ability to 
perform (some of) its cellular functions. These assays include the determination of 
transcription activity, small colony phenotype, ubiquitin ligase activity, rescue of 
radiation resistance, embryonic stem cell-based functionality, homologous recombi-
nation, mitomycin C survival, and centrosome amplification 
Transcript analyses Transcript analysis can efficiently identify variants affecting the stability and integrity 
of mRNA transcripts. 
In silico tools Computation analysis of the UV can be used to predict the effect on mRNA splicing 
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variants (polygenic model) with multiplicative 
effects on risk may be responsible for this 
substantial proportion of hereditary breast 
cancer (114, 134-137). Researchers have come to 
this conclusion after investigation of a large 
cohort of 149 non-BRCA1/2 breast cancer 
families in which linkage analysis has not been 
able to provide a locus on which a third major 
breast cancer gene might be located with statisti-
cal significance (138). Different approaches are 
now being examined to decrease the genetic 
heterogeneity and increase the statistical power 
of finding a breast cancer susceptibility locus, 
thus far without success (139). The difficulty in 
obtaining genetic homogeneous groups is the 
lack of specific familial phenotypes such as in 
families carrying a BRCA1 or BRCA2 mutation 
where ovarian and male breast cancer were 
recognized to be common. Additionally, study-
ing families with high breast cancer incidence at 
early age could provide a more genetic homoge-
neous group but increases the likelihood of 
involvement of the BRCA1 or BRCA2 genes 
(140). New ways are needed to cluster families 
into subgroups of single-gene disorders. 
Treatment 
 Patients with hereditary breast cancer are 
offered bilateral mastectomy as treatment and to 
simultaneously decrease the risk for local 
recurrences or secondary primaries. As such, 
breast conserving surgery (BCS) is not the best 
therapy in BRCA-mutation carriers as these 
patients still have a substantial increased risk for 
local recurrences compared to sporadic breast 
cancer patients or BRCA-mutation carriers 
undergoing mastectomy; nevertheless, survival 
after mastectomy or BCS has not been shown to 
be significantly different (141). Chemotherapy 
after BCS has been shown to decrease the risk for 
local recurrence from 23.5% to 11.9% in BRCA-
mutation carriers, however, adjuvant chemo-
therapy by itself does not have any additional 
effect (positive or negative) on survival com-
pared to patients with sporadic breast cancer 
(141, 142). It is thought that BRCA deficient 
tumors might be more sensitive to poly(ADP-
ribose) polymerase inhibitors, but limited 
clinical data are available (this will be discussed 
in more detail further on) (143). In vivo and in 
vitro, homozygote BRCA-mutated cells have 
been found to be more radiosensitive due to the 
lack of proper DNA repair by homologous 
recombination and, additionally in BRCA1 
deficient cells, due to the lack of the cell-cycle 
G2-M checkpoint to stop cells before mitosis 
upon DNA damage (144-146). It would be very 
interesting to exploit this in cancer treatment; on 
the other hand, radiotherapy could then also 
increase the risk for secondary cancers. How-
ever, the currently available data from clinical 
studies do not provide evidence of hypersensitiv-
ity for radiotherapy in breast cancer patients 
carrying a BRCA-mutation or increased cancer 
sensitivity, cancer recurrences are reported to be 
similar compared to patients with sporadic 
breast cancers (147). Taken together, so far the 
clinical treatment of hereditary breast cancer 
patients does not differ from the treatment given 
to patients with sporadic breast cancer although 
the roles of BRCA1 and BRCA2 in DNA repair 




 Breast cancer type, histological grade, 
invasion, estrogen receptor (ER) status, proges-
terone receptor (PR) status, and ERBB2 (human 
epidermal growth factor receptor 2) status are 




Hereditary breast cancers have several apparent 
features that separate them from sporadic breast 
cancers. Compared to sporadic breast tumors, 
BRCA1-associated breast tumors generally are 
grade III, hormone (ER and PR) and ERBB2 
receptor negative (also referred to as triple-
negative), often show p53 protein accumulation, 
much lymphocyte infiltration and a high 
expression of K5/6 (149-151). Most BRCA2-
associated breast tumors are grade 2/3 and are 
often ER and ERBB2 positive (149). In contrast 
to BRCA1-related breast tumors, BRCA2-related 
breast tumors show much less distinctive 
features as compared to age-matched sporadic 
breast tumors (Table 7). Similar to BRCA2-
associated breast tumors, non-BRCA1/2 breast 
cancer is a heterogeneous group that is 
comparable to sporadic breast cancer. Significant 
differences have been found in keratin 
expression, as K14 and K5/6 are higher 
expressed in BRCA2-associated and non-
BRCA1/2 breast cancer (148, 149). Although 
several studies have been performed to classify 
hereditary breast cancer based on 
histopathological features (152), it should be 
noted that none of these features in itself or in 
combination is unique to any of the hereditary 
breast cancers; therefore, histopathological 
features are not being used to identify hereditary 
breast cancer cases. 
Table 7 - Common histopathological features of hereditary and sporadic breast tumors. Negative status for ER, PR and ERBB2 is 
also referred to as "triple-negative". Data summarized from (148-151). 
 
 BRCA1 (%) BRCA2 (%) non-BRCA1/2 (%) Sporadic (%) 
Invasive lobular carcinoma 7 13 14 12 
Invasive ductal carcinoma 74 71 73 69 
Medullary carcinoma 18 3 2 3 
Grade I 2 20 24 22 
Grade II 24 42 44 42 
Grade III 73 38 32 36 
ER      
positive 21 65 72 66 
negative 79 35 28 34 
PR     
positive 20 49 60 56 
negative 80 51 40 44 
ERBB2     
positive 7 6 3 18 
negative 93 94 97 82 
     
Triple-negative 57 23 14 11 
p53     
positive 45 27 12 27 
negative 55 73 88 73 
KRT5/6     
positive 65 7 13 8 
negative 35 93 87 92 
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Molecular biology of 
hereditary breast cancer 
The BRCA1 gene 
 The human BRCA1 gene contains 24 exons, 
encoding for a protein of 1863 amino acids (33). 
The protein contains multiple functional 
domains, including a highly conserved RING 
finger domain in its N-terminal region, two 
nuclear localization signals (NLS) that are 
located in the BRCA1 gene in exon 11, a DNA 
binding domain between amino acids 452-1079, 
an SQ-cluster domain (SCD) between amino 
acids 1280–1524, and tandem BRCT repeats in 
its C-terminal region (Figure 3) (153). The 
BRCA1 protein interacts directly or indirectly 
with many other molecules, including tumor 
suppressors, proto-oncogenes, DNA damage 
repair proteins, cell cycle regulators, as well as 
with transcriptional activators and repressors 
(114, 154). Normally, BRCA1 is part of a het-
erodimer together with BARD1 of which the 
interaction is mediated by alpha-helical units 
adjacent to the RING domain (155). Without 
BARD1, BRCA1 is unstable and is rapidly 
degraded; it would be unable to perform its 
tumor suppressor functions (156). The BRCA1-
BARD1 complex serves as an ubiquitin ligase in 
vitro (157), however, in vivo it is largely un-
known what its substrates are. BRCA1 is local-
ized to the site of the double-strand break by 
binding Abraxas at the BRCT repeats, followed 
by interaction with RAP80 (158, 159). Not only 
is the BRCA1-Abraxas-RAP80 complex involved 
in DNA repair, it also regulates phosphorylation 
of CHK1 kinase through a yet still unknown 
mechanism (160). CHK1 kinase is involved in 
DNA damage-driven cell cycle checkpoint 
control and is important to arrest cells to allow 
them time for DNA repair before mitotic entry. 
Furthermore, BRCA1 plays a role in replication 
checkpoints that are activated in response to 
replicative stress such as collapsed or stalled 
replication forks (146, 161), but also in mitosis 
control where the BRCA1/BARD1 heterodimer 
is required for mitotic spindle pole assembly 
(162). Finally, the ubiquitination of topoisom-
erase IIa, which is involved in the decatenation 
of replicated DNA, is regulated by BRCA1 (163). 
Loss-of-function mutations of BRCA1 would 
therefore result in pleiotropic phenotypes, 
including defective DNA damage repair, a 
defective G2/M cell cycle checkpoint, abnormal 
centrosome duplication, chromosome damage, 
aneuploidy, and impairment of the spindle 
checkpoint (164, 165). 
The BRCA2 gene 
 The human BRCA2 gene covers 70kb of 
genomic DNA and has 27 exons, encoding for a 
protein of 3418 amino acids (35).  While BRCA1 
has a wide range of functions in many different 
cellular processes, the primary function of 
BRCA2 is limited to homologous recombination, 
both in meiosis and repair of double-strand 
breaks (154, 166). Through the interaction with 
PALB2, BRCA2 is located to the site of damage 
together with BRCA1. BRCA2 is able to bind to 
single strand DNA through interaction with 
DSS1 to the helix-rich domain (HD) (Figure 4). 
A tower domain emerges from the second OB 
(oligonucleotide binding) fold, which is topped 
 
Figure 3 - Functional domains in the BRCA1 protein (dark 
gray) and interacting proteins (bottom). 
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by a three-helix bundle for DNA binding. 
Although ssDNA is preferred by BRCA2, the 
structure of the tower domain suggests the 
possibility of binding to duplex DNA too (167). 
Next, RAD51 is loaded onto the 3'-strand 
overhang, which is bound to the BRC repeats of 
BRCA2 to facilitate DNA repair (Figure 6). 
Trough the CTRM domain, BRCA2 stabilizes 
the resulting nucleoprotein filament. Because 
RAD51 is required for DNA-repair by homolo-
gous recombination, it is not surprising that 
BRCA2-deficient cells exhibit genetic instability 
(168, 169). 
BRCA1 and mammary stem cell 
differentiation 
 Normal stem cells are primitive undifferenti-
ated cells that are capable of self-renewal while 
maintaining the undifferentiated state but have 
the potency to differentiate into specialized cell 
types. Stem cells maintain the growth of normal 
proliferative tissue such as intestinal epithelium, 
skin, or bone marrow but also guarantee tissue 
regeneration after injury. Stem cells are the top 
of the cellular hierarchy and give rise to progeni-
tors with more restricted lineage potential 
(Figure 5) (170). It is postulated that similar to 
normal proliferative tissue, the growth of a 
tumor is driven by a limited number of so called 
cancer stem cells (CSC) (171). Cancer stem cells 
maintain the growth of the neoplastic clone and 
give rise to rapidly proliferating and more 
differentiated cells that form the bulk of the 
tumor. One of the CSC concepts is that the 
tumor-initiating cell was originally an adult stem 
cell or a progenitor cell that has accumulated 
(epi)genetic damage resulting in tumorigenesis 
(172, 173). 
 The cyclical nature of mammary gland 
growth and involution during each pregnancy 
suggests the presence of stem cells in breast 
tissue (176, 177), but a consensus on the pheno-
typic definition of normal human mammary 
stem cells is still lacking at this point (178). 
Mammary adult stem cells can differentiate into 
two distinct cell types: luminal and myoepithelial 
(Figure 5). The luminal cell layer in mammary 
ducts is composed of progenitor luminal cells 
 
Figure 4 - BRCA2 protein organization, domains indicated in 
dark gray and interacting proteins below (154, 166). HB: 
helical domain, OB: oligonucleotide-binding, CTRM: c-






Figure 5 - Stem cells have the ability to self-renew and give rise 
to more differentiated progenitor cells. The progenitor cells will 
further differentiate into myoepithelial, ductal, and alveolar cells 
and form the lobules and ducts in the breast. Depending on the 
cell of origin, different subtypes of breast cancer can arise. Source: 
(174, 175). 
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lacking expression of estrogen receptor (ER) and 
differentiated luminal cells that express ER and 
progesterone receptor (PR) (179, 180). BRCA1 
plays an important role in the differentiation 
from ER negative progenitor cells to mature ER 
positive luminal cells. Women with a BRCA1-
mutation often show entire lobules in the breast 
tissue to be ER negative and ALDH1 (a stem cell 
marker) positive, although histological normal, 
whereas this is not seen in non-mutation carriers 
(181). Loss of BRCA1 function results in blocked 
epithelial differentiation which leads to growth 
of undifferentiated luminal progenitor cells. 
Because BRCA1 also functions in DNA repair, 
these progenitor cells are prime targets for 
further carcinogenic events (182). 
The roles of BRCA1 and BRCA2 
in DNA repair 
 DNA damage occurs continuously through-
out a person's whole life, and is caused by both 
exogenous and endogenous stresses. Different 
DNA damaging sources cause different types of 
DNA damage and of these, double strand breaks 
are the severest because it affects both strands of 
the duplex, thus no intact complimentary strand 
is available as a template for repair (73). Inap-
propriate repair of such DNA damage in a cell 
can lead to either loss of viability or to chromo-
somal alterations that increase the likelihood of 
cancer development (183). Fortunately, all 
mammalian cells possess two enzymatic path-
Figure 6 – (left) Upon formation of a DNA double strand 
break, the MRN complex recognizes the lesion and recruits 
CtIP and BRCA1/BARD1. On either sites of the break, 3’-
single stranded DNA overhangs are generated that bind RPA. 
Next, BRCA2 is recruited by BRCA1 through interaction with 
PALB2. BRCA2 loads RAD51 recombinase, displacing RPA. 
The sister chromatid is invaded by the strand overhang with 
RAD51 nucleoprotein and the homology search is initiated. 
(right) Once homology is established, DNA synthesis is started 
using the sister chromatid as a template for both 3’-
overhangs. The resulting structure is called a double Holliday 
Junction and is resolved by Holliday junction resolving 
enzymes (figure adapted from [154]). 
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ways that mediate the repair of DNA double-
strand breaks (DSB): homologous recombina-
tion (HR) and non-homologous end-joining 
(NHEJ). The HR pathway is a very accurate 
repair mechanism in which a homologous 
stretch of DNA on a sister chromatid serves as a 
template to guide repair of the broken strand. It 
is most active in the late S-G2 phase of the cell 
cycle and accounts for the repair of ~10% of 
DSBs in mammalian cells. The role of BRCA1 is 
to remodel the chromatin to make the DNA 
damaged site become accessible to the DNA 
repair machinery; next BRCA2 directly translo-
cates the DNA repair protein RAD51 to facilitate 
the repair (Figure 6). As both BRCA1 and 
BRCA2 are involved in DSB repair by homolo-
gous recombination, lack of one of these genes 
will result in HR defects and leaves a cell with 
only NHEJ to repair double strand breaks (184).  
In NHEJ, which can take place during the whole 
cell cycle, the two ends of the broken DNA 
molecule are processed to form compatible ends 
that are directly ligated. Because this repair 
mechanism lacks a homologous sequence 
control system, deletion, inversion, or any other 
type of abnormality in the genome could occur 
as a consequence (185). NHEJ is therefore 
recognized as a potentially less accurate form of 
DSB repair. The functions of BRCA1 and 
BRCA2 can become completely inactivated only, 
when both maternal and paternal genes have 
been silenced. The chances of losing both gene 
copies during a lifetime have been shown to be 
relatively small (186, 187); however, women 
carrying a germline mutation in BRCA1 or 
BRCA2 already have one silenced copy and the 
chance of losing the second copy is relatively 
high. The loss-of-function of the second allele, 
often revered to as the 'second-hit' (188) and in 
most cases caused by loss of heterozygosity 
(LOH), can lead to cancer formation (189). 
Synthetic lethality in BRCA 
mutated tumors 
 PARP1 and PARP2 are proteins involved in 
the repair mechanism called base excision repair 
(BER), which is a key pathway for the repair of 
DNA single-strand breaks (SSB) (190). When a 
single-strand break is not repaired and encoun-
tered by a DNA replication fork, the fork will 
stall and eventually collapse, which will lead to 
DNA double-strand break formation (191). 
Usually, such breaks are repaired by homologous 
recombination (HR) or non-homologous end 
joining (NHEJ); however, in BRCA1- or 
BRCA2-deficient cells, the homologous recom-
bination repair pathway is impaired and the cell 
has to resort to NHEJ only, which is error-prone. 
This has led to the hypothesis that homologous 
recombination deficient (HRD) cells, such as 
tumor cells in BRCA1-mutated breast cancer, 
might be hypersensitive to the inhibition of 
PARP and crippling the BER mechanism. In 
contrast, normal cells with at least one functional 
copy of BRCA1/2 should be able to repair the 
breaks, resulting in chromosomal stability and 
cell viability (192). Indeed, preclinical studies 
have shown that PARP inhibitors are synthetic 
lethal in BRCA mutated cells (193, 194). 
 To date, clinical data on the use of PARP 
inhibitors as anticancer drugs are limited and 
only Phase I and II studies have been performed; 
however, these studies have shown promising 
results in terms of antitumor activity (143, 195-
197). This new therapy has the potential to 
improve current therapy options for BRCA-
mutation carriers, but patients with sporadic 
breast cancer with HRD might also benefit from 
this synthetic lethality. It should, however, be 
noted that there is currently no clinical test 
available to routinely investigate BRCA or 
homologous recombination status in sporadic 
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breast cancer. As BRCA-deficient breast tumors 
have not shown to be a histopathological unique 
entity, genetic markers found by microarray 
experiments might form the basis for a tool that 
is able to indicate HRD or BRCA-deficiency in 
the future. 
Microarray technology 
 A microarray is a solid surface, generally a 
glass slide, on which multiple known nucleotide 
sequences, called probes, have been immobilized 
in gridded formation. The probes function as 
target on which fluorescently labeled DNA or 
cDNA can be hybridized. A quantitative meas-
urement of hybridized sample to each probe can 
be made by comparison to a reference sample. In 
this thesis, two different microarray technologies 
are described, the first technique can be used to 
measure gene expression levels and the second 
to measure DNA copy number levels. The 
advantage of using microarrays as compared to 
other techniques that are able to quantitatively 
measure gene expression or copy number levels 
is its ability to perform thousands to even 
millions of measurements in parallel. Gene 
expression (GE) microarrays can be used to 
measure the amount of mRNA expression of 
basically every known gene in the human 
genome compared to a standard (198). The 
technique to study copy number levels is called 
comparative genomic hybridization (CGH) and 
as a microarray application array-CGH (aCGH). 
This technique can be used to measure the 
amount of DNA copies of most part of the 
genome (199). Both microarray techniques have 
been employed to search for markers that can be 
used as a target for anticancer drugs, but also to 
identify profiles on which breast cancer can be 
separated into molecular subtypes. This thesis 
will concentrate on the latter methodology, the 
identification of profiles specific for tumor 
subclasses. 
Breast cancer subtypes 
 Clinically, breast cancer can be classified into 
two main groups: the estrogen receptor (ER) 
negative and ER positive breast tumors. How-
ever, an important hallmark in breast cancer 
classification was the identification of multiple 
subtypes within the ER negative and positive 
Table 8 - Data from 214 breast tumors, metastasis and normal tissue were excluded from the original study (200). 
 












Prevalence 31 18 13 24 11 3 
Grade I 23 3 4 2 0 17 
Grade II 49 26 39 10 24 17 
Grade III 28 71 57 86 76 66 
ER        
positive  87 86 22 13 10 67 
negative 13 14 78 87 90 33 
PR       
positive 73 56 21 5 30 40 
negative 27 44 79 95 70 60 
ERBB2       
positive 10 26 70 9 31 60 
negative 90 74 30 91 69 40 
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tumors based on gene expression profiles (201). 
To date, six different molecular subtypes have 
been described and are known as luminal A, 
luminal B, ERBB2-enriched, basal-like, normal-
like and claudin-low (202); the latter group was 
formerly classified as a subgroup within the 
basal-like subtype and was called basal-like B 
(203). The molecular subtypes are associated 
with differences in histopathological feature, 
clinical outcome and response to chemotherapy. 
Patients with luminal  A tumors have the longest 
survival times, patients with basal-like or 
ERBB2-enriched subtypes have the shortest 
survival times, and patients with luminal B or 
claudin-low tumors have an intermediate 
survival (200, 204). Basal-like and claudin-low 
breast tumors are in general ER, PR and ERBB2 
negative (triple-negative) while ERBB2-enriched 
generally show overexpression of ERBB2 (Table 
8). It is postulated that the basal-like and 
ERBB2-enriched breast tumors originate from 
ER negative luminal progenitor cells, while 
claudin-low tumors originate directly from 
mammary stem cells  (Figure 5) (174, 175, 205). 
Luminal breast tumors are often ER positive and 
originate from differentiated luminal cells. 
Studies investigating hereditary breast cancer 
have shown that the majority of breast tumors 
from BRCA1 mutation carriers are of the basal-
like subtype (74-90%), while breast tumors from 
BRCA2 mutation carriers are more heterogene-
ous but predominantly of luminal B type (204, 
206, 207). 
Genomic instability and CGH 
 Genomic instability is one of the main 
characteristics of cancer and includes ane-
uploidy, polyploidy, translocations and amplifi-
cation (1). Genomic changes are the causative 
factors in the initiation, development, and 
progression in breast neoplasms (208). These 
aberrations can be studied and characterized to 
better understand the evolutionary pathways a 
cell undergoes to ultimately grow out to cancer. 
Errors in chromosome duplication, segregation 
and telomere dysfunction in the absence of 
caretaker genes are examples from which 
chromosomal aberrations can arise (209). 
During tumorigenesis, DNA regions that include 
oncogenes are frequently amplified causing 
overexpression of the gene and giving the cell 
growth advantage; tumorsuppressor genes are 
often lost during the evolutionary process of 
cancer so cells can escape cell death. It has been 
noticed that several aberrations are recurrent in 
breast cancer such as amplifications of the genes 
MYC on chromosome 8q24 and ERBB2 on 
chromosome 17q12 (210). Investigating DNA 
copy number alterations across a tumor's entire 
genome was a challenging task until the intro-
duction of comparative genomic hybridization 
(CGH) technology (211). Improvements in the 
conventional or metaphase CGH, together with 
the development of microarray technology, led 
to the introduction of array CGH. Compared to 
metaphase CGH, array CGH has the advantages 
of being a high-throughput technology and 
providing a better resolution (199). The array 
CGH platform used in this thesis consisted of 
large-insert clones called BAC (bacterial artificial 
chromosome) clones, providing a genome wide 
resolution of 1 Mb on average. The procedure of 
performing an array CGH experiment is devised 
from several steps: DNA extracted from tumor 
material and reference DNA are differentially 
labeled with fluorescent dyes Cy5 and Cy3, 
respectively, and mixed in a 1:1 ratio. To block 
repetitive sequences, C0t-1 DNA is added. 
Subsequently, the mixture is co-hybridized on a 
glass slide spotted with DNA probe sets under 
controlled temperature and humidity condi-
tions. Lastly, the fluorescence of the hybridized 
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DNA is measured and specialized software 
converts the fluorescent intensity data to a linear 
red-to-green ratio profile (called CGH profile) 
that correlates with the hybridization intensity, 
which mainly depends on the extend and size of 
the tumor's DNA copy number changes (Fig-
ure 7).  
CGH profiles 
 Since the development of comparative 
genomic hybridization (CGH), chromosomal 
aberrations (i.e., aneuploidy, polyploidy and 
amplifications) of genomic DNA in breast 
cancer, have been under extensive study to 
identify novel candidate cancer genes (212). 
Currently, three different types of profiles of 
genetic alterations detected by array-CGH are 
described (Figure 8). The first profile exhibits 
only few gains or losses of whole chromosome 
arms with most characteristically gain of chro-
mosome 1q and 16p and loss of 16q. This profile 
is mainly associated with ER positive breast 
cancers and those of the Luminal A subtype. The 
second type of profiles contains high-level DNA 
amplifications with a moderate complex pattern 
of other gains and losses seen along the whole 
genome, typically for Luminal B and ERBB2-
enriched subtype breast tumors. The last type of 
profiles is characterized by a complex pattern of 
numerous small aberrations including gains, 
losses and amplifications, and is associated with 
TP53 mutated, basal-like and claudin-low 
 
 
Figure 7 - Sample DNA labeled with red fluorescent dye and reference DNA labeled with green fluorescent dye are co-hybridized to a 
microarray. A red-to-green ratio profile is generated from the intensity measurements. A higher red signal compared to green signal 
means gain/amplification of sample DNA, whereas less red signal means loss/deletion of sample DNA. 
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subtype breast tumors (209). Because both 
BRCA1 and BRCA2 genes are part of DNA 
repair pathways, lack of function of one of these 
genes causes impaired DNA repair by homolo-
gous recombination, resulting in an accumula-
tion of genetic errors and chromosomal instabil-
ity (184). This thesis concentrates on character-
izing the CGH profiles of BRCA1- and BRCA2-
mutated breast tumors, and to extract the 
aberrations specific for BRCA1- or BRCA2-
deficiency. 
This thesis 
Tumor based prediction of 
BRCA status 
 Although the inclusion criteria for BRCA 
mutation screening mentioned earlier cover 
many of the characteristics of typical BRCA 
families, mutation carriers might be missed 
because of lack of a family history of cancer or 
due to late age at breast cancer onset. In addition 
to pedigree-based risk assessment for BRCA 
mutations, a number of strategies exist to 
determine tumor-specific characteristics on 
which association with BRCA defects might be 
deduced. A recent study showed that on mam-
mography and MRI, BRCA-associated lesions 
were more often described as rounded and with 
sharp margins compared with an age- and tumor 
type-matched control group; however, the 
prognostic value of this has yet to be evaluated 
(213). Morphological investigations show clear 
differences between BRCA1-mutated and age-
matched sporadic breast tumors: the lesions are 
mainly of higher grade, have more pleomor-
phisms, a higher mitotic count, and less tubule 
formation. In addition, BRCA1-associated 
carcinomas are more often of the medullary 
type. BRCA2-mutated breast tumors, on the 
other hand, are generally more similar to 
sporadic breast tumors, but they show less 
tubule formation and the occurrence of tubular 
carcinoma is less common (214-218). 
 Histological, BRCA1-mutated breast tumors 
are in general estrogen receptor (ER), progester-
one receptor (PR) and ERBB2 negative; whereas 
 
 
Figure 8 - Three different types of array-CGH profiles are identified in breast cancer research. A simple profile with only a few 
aberrations (upper), a moderate complex profile with high-level amplifications and several other aberrations (middle), and a 
complex profile with many gains, losses and amplifications (bottom). 
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this "triple-negative" phenotype is present in 
only 11% of sporadic breast tumors (152, 219-
221). Other characteristics can be found at the 
molecular level; these include loss of heterozy-
gosity (LOH) of the BRCA genes (222), frequent 
TP53 mutations in BRCA1-mutated tumors 
(223), hypermethylation of BRCA1 gene pro-
moter CpG islands (224), and chromosomal 
aberrations (225). Although these characteristics 
are not unique to BRCA-mutated breast tumors 
and can therefore not be solely used to identify 
association with mutated BRCA, they might be 
of indicative value in cases of naïve inherited 
breast cancer susceptibility. Tumor characteris-
tics can be informative not only for untested but 
also for BRCA-tested individuals. Members of 
breast cancer families may misinterpret unin-
formative mutation screening test results (57, 
226, 227); hence, for such families, deciding for 
the right prevention and treatment strategies can 
be difficult. The reasons for an uninformative 
BRCA status test result might be defects in other 
genes that have thus far not been correlated with 
breast cancer predisposition (i.e., BRCAX) or 
(epi)genetic defects located in the BRCA1 or 
BRCA2 genes missed by genetic testing (115). 
Besides the pedigree based risk assessment for 
BRCA mutations, so far no other strategies exist 
that identify association with BRCA defects after 
routine diagnostics has not been able to identify 
a mutation. The work described in this thesis 
explored the possibility to predict the likeliness 
of BRCA association in breast cancer based on 
the tumor's chromosomal aberrations using 
array CGH.  
Array CGH — When and How 
 After a tumor has been surgically removed, 
the tissue will usually be fixed in formalin and 
subsequently embedded in paraffin for histopa-
thological diagnosis and long-term storage. 
Quality of the tissue's DNA is mostly affected by 
variability in sample fixation time and duration 
of storage (228). To improve efficiency of array 
CGH experiments, we investigated whether we 
could assess the quality of the tumor's DNA 
prior to array CGH assays. Chapter 2 of this 
thesis describes a relatively easy to perform 
multiplex PCR test to determine whether the 
DNA quality is sufficient for a successful array 
CGH hybridization (229). After DNA of suffi-
cient quality has been collected, array CGH 
experiments can be carried out. Hybridization 
and slide washing was formerly performed by 
hand, due to technical advances this process can 
now also be performed in an automated fashion. 
Automated hybridization will reduce handling 
time and, most importantly, improve the 
reproducibility compared to manual array CGH 
hybridization. Chapter 3 describes the optimiza-
tion of automated array CGH for formalin-fixed, 
paraffin-embedded breast cancer tissues (230).  
Predicting BRCAness by array 
CGH 
 The current strategy to identify BRCA1 and 
BRCA2 mutation carriers is direct sequencing 
preceded by pre-screening for abnormalities; 
however, it still remains unclear to what extent 
BRCA mutation carriers are missed by this 
approach. Additionally, the detection of variants 
of unknown clinical significance is emotionally 
and clinically challenging. Therefore, an addi-
tional tool that would indicate the involvement 
of BRCA in the development of the individual 
breast tumor would be an asset to current 
clinical diagnostics. Since both BRCA1 and 
BRCA2 genes are involved in DNA repair, 
BRCA-associated tumors are characterized by 
intensive genomic instability (231-233). This 
thesis describes the studies of these chromoso-
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mal aberrations by array CGH, which has led to 
the identification of the specific aberrations of 
BRCA1- and BRCA2-associated breast tumors 
separately (234, 235). Chapter 4 describes the 
usage of BRCA1 specific chromosomal aberra-
tions to identify BRCA1-associated breast 
tumors from a cohort in which no BRCA1/2 
mutations had been found by routine diagnos-
tics. Chapter 5 describes a similar process, but 
for BRCA2-association. 
BRCAness in sporadic breast 
cancer 
 In contrast to other cancer predisposition 
genes, neither BRCA1 nor BRCA2 has been 
found to be mutated in sporadic breast cancer 
(186, 187). It has however, come to the attention 
of investigators that a small subset of sporadic 
breast cancers is remarkably similar in many 
aspects to BRCA1-mutated tumors, this cancer 
group is known as the basal-like breast cancer 
subtype (236, 237). Tumors of the basal pheno-
type are seen in 2-18% of sporadic breast tumors. 
They show IHC positivity for basal intermediate 
filaments (e.g., K5, K14), are usually of high 
grade with large central acellular zones compris-
ing necrosis, tissue infarction, collagen, and 
hyaline material, and are generally estrogen 
receptor (ER), progesterone receptor (PR), and 
ERBB2 negative (152, 220). Not only phenotypi-
cally but also genetically, sporadic basal-like 
tumors are similar to hereditary BRCA1-mutated 
breast tumors, as has been shown by genome 
wide gene expression profiling (238). Chapter 6 
in this thesis shows that also a set of characteris-
tic cytogenetic changes in BRCA1-associated 
breast cancers can be found in sporadic basal-
like breast tumors. These microarray studies 
suggest that similar cancer promoting pathways 
may lead to the development of these two tumor 
groups (239). It is therefore hypothesized that 
sporadic breast cancer displaying genomic 
similarities with hereditary BRCA-mutated 
tumors, exhibit dysfunctional BRCA pathways 
and therefore deregulated homologous recombi-
nation. Tumors with homologous recombina-
tion deficiency (HRD) are highly sensitive to 
agents inducing DNA double strand breaks. 
Chapter 8 of this thesis will, among other 
subjects, discuss how prediction of BRCA-
association can assist in clinical care of sporadic 
breast cancer patients by demonstrating its 
predictive value for therapy response and 
survival. 
BRCAX 
 In many of the breast cancer families, no 
mutation is found in any of the known breast 
cancer susceptibility genes and so far, identifica-
tion of a third BRCA gene has been unsuccessful. 
It is therefore likely that the non-BRCA1/2 
breast tumors are a heterogeneous group 
consisting of a collection of low penetrance 
genes or a combination of common variants 
with multiplicative effects on breast cancer risk 
(114, 134-137). To be able to locate potential loci 
on which breast cancer susceptibility genes 
might be located, homogeneous groups have to 
be identified first; however, non-BRCA1/2 breast 
cancer families do not show any typical pheno-
types such as the BRCA1 or BRCA2 families do. 
Because it has been shown that BRCA1- and 
BRCA2-mutated breast tumors display distinc-
tive chromosomal aberrations (Chapter 4 & 5), 
it might be possible that tumors caused by other 
breast cancer susceptibility genes (i.e., BRCAX) 
could also display such characteristic profiles. 
Chapter 7 discusses the use of array CGH with 
the aim to describe more homogeneous groups 
in non-BRCA1/2 families, which could be 
applied for linkage studies in the future. 
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A multiplex PCR predictor for aCGH 
success of FFPE samples 
 
Erik H van Beers, Simon A Joosse, Marjolijn J Ligtenberg, Renske Fles, 
Frans BL Hogervorst, Senno Verhoef and Petra M Nederlof 
 
Formalin-fixed, paraffin-embedded (FFPE) tissue archives are the largest and longest time-spanning 
collections of patient material in pathology archives. Methods to disclose information with molecular 
techniques, such as array comparative genomic hybridization (aCGH) have rapidly developed but are 
still not optimal. Array comparative genomic hybridization is one efficient method for finding tumor 
suppressors and oncogenes in solid tumors, and also for classification of tumors. The fastest way of 
analyzing large numbers of tumors is through the use of archival tissue samples with first, the huge 
advantage of larger median follow-up time of patients studied and second, the advantage of being able 
to locate and analyze multiple tumors, even across generations, from related individuals (families). 
Unfortunately, DNA from archival tissues is not always suitable for molecular analysis due to insuffi-
cient quality. Until now, this quality remained undefined. We report the optimization of a genomic-
DNA isolation procedure from FFPE pathology archives in combination with a subsequent multiplex 
PCR-based quality-control that simply identified all samples refractory to further DNA-based analyses. 




 Cancer cytogenetics has benefited greatly 
from the introduction of comparative genomic 
hybridization (CGH) for mapping chromosomal 
gains and losses at a genome-wide scale (1, 2). 
Subsequent development of the technique into 
array-CGH (also named matrix-CGH) has 
allowed increased automation, improved 
reproducibility and precision due to more 
accurate mapping of aberrations. This technol-
ogy has been applied successfully to characterize 
congenital abnormalities at unprecedented 
precision (3) and to characterize and classify 
tumors (4, 5). 
 In most pathology laboratories, large ar-
chives of formalin-fixed, paraffin embedded 
(FFPE) material are often the only source of 
material for cancer research. It is our experience 
(5, 6) that a proportion of archival specimens 
appear unsuited for aCGH analysis, which is 
troublesome because array comparative genomic 
hybridization (aCGH) experiments are tedious 
and expensive. In the past, we have noticed that 
this was not solved by repeating aCGH experi-
ments, even when DNA was isolated from new 
sections from the same tissue blocks (6). Never-
theless, it is possible to obtain high-quality data 
using archival DNA samples in array CGH 
experiments (Figure 1) (1, 7-11), even from 20-
year-old tissue blocks, provided that robust 
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procedures, high-quality reagents and ‘good’ 
sample DNA quality are being used. A ‘good 
sample quality’ definition and an assay to 
determine this FFPE DNA sample quality would 
therefore be of great value. 
 Molecular biological assays, including aCGH 
on FFPE archival specimens, would be more 
efficient when good and bad quality samples 
were identified prior to aCGH assays, by a quick, 
cheap, simple and reliable assay. Variability, 
mostly in sample fixation (time), and also 
duration of storage affect DNA quality. Im-
provements in many pathology laboratories in 
sample handling, including shortening of the 
fixation duration to 24–48 hours and using 
buffered formalin may have contributed to the 
increased quality of tissue-extracted DNA (12). 
In an attempt to predict the success of aCGH 
hybridization, many laboratories have assessed 
DNA quality by DNA gel electrophoresis. 
Although such analyses provide information on 
the size, amount and distribution of the frag-
ment sizes of the (partially) degraded DNA, this 
did not correlate well with aCGH success in our 
hands. Our hypothesis is that apart from the 
fragment length, DNA crosslinks caused by 
fixation are of major importance for hybridiza-
tion results. We therefore focused on improve-
ment of the DNA isolation method to reduce 
DNA crosslinks, and on an assay to determine 
the abundance of DNA crosslinks as a measure 
of DNA quality. This prompted us to evaluate 
retrospectively our good and bad aCGH experi-
ments and devise a method that indicates DNA 
quality and aCGH success. This resulted in a 
modified DNA isolation method and a quality 
test using a multiplex-PCR assay for sample 
DNA quality control together with measurement 
of specific labeling of Cyanin cis-platinum-
labeled nucleotides in the test DNA. 
Materials and Methods 
DNA isolation 
 Genomic DNA was isolated from 10x 10 μm-
thick paraffin-embedded tissue sections. Sections 
were deparaffinated twice for 5 min in xylene, 
rehydrated in 100, 96 and 70% ethanol for 30 s 
each, stained with haematoxylin for 30 s, rinsed 
with water and incubated overnight in 1 M 
NaSCN at 37°C to remove crosslinks. Slides were 
rinsed twice 10 min in 1 x PBS at room tempera-
ture, and completely air-dried. Tumor tissue was 
scraped from the glass with a scalpel to obtain at 
least 70% tumor cells in 200 μl Qiagen ATL 
buffer (QIAamp DNA extraction kit cat. 
51306), transferred to eppendorf tubes and 
incubated with 27 μl proteinase-K (20 mg/ml 
stock) at 450 rpm (Eppendorf Thermomixer R) 
at 55°C. Three more aliquots of 27 μl proteinase-
K were added at 4, 20 and 28 h. After a total 
protK incubation of ~44 h, DNA isolation 
proceeded as in the manufacturer’s protocol 
(Qiagen, Cat. 51306). Samples of isolated 
genomic DNA were analyzed by 0.8% agarose 
gel electrophoresis to visualize DNA concentra-
tion and size distribution. In case of tumor 
tissue, we scraped regions containing at least 
70% tumor as indicated by an experienced breast 
cancer pathologist. aCGH reference DNA was 
isolated from peripheral blood lymphocytes 
from six apparently healthy female individuals. 
It was pooled and sonicated until its median 
fragment length was similar to that of the test 
samples. 
Multiplex PCR 
 We analyzed 100 ng as measured by optical 
density at 260/280 nm of each archival genomic 
DNA sample by a multiplex PCR. The PCR 
reaction was performed with four primer sets 
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that produce 100, 200, 300 and 400 bp fragments 
from non-overlapping target sites in the 
GAPDH gene (chr12) in 30 μl with final concen-
trations: 0.133 μM of each of the following eight 
5'–3' primers: 100F gttccaatatgattccaccc; 100R 
ctcctggaagatggtgatgg; 200F aggtggagcgaggctagc; 
200R ttttgcggtggaaatgtcct; 300F aggtggacattcttgc-
tgg; 300R tccactaaccagtcagcgtc; 400F acagtccat-
gccatcactgc and 400R gcttgacaaagtggtcgttg in a 
reaction with 10 mM Tris-HCl pH 8.8, 1.5 mM 
MgCl2, 75 mM KCl, 0.2 mM dNTPs, 1 U Taq 
DNApolymerase (Invitrogen cat. 18038-26). 
PCR was performed in thin-wall tubes in an MJ 
Research PCR apparatus for 4 min 94°C, 35 
cycles each of 1 min 94°C, 1 min 56°C and 3 min 
72°C, followed by 7 min 72°C ending at 51°C. 
After addition of 6 μl (5x) loading dye, 10 μl of 
each sample was analyzed on a 1.5% TBE 
agarose ethidium bromide-stained gel. Samples 
were classified based on the largest of four 
possible PCR products detected, namely 100, 
200, 300 and 400 bp. The GAPDH genomic 
target for amplification is more or less arbitrary 
but the lengths of the products were purposely 
chosen based on earlier experience with FFPE 
DNA amplification (MJL, unpublished results).  
Genomic DNA labeling 
 All labeling reactions were performed with 
the Cy3 and Cy5 conjugates from the Universal 
Linkage System (ULS, Kreatech Biotechnology, 
Amsterdam the Netherlands) (13). Labeling 
efficiency for ULS-Cy3 and ULS-Cy5 was 
calculated from A260 (DNA), A280 (protein), 
A550 (Cy3) and A649 (Cy5) after removal of 
unbound ULS, on a NanoDropsND-1000 
spectrophotometer (NanoDrop Technologies, 
Wilmington, DE, USA). The degree of labeling 
(DOL) was calculated from the specific molar 
extinction ratios for Cy3, Cy5 and DNA and 
must be between 1 and 4% (between 1 and 4 ULS 
molecules per 100 bp) for optimal hybridization 
signals. 
Array CGH 
 The human 3600 BAC/PAC genomic clone 
set, covering the full genome at 1 Mb spacing 
used for the production of our arrays, was 
obtained from the Welcome Trust Sanger 
Institute (http://www.sanger.ac.uk/). Informa-
tion on this clone set can be obtained at the 
BAC/PAC Resources Center Web Site 
(http://bacpac.chori.org). Degenerate oligonu-
cleotide PCR-products from all BAC clones were 
prepared for spotting on CodeLinkt Activated 
Slides (Amersham Biosciences, Prod. No. 300011 
00) according to detailed protocols (14) with 
some modifications (15). All clones (three 
replicates for each probe) were spotted in 
randomized fashion across 48 sub arrays, each 
containing 270 spots and hybridized for 48–72 h 
at 37°C on an orbital shaker (300 rpm) in a 
humidified chamber with 2 μg tumor-DNA 
labeled with ULS-Cy5 and 2 μg sonicated 
lymphocyte control DNA labeled with ULS-Cy3. 
After washing, arrays were scanned on a Mi-
croarray Scanner (G2505B Agilent Technolo-
gies), and spots quantified with ImaGene 
software (version 6.0.1 BioDiscovery, Marina 
Del Rey, CA, USA). Computation of the profiles 
included local background subtraction, Cy5/Cy3 
ratio, log2-transformation and sub array nor-
malization to its median. The log2-ratios for all 
non-flagged spots are then plotted (Figure 2D) 
along with the standard deviation for each 
triplicate as smaller dots (red) closer to the X-
axis using the secondary y-scale to the right. Bad 
morphology or uniformity spots were flagged in 
ImaGene. When flagged spots accounted for 
>5% of all spots, hybridizations were excluded. 
The BAC clones are ordered by position as 
assigned by NCBI-Build 35 (http://genome.ucsc. 
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edu/cgi-bin/hgGateway) in the genome begin-
ning at the telomere of 1p and ending at the 
telomere of Yq. 
Results and Discussion 
 In a systematic approach, we have identified 
and optimized the selection steps for FFPE 
archival material to be used in downstream 
applications, particularly for aCGH. 
Formalin-fixed, paraffin-
embedded archival tissue DNA 
quality 
 In the past, we have used size and size 
distribution of genomic DNA as a surrogate 
quality end point. The resulting aCGH profiles 
were sometimes inconsistent with the estimated 
sample quality. Figure 1A shows a typical series 
of 12 isolated genomic DNA samples from FFPE 
tissue sections. Each lane contains 5 μl (10%) of 
each isolate. The oldest sample was embedded 
and stored 26 years before DNA extraction (lane 
L). The amount of DNA is variable due to the 
variability in number of nuclei, and dependent 
on size of the tissue scraped. Furthermore, 
Figure 1A shows that genomic DNA from 
archival tissue is severely fragmented with an 
estimated median DNA fragment size often 
below 1 kb and varies substantially between 
samples (cf. lanes B vs J). In addition, we ob-
served variability in the size distribution (i.e., 
long vs short smear) between samples (cf. lanes B 
vs J). 
Multiplex PCR quality assay 
 An unknown fraction of these samples are 
refractory to molecular assays including aCGH. 
The challenge was to identify these samples 
before performing aCGH. We hypothesized that 
FFPE samples even after de-crosslinking may 
still contain DNA crosslinks that prevent specific 
hybridization and therefore render the sample 
useless for aCGH. We assumed that with 
increasing occurrence of DNA crosslinks, the 
400, 300, 200 and 100 bp PCR products would 
become less abundant or even disappear in that 
order. We thus used the relative amounts of the 
four possible PCR products as a reporter of DNA 
quality, and therefore suitability in aCGH. Our 
quality assay requires 100 ng genomic DNA of 
each sample in a single multiplex PCR reaction. 
Representative archival DNA preparations are 
shown in Figure 1. Two samples (e and l) failed 
to produce the 100 bp PCR fragment (Figure 1B) 
and were not successful in subsequent aCGH. 
Three samples (c, g, i) only produced the 100 bp 
fragment and each failed in aCGH. All seven 
samples with a PCR displaying fragments of 
200 bp or more were successful in aCGH. Then, 
 
 
Figure 1 - A total of 12 unselected DNA preparations from FFPE 
breast tumors with corresponding multiplex PCR quality 
controls. (A) DNA was isolated from archival blocks stored 
between 6 (lane b) and 29 (lane l) years. Lane M indicates the 
molecular size standard (bp). Sample a through l were fixed and 
stored 11, 6, 22, 20, 18, 11, 8, 7, 19, 17, 16 and 29 years ago, 
respectively. Lanes in bold a, b, d, f, h, j and k indicate samples 
with successful aCGH. The oldest samples in this panel successful 
in aCGH are in lanes d, k and j (20, 17 and 16 years). (B) 
Agarose gel showing multiplex PCR product sizes in bp (see 
Materials and Methods) for the corresponding samples above. 
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we tested DNA samples retrospectively for cases 
(N = 26) (Table 1) with known aCGH outcome. 
We found a good correlation between the ability 
to obtain PCR products and the quality of the 
aCGH experiment. There were 24 samples with 
PCR product and two without (Table 1). The 
two samples without PCR product as well as two 
out of three samples with the 100 bp PCR 
fragment only were not successful in aCGH (cf. 
Figure 2D lower panel). All samples with a 
200 bp or greater size PCR fragments resulted in 
successful aCGH profiles (cf. Figure 2D upper 
panel). Then, in a prognostic approach, we used 
the multiplex assay outcome to decide when to 
perform aCGH, that is, aCGH was only per-
formed if a sample had at least the 100 bp PCR 
fragment (83 of 93 samples). Only six of 37 
(16%) samples that had the 100 bp as largest 
PCR product resulted in good aCGH results. For 
the samples with 200 bp as the largest product, 
38 of 39 (97%) resulted in good aCGH profiles. 
All seven samples with 300 or 400 bp products 
were successful in subsequent aCGH. These 
results indicate that samples without a 100 bp 
fragment should not be used in aCGH and that 
DNA samples with amplification of the 200 bp 
fragment or larger seem to be of sufficient 
quality for aCGH analysis. 
aCGH profiles for FFPE breast 
tumor samples 
 Figure 2 illustrates our findings on aspects of 
DNA quality vs. aCGH success. All four upper 
panels represent a good quality archival DNA 
sample, whereas the four lower panels represent 
a poor quality archival DNA sample. Both 
panels A show the amount and fragment size 
distribution for these samples after isolation 
without further restriction digestion. Even 
though the DNA fragments from the lower 
sample are somewhat smaller, both DNA 
samples theoretically consist of appropriately 
sized fragments for aCGH. Both panels B show 
 
 
Figure 2 - aCGH success is determined by the ability to PCR-amplify fragments of > 100 bp from the sample (FFPE) DNA template. 
(A) 0.8% agarose gel electrophoresis shows amount, size and smear-lengths of sample DNA isolated from FFPE tumor tissues. (B) 
Multiplex-PCR reveals whether a 100, 200, 300 or 400 bp fragment are amplified from 100 ng total genomic DNA. (C) Representative 
partial images of array CGH hybridizations. Array CGH was performed on 3500, DOP-amplified BAC-DNA microarrays (see 
Materials and Methods) printed on Codelink® slides. (D) Gain and loss profiles were plotted where the ordinate represents the log2 
ratio for the mean of triplicates for each BAC, and abscissa the mapping on the genome (from chromosome 1 to Y, left to right). In red, 
the standard deviation of the triplicate measurements is plotted to a secondary Y-axis on the right. 
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the result of multiplex quality control PCR using 
100 ng of input DNA. It is here, and only here, 
that we detect the crucial difference between 
good and bad samples, defined as a minimum of 
200 bp amplifiable target sequence. Both pan-
els C show the resulting hybridization and are 
highly similar in quality (area shown is not the 
same for both arrays). Finally, panels D show 
gains (positive log ratios) and losses (negative 
log ratios) of (parts of) chromosomal material in 
the breast tumors. The upper panel shows a 
successful aCGH experiment whereas the lower 
panel represents a ‘noisy’ and therefore useless 
aCGH. Each black dot of the profile represents 
the mean of three replicates on the same array 
(triplicate) and the standard deviation of the 
replicate is plotted below to a secondary Y-scale 
on the right. Most standard deviations are well 
below 0.2 and many below 0.1, which indicate 
very reproducible hybridizations for the good 
but notably also for the bad DNA sample. The 
decisive difference between good and bad 
samples that can be easily scored is the presence 
of the 200 bp multiplex PCR fragment. 
DNA quality from three 
pathology archives across three 
decades 
 With our DNA isolation protocol, we were 
able to obtain high-quality DNA from the 
majority of samples from different pathology 
archival paraffin blocks as old as 25 years. An 
independent estimation of DNA quality in FFPE 
samples that almost entirely consisted of samples 
from our own institute was calculated using a 
different PCR, in this case generating a 157 bp 
fragment on 1345 samples, 1264 (94%) of which 
were positive in this PCR. We found no evidence 
for different success rates of the 157 bp PCR 
using samples fixed during the last 25 years 
studied, whereas DNA from samples fixed before 
1970 was often problematic defined by the 
failure to produce the 157 bp PCR fragment 
(results not shown). There were 202 of 246 
(82%) positive PCR reactions in samples fixed 
between 1970 and 1980, 666 of 682 (97%) 
samples fixed between 1980 and 1990, and 397 of 
418 (95%) fixed after 1990 (M Schmidt, 
NKI/AvL personal communication). There 
appeared to be a surprisingly large difference 
between the archives that we sampled. We then 
compared the multiplex PCR quality assessment 
across three FFPE breast cancer sample series 
mentioned in this study, that is, 26 retrospective 
Table 1 - Correlation between PCR result and subsequent 
successful array comparative genomic hybridization (aCGH) 
 
(A) Retrospective correlation of 26 breast tumor formalin-
fixed, paraffin-embedded (FFPE) DNA samples aCGH success 










400 bp 100 11 0 11 
300 bp 100 8 0 8 
200 bp 100 2 0 2 
100 bp 33 1 2 3 
No product 0 0 2 2 
     
Totals  22 4 26 
 
(B) Prospective correlation of 93 breast tumor FFPE DNA 












400 bp  100 2 0 2 
300 bp 100 5 0 5 
200 bp 97 38 1 39 
100 bp 16 6 31 37 
No product ND — — 10 
     
Totals  51 32 93 
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samples, 93 prospective samples and, the 
independent study of 1345 breast cancer samples 
for which PCR success rates were 85, 55 and 
94%, respectively. Although, the latter percent-
age (94%) in this comparison is undoubtedly an 
overestimation due to the fact that it is only 
analyzed for production of a 157 bp fragment 
compared to 200 bp fragment in the other two 
series, it seems that no a priori success rate can 
be assumed when different archives are being 
sampled. 
DpnII digestion or not? 
 Array CGH requires that high molecular 
weight genomic DNA is fragmented to an 
appropriate fragment size (e.g., by sonication or 
restriction digestion). Fragmentation can be 
omitted for aCGH when DNA is isolated from 
FFPE archival material since it is already frag-
mented. We compared array CGH using archival 
DNA with and without prior DpnII restriction 
and found similar results (data not shown). As 
expected, DNA gel electrophoresis of archival 
DNA samples clearly showed the typically 
fragmented DNA for FFPE samples (Figure 1) 
explaining why restriction digestion is unneces-
sary on such samples. 
Conclusion 
Since concentration and size distribution (as 
assessed by ethidium bromide agarose gel 
electrophoresis) of genomic DNA isolated from 
FFPE tissue are inadequate predictors per se for 
aCGH success, we have developed a method for 
DNA isolation from FFPE tissue with a subse-
quent simple and reliable multiplex PCR proto-
col that predicted successful aCGH with high 
accuracy. Of our archival samples, 11% (12 out 
of 107) proved unsuitable for any of the four 
PCR products and were refractory to aCGH 
analysis. Furthermore, when genomic DNA was 
re-isolated from adjacent serial sections of those 
paraffin tissue blocks that failed the multiplex 
PCR test and aCGH, both multiplex PCR and 
aCGH results remained unchanged indicating 
that DNA suitability for aCGH seems intrinsic to 
the embedded tissue and is probably related to 
tissue treatment and duration of storage. Finally, 
the 157 bp product PCR was used to assess the 
quality of a much larger set of 1345 DNA 
samples isolated from three independent 
pathology archives from samples fixed between 
1970 and present. This series was positive for the 
157 bp PCR in 94% of the cases, suggesting that 
aCGH should be widely applicable to archival 
samples when isolated and selected as indicated 
above. 
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Automated array-CGH optimized for 
archival formalin-fixed, paraffin-embedded 
tumor material 
Simon A Joosse, Erik H van Beers and Petra M Nederlof 
Array Comparative Genomic Hybridization (aCGH) is a rapidly evolving technology that still lacks 
complete standardization. Yet, it is of great importance to obtain robust and reproducible data to enable 
meaningful multiple hybridization comparisons. Special difficulties arise when aCGH is performed on 
archival formalin-fixed, paraffin-embedded (FFPE) tissue due to its variable DNA quality. Recently, we 
have developed an effective DNA quality test that predicts suitability of archival samples for BAC 
aCGH. In this report, we first used DNA from a cancer cell line (SKBR3) to optimize the aCGH protocol 
for automated hybridization, and subsequently optimized and validated the procedure for FFPE breast 
cancer samples. We aimed for highest throughput, accuracy, and reproducibility applicable to FFPE 
samples, which can also be important in future diagnostic use. Our protocol of automated array-CGH 
on archival FFPE ULS-labeled DNA showed very similar results compared with published data and our 
previous manual hybridization method. This report combines automated aCGH on unamplified 
archival FFPE DNA using non-enzymatic ULS labeling, and describes an optimized protocol for this 
combination resulting in improved quality and reproducibility. 
BMC Cancer. 2007 Mar 7;7:43. © Joosse et al; 
Background 
 Array CGH has become a successful and 
valuable tool for the analysis of chromosome 
copy-number alterations including the detection 
of sub-megabase alterations and has been 
applied to e.g., cell lines, (tumor) tissues, and 
lymphocytes (1-5). The power of aCGH technol-
ogy to detect low-level copy number changes is 
critically dependent on DNA quality (e.g., DNA 
fragmentation and cross-links) and sample 
heterogeneity. Therefore, selection of DNA of 
sufficient quality, especially when using FFPE 
material, is of great importance for aCGH (6). 
Furthermore, whole genome amplification may 
be performed when insufficient DNA is available 
from a sample (7-9). In addition to sample 
quality, enzymatic labeling protocols decrease 
average DNA size further which results in 
increased noise due to non-specific binding (10), 
especially when the average PCR length of the 
sample template drops below 200 bp (6). As an 
alternative, chemical labeling protocols with 
cyanin cis-platinum-labeled DNA resulted in 
good aCGH results (11), also for FFPE archival 
samples (6). One of the challenges of aCGH is its 
lower hybridization signal-intensity compared 
with metaphase-CGH. Based on literature and 
our previous experiments we hypothesized that 
the hybridization improves with increasing 
effective concentration of labeled DNA, which is 
limited by the viscosity of the hybridization 
mixture, as well as by the duration and tempera-
ture of the hybridization. In this study we 
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performed in total 70 aCGH hybridizations 
across these parameters and report how these 
impact on the CGH profile quality. We first used 
SKBR3 DNA to explore hybridization variables 
that are important for aCGH and then show how 
this expertise can be applied to FFPE primary 
human tumors. 
 There have been earlier reports on array 
CGH of FFPE material (6-8, 12-14) and other 
reports on automated hybridization (15). This 
report however, is the first that combines 
automated hybridization of FFPE tumor mate-
rial on a BAC array, using non-enzymatic 
labeling and provides a method without forma-
mide in the post-hybridization washes. 
Methods 
 DNA was isolated from the breast cancer cell 
line SKBR3 (obtained from ATCC) or from 
FFPE tumor tissue with at least 70% tumor cells 
as described before (6). Two micrograms of total 
genomic DNA were labeled with ULS-Cy5 
according to the manufacturer's instructions 
(Kreatech Biotechnology, Amsterdam). Refer-
ence DNA was isolated from lymphocytes of six 
apparently healthy women, pooled, and soni-
cated as was done with the SKBR3 genomic 
DNA to obtain fragments of similar size distri-
bution as DNA from FFPE material (approxi-
mately 300-800 bp). Two micrograms of pooled 
reference DNA were labeled with ULS-Cy3. 
Corning CodeLink® slides containing the human 
3.5k BAC/PAC genomic clone set in triplicate 
were used as before (6). As optimization target, 
we used CGH profiles of six FFPE tumors 
containing at least 70% tumor cells and the 
SKBR3 cell line profile, obtained by the manual 
hybridization method described before (6). 
Automated hybridizations were done in 
63.5 x 21 mm chambers in a Tecan HS4800 
hybridization station, which uses liquid agitation 
during hybridization. Experiments involving 
human tissues were conducted with permission 
of our institute's medical ethical advisory board. 
Optimal (pre-)hybridization 
mixture 
 Labeled sample and reference DNA were 
pooled with 125 μg C0t-1 DNA (Roche, 1581-
074) and precipitated. The pellet was dissolved 
in 140 μl 0.22 μm filtered hybridization buffer 
(50% formamide, 15% dextran sulphate (USB 
14489, Mw 40-50 kDa), 0.1% Tween20, 2 x SSC, 
10 mM Tris pH 7.4, and 25 mM EDTA) and 
10 μl (100 μg/μl) yeast tRNA (Sigma, R-8759). 
The pre-hybridization solution consisted of 
400 μg single stranded sheared herring sperm 
DNA (Sigma, D7290) and 125 μg C0t-1 DNA 
dissolved in 150 μl hybridization buffer. Both 
hybridization and pre-hybridization mixtures 
were dissolved at 37°C continuously shaking at 
650 rpm (Eppendorf Thermomixer) for at least 
one hour, denatured for 10 min at 95°C and 
spun for 1 min at 14000 rpm (Eppendorf 
centrifuge) to pellet potential particles prior to 
injecting 120 μl pre-hybridization mixture 




 Optimal hybridization parameters for the 
hybridization station: step 1; wet the array with 
2 x SSC for 30 s at 37°C, no soak. Step 2; 120 μl 
pre-hybridization solution was slowly injected 
and incubated for 1 hour at 37°C, agitation set at 
‘high’. Step 3; 15 s wash at 37°C with 2 x SSC, no 
soak. Step 4; 120 μl sample mixture was injected 
and hybridized for 72 hours at 37°C, agitation set 
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at ‘high’. Step 5; 12 x (1 min wash, 1 min soak) 
with 2 x SSC + 0.1% SDS at 37°C. Step 6; 6 x 
(1 min wash + 1 min soak) with 2 x SSC + 0.1% 
SDS at 68°C. Step 7; 2 x (1.5 min wash + 1 min 
soak) with 2 x SSC at 68°C. Step 8; 1.5 min wash 
with 0.1 x SSC at 23°C, no soak. Step 9; 2 min 
with nitrogen gas at 23°C. Slides were scanned 
with an Agilent DNA Microarray Scanner BA on 
the same day. Data processing included signal 
intensity measurement in ImaGene Software 
followed by median pintip (c.q. subarray) 
normalization and plotting in custom Matlab 
code as before (6).  
Data analysis 
 Three statistics were used to determine the 
quality of the hybridization, the CGH profile, 
and to compare experiments with each other. 
For each CGH profile, we calculated the variance 
across all log2 ratios relative to the ratios of the 
underlying true ploidy levels as estimated by 
CGH-segmentation (16), secondly, we defined 
the dynamic range as the difference between the 
minimum log2 ratio and the maximum log2 
ratio calculated by CGH-segmentation (16), and 
the average of all the standard deviations of the 
triplicate spot measurements of each probe was 
used as a third statistic. Thus, an optimal CGH 
profile has a low variance to give a better esti-
mate of the copy number level, a high dynamic 
range to give the best resolution of copy num-
bers and a low average standard deviation for 
reproducibility. 
GEO 
 Microarray data have been deposited in 
NCBIs Gene Expression Omnibus and are 
accessible through GEO Series accession number 
GSE7122. 
Results and Discussion 
Optimization of aCGH on a 
hybridization station 
 Further automation of CGH is indispensable 
to meet the demand for higher quality, higher 
throughput, and improved reproducibility. We 
here describe automated and reproducible array-
CGH on FFPE material. As optimization goals 
we aimed to reproduce results from manual 
hybridizations and published results, to mini-
mize the variance, to maximize dynamic range, 
to minimize standard deviation of the triplicate 
spot measurements, and to maximize signal-to-
noise.  
It is difficult to determine the quality of aCGH 
profiles without an independent methodology to 
verify gains and losses. Therefore, we chose to 
use the widely studied cell line SKBR3 as a model 
for which chromosomal aberrations have been 
well documented (2, 3, 17), although the exis-
tence of minor sub-clone related alterations 
cannot be ruled out. In a previous study (6), we 
performed manual hybridizations of over one 
hundred BAC arrays that helped us to develop 
the quality criteria that were now used to 
optimize automated hybridization. In this study 
we describe multiple hybridizations that were 
performed in synchronous pairs with one 
variable tested in each run, including hybridiza-
tion duration of 24, 48, or 72 hours, hybridiza-
tion temperature of 37, 42 or 45°C, pre- and 
post-hybridization wash temperatures of 37, 42, 
45, 46, 65 or 68°C, viscosity of the hybridization 
mixture with 7, 10, 15, 17.5, or 20% dextran 
sulphate of 5, 10, or 50 kDa average molecular 
weight, pH 6, 7 or 8 of the hybridization mixture 
and with or without pre-hybridization. All 
hybridization parameters studied are relevant to 
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nucleic acid hybridization in general, and here 
optimized for the 3.5k BAC arrayCGH platform 
and may thus be different for other platforms. 
Hybridizations were done with genomic DNA 
isolated from the well-described SKBR3 cells or 
from FFPE breast tumor archival sections to 
optimize and validate the protocol. 
 
Optimal conditions for 
automated hybridization 
 Using 2 μg unamplified sample DNA from 
FFPE tissue and 2 μg reference DNA both 
CyDye labeled, incubation duration was optimal 
at 72 hours at 37°C after pre-hybridization with 
a mixture of herring sperm and C0t-1 DNA for 
1 hour at 37°C. The optimal hybridization buffer 
contained 15% 50 kDa dextran sulphate. Wash-
ing was performed as described in Material and 
Methods. The steps that led to this protocol are 
described in detail below. 
 
Figure 1 - SKBR3 CGH profiles obtained by various methods. 
Chromosomes  1 to X  (X-axis, alternate shading per chromo-
some) versus the log2 ratios (Y-axis) for the breast cancer cell 
line SKBR3, hybridized by Pollack et al. (PNAS 1999) on a 6.7k 
cDNA micro array, redrawn form values available on-line (A), 
hybridized by Shadeo and Lam (Breast Cancer Res 2006) on a 
whole-genome tiling path BAC array containing 32,433 
overlapping BAC-derived DNA segments (B), hybridized by 
Jong et al. (Oncogene 2006) to a human oligonucleotide array 
containing 28,830 unique genes (C), manually hybridized to a 
3.5k BAC/PAC array (D), and hybridized using our optimal 
automated method (E). Formalin-fixed paraffin-embedded 
SKBR3 cell line hybridized using our automated method (F). 
Red lines in panel A-F represent the breakpoint locations and 
copy number chances calculated by CGH-segmentation (BMC 
Bioinformatics 2005). Panel G contains all segmentation calls of 
the profiles depicted in panel A-F:  Pollack et al.,  Jong et al., 
 Shadeo et al.,  Manual hybridization,  Automated 
hybridization,  FFPE material. 
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Optimization model SKBR3 cell 
line 
 We used SKBR3 as a model cell line and 
compared its CGH profile with published (2, 3, 
17) and our own manual hybridizations. Fig-
ure 1A represents the SKBR3 CGH profile 
published by Pollack et al., hybridized to a 
human cDNA micro array containing 6,691 
different mapped human genes (2). Figure 1B 
represents the SKBR3 CGH profile published by 
Shadeo and Lam, hybridized to a whole-genome 
tiling path BAC array containing 32,433 over-
lapping BAC-derived DNA segments (3). 
Figure 1C represents the SKBR3 CGH profile 
published by Jong et al., hybridized to a human 
oligonucleotide array containing 28,830 unique 
genes (17). Figure 1D represents our manually 
hybridized SKBR3 CGH profile. Depicted in 
figure 1E is the very similar SKBR3 CGH profile 
hybridized with our optimal protocol for the 
hybridization station except for the slightly 
different variance and dynamic range. Figure 1F 
depicts the CGH profile of paraffin embedded 
SKBR3 (discussed later). To compare these data 
from different platforms and different methods 
we looked at the breakpoint locations and copy 
number estimates as is illustrated in figure 1G. 
This figure summarizes all the breakpoints and 
estimated copy number levels as plotted in red in 
figure 1A-1F calculated by CGH-segmentation 
(16). Breakpoint locations and calling of copy 
number levels (gain, unchanged, heterozygous 
loss, and homozygous loss) are provided as 
Table 1: Manual and automated hybridization of SKBR3
 
Sample Hyb method Variance StDev DR Correlation 
SKBR3 manual 0.13 0.05 3.7  
SKBR3 automated 0.11 0.04 3.9 
SKBR3 automated 0.11 0.07 3.7 
0.85 
FFPE SKBR3 automated 0.12 0.05 3.2 0.87 
 
Variance (Variance), standard deviation (StDev), dynamic range (DR) and Pearson correlation (Correlation) of SKBR3 performed 
using our manual and our automated hybridization method (Hyb method). 
 
 
Figure 2 - CGH profiles of manual and three automated methods 
Chromosome 7 (X-axis), versus the log2 ratios (Y-axis) for the breast cancer cell line SKBR3 (alternate shading for aberration 
legibility); manual hybridization (A, detail from figure 1D); 24 hours automated hybridization (B); 72 hours automated hybridization 
(C); 72 hours automated hybridization using 15% 50 kDa Dextran Sulphate (D). With increasing hybridization duration from 24 to 
72 hours, the CGH profile was more similar to the manual hybridization CGH profile. The aberration in panel C is detected in 
contrast to panel B (grey), even better with an increased concentration of dextran sulphate from 7 to 15% (D). Red lines in all panel 
represents the segmentation calls as calculated by CGH-segmentation. 
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Additional File 1 and 2. Although a lower 
density 3.5k BAC array was used, figure 1G 
illustrates that nearly all aberrations and break-
point in our results (figure 1D and 1E) are 
similar to the three published data sets (2, 3, 17). 
We concluded that the dynamic ranges of both 
our manual and automated hybridization 
protocols are adequate to detect single copy 
number losses and gains. Reproducibility of this 
automated protocol is shown by replicate 
hybridizations with a Pearson correlation of 
0.85, dynamic ranges of 3.7 versus 3.9, the 
variances for both experiments 0.11, and the 
mean standard deviations of 0.07 versus 0.04 
(table 1). 
Hybridization duration and 
temperature 
 The effects of hybridization duration and 
temperature were measured in two experiments 
using SKBR3 DNA and reference DNA hybrid-
ized for 24 or 48 hours at 37°C. Hybridization 
mixture containing 7% 50 kDa dextran sulphate 
was used. Figure 2A shows the CGH profile for 
SKBR3 chromosome 7 (detail from figure 1B, 
chosen for its clear and multiple aberrations), 
hybridized according to our manual method. 
Figure 2B shows the CGH profile after 24 hours 
of automated hybridization at 37°C. After 
24 hours, no aberrations were detected in this 
CGH profile. After 48 hours only large copy 
number changes were found and the small 
deletions and amplifications were not (data not 
shown). Also, the dynamic range was small (log2 
ratios from –1.0 to 2.2) compared with our 
manual method (from –1.0 to 2.7). CGH profiles 
after 24 and 48 hours were inferior to our 
manual method, this is likely due to lower 
specific signals. To improve this, the hybridiza-
tion duration was increased to 72 hours and 
performed at 37, 42 or 45°C. At all three tem-
peratures, the CGH profiles were approaching 
the quality of the manual hybridization. Fig-
ure 2C shows the result of 37°C, as can be seen it 
Table 2: Hybridization duration and temperature 
 
Sample Duration Temp. Variance StDev DR 
SKBR3 24h 37°C 0.13 0.11 1.9 
SKBR3 48h 37°C 0.12 0.06 3.1 
SKBR3 72h 37°C 0.07 0.03 3.1 
SKBR3 72h 42°C 0.11 0.05 3.6 
SKBR3 72h 45°C 0.13 0.11 3.7 
 
Variance (Variance), standard deviation (StDev) and dynamic 
range (DR) of the hybridization of SKBR3 under the conditions 
of different hybridization duration (Duration) and temperature 
(Temp.). 
Table 3: Hybridization temperature and dextran sulphate concentration
 
DS 
Sample Duration Temp. 
conc. Mw. 
Variance StDev DR 
SKBR3 72h 37°C 10% 50kDa 0.11 0.06 3.5 
SKBR3 72h 37°C 15% 50kDa 0.11 0.07 3.7 
SKBR3 72h 42°C 10% 50kDa 0.14 0.10 3.8 
SKBR3 72h 42°C 15% 50kDa 0.12 0.09 3.8 
 
Variance (Variance), standard deviation (StDev) and dynamic range (DR) for testing the effects of different dextran sulphate concentra-
tions (DS conc.) and temperature (Temp.) at hybridization duration (Duration) of 72 hours, hybridizing SKBR3. 
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is quite similar to the manual hybridization 
(figure 2A). However, the variances and stan-
dard deviations of the triplicate spot measure-
ments increased with hybridization temperature. 
Mean standard deviations were 0.03, 0.05 and 
0.11 at 37, 42 and 45°C respectively. Although 
45°C seemed to provide the highest dynamic-
range (from -1.1 to 2.6), it was accompanied by 
the highest noise levels after 72 hours (p < 
0.00001). The variances were 0.07, 0.11 and 0.13 
for 37, 42 and 45°C respectively (table 2). 45°C 
was therefore excluded from further testing and 
37 and 42°C were used to optimize dynamic 
range in the following experiments. 
Hybridization buffer 
composition 
 A major further improvement of the hy-
bridization was obtained by increasing the 
50 kDa dextran sulphate concentration from 7 to 
15%. Here we describe our results for 10 and 
15%. Four hybridizations were done at 37 and 
42°C each with 10 or 15% dextran sulphate. The 
resulting profiles were very similar to each other 
and to our manually hybridized aCGH. A slight 
systematic difference was detected in the vari-
ance, standard deviation of the triplicates and 
dynamic range. Hybridizing at 37°C, standard 
deviations were 0.06 and 0.07 at 10 and 15% 
dextran sulphate, respectively, and at both 
concentrations the variances were 0.11. At 42°C, 
both the variances increased to 0.14 and 0.12 and 
the mean standard deviations to 0.10 and 0.09 at 
10 and 15% dextran sulphate, respectively (table 
3). Of these four hybridizations, the best profile 
is shown in figure 2D, this is at 37°C using 15% 
dextran sulphate. In this experiment, the dy-
namic range was 3.7 (from –1.0 to 2.7). We 
chose not to hybridize at 42°C anymore because 
of the significant higher variance and standard 
deviation as a result (p < 0.00001). We chose to 
use 15% dextran sulphate in further experiments 
at 37°C because of its low variance and standard 
Table 4: Dextran sulphate concentration
 
DS 
Sample Duration Temp. 
conc. Mw. 
Variance StDev DR 
SKBR3 72h 37°C 15% 5kDa 0.10 0.04 3.2 
SKBR3 72h 37°C 17.5% 5kDa 0.10 0.05 3.7 
SKBR3 72h 37°C 20% 5kDa 0.10 0.05 3.4 
SKBR3 72h 37°C 15% 10kDa 0.11 0.04 3.7 
SKBR3 72h 37°C 17.5% 10kDa 0.11 0.04 3.6 
SKBR3 72h 37°C 20% 10kDa 0.11 0.03 3.6 
SKBR3 72h 37°C 15% 50kDa 0.11 0.04 3.9 
SKBR3 72h 37°C 17.5% 50kDa 0.11 0.04 3.7 
SKBR3 72h 37°C 20% 50kDa 0.09 0.03 3.4 
 
Variance (Variance), standard deviation (StDev) and dynamic range (DR) for testing the effects of different dextran sulphate 
concentrations (DS conc.) and molecular weights (DS Mw.), and temperature (Temp.) at a hybridization duration (Duration) of 
72 hours, hybridizing SKBR3. 
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deviation and its higher dynamic range com-
pared to using 10% dextran sulphate. 
 Increasing the concentration of 50 kDa 
dextran sulphate from 15% to 17.5 or 20% did 
not further improve the array results. At these 
concentrations the variance was 0.11 and 0.09 at 
17.5 and 20% dextran sulphate respectively, 
notably at 20% dextran sulphate the dynamic 
range decreased below 3.5. Elevated concentra-
tions of dextran sulphate render the hybridiza-
tion mixture viscosity beyond the mixing 
capability of the hybridization station. This 
prompted us to evaluate the effect of lower 
molecular weight dextran sulphate (i.e., lower 
viscosity at the same concentration). We used 
5 kDa (Sigma) and 10 kDa (pK Chemicals, 
Denmark) dextran sulphate at 15, 17.5 or 20% 
for SKBR3 profiling. All six hybridizations 
showed inferior dynamic ranges compared with 
the 50 kDa dextran sulphate experiments, shown 
in table 4. Therefore, 50 kDa dextran sulphate at 
a concentration of 15% was used in all subse-
quent hybridizations. 
Post-hybridization washes 
 Most wash protocols use large amounts of 
formamide to wash off non-specifically bound 
probe. Formamide is a toxic that we wished to 
exclude from all washes. The wash procedure 
now consists of: step 5; 12 x (1 min wash, 1 min 
soak) with 2 x SSC + 0.1% SDS at the hybridiza-
tion temperature of 37, 42 or 45°C  (previously 
discussed), step 6; 6 x (1 min wash, 1 min soak) 
with 2 x SSC + 0.1% SDS at 37, 46 or 65°C, step 
7; 2 x (1.5 min wash, 1 min soak) with 2 x SSC at 
37, 46 or 65°C, step 8; 15 sec wash with 0.1 x SSC 
at 23°C, step 9; dry slides for 2 minutes with 
nitrogen gas at 23°C. 
 As described before, hybridization was 
performed at 37, 42 or 45°C. Step 5 was done at 
these temperatures and results are discussed 
above. Step 6 and 7 were done at 37 or 46°C, 
both resulting in inferior profiles compared with 
the manual hybridization. A large proportion of 
the deletions and amplifications in the CGH 
profile could not be detected and the data were 
essentially as in figure 2B. Increasing the tem-
Table 5: pH of the hybridization buffer
 
Sample Hyb pH Variance StDev DR Max CGHseg Correlation 
FFPE tumor 2 6 0.07 0.04 1.4 0.6 
FFPE tumor 2 6 0.08 0.04 1.6 0.7 
0.98 
FFPE tumor 2 7 0.09 0.04 1.5 0.7 
FFPE tumor 2 7 0.08 0.05 1.2 0.6 
0.97 
FFPE tumor 2 8 0.08 0.04 1.3 0.6 
FFPE tumor 2 8 0.10 0.05 1.7 0.8 
0.94 
 
Variance (Variance), standard deviation (StDev), dynamic range (DR), the highest log2 ratio calculated by CGH-segmentation 
(Max CGHseg), and Pearson Correlation (Correlation) for testing the effects of pH (Hyb pH) of the hybridization buffer on a CGH 
profile of FFPE tumor #2. The log2 ratios associated with homozygous deletions vary widely since they depend heavily on dividing 
very small intensities by large intensities. This can have disproportionate impact on the dynamic ranges, therefore only the highest 
ratio is taken as a measurement for the dynamic range (Max CGHseg). 
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peratures of steps 6 and 7 to 65°C resulted in 
good CGH profiles. We concluded that 37°C is 
the optimum temperature for step 5 and 65°C 
for steps 6 and 7 when hybridizing a cell line. 
FFPE tumor tissue optimization 
and validation 
 To develop aCGH also as a diagnostic tool, it 
will be essential to validate its applicability on 
patient tumor samples and especially on archival 
FFPE tissue (18). Extracted DNA from this 
material is often heavily cross-linked, heteroge-
neous (i.e. mix of cells of different genomic 
composition), fragmented, and rarely composed 
of 100% tumor cells. Therefore, aCGH profiles of 
FFPE material generally have larger variances 
(defined as the spread around the common levels 
between adjacent chromosome breakpoints), 
lower intensities and lower dynamic range 
compared with hybridizations of cell line DNA. 
 To validate our automated hybridization 
method for FFPE material we compared CGH 
profiles from unfixed and formalin fixed paraffin 
embedded SKBR3 cells. Figure 1E shows the 
CGH profile of the formalin fixed SKBR cell line. 
The fresh and FFPE SKBR3 CGH profiles were 
highly similar and showed a Pearson correlation 
of 0.87 (table 1). Variances were 0.11 and 0.12, 
dynamic ranges 3.9 and 3.2, and mean standard 
deviations 0.04 and 0.05, for fresh and fixed 
DNA, respectively. However, the DNA quality 
from a paraffin embedded cell line does not 
necessarily represent the quality of DNA from 
archival tumor tissue that can be more than 25 
years old and fixed under widely varying condi-
tions. 
 Therefore, we validated our method on 
archival material. The first hybridization was 
done with tumor #1 DNA with or without pre-
hybridization after the first wash step (step 1: 
wetting or chamber filling), for 1 hour at 37°C. 
The pre-hybridization mixture consisted of 
400 μg single stranded sheared herring sperm 
DNA and 125 μg C0t-1 DNA dissolved in 150 μl 
hybridization buffer. With pre-hybridization, 
signal intensities were almost 50% higher and 
the mean standard deviation of the triplicate 
spots 15% lower compared to the protocol 
without pre-hybridization resulting in good 
CGH profiles of FFPE material (data not 
shown). Although CGH profiles of SKBR3 did 
not improve upon adding pre-hybridization, it 
clearly benefited CGH profiles of DNA extracted 
from FFPE patient tissue (data not shown). 
 Because Tris is the only buffering compo-
nent in the hybridization mixture, we wished to 
test the possibility that the formamide could 
 
Figure 3 - CGH profiles of one FFPE tumor with post 
hybridization wash at different temperatures. 
CGH profiles with post-hybridization wash steps 6 and 7 at 
65°C (A) or at 68°C (B) of averaged duplicates of one FFPE 
primary breast tumor, hybridized according to our optimized 
protocol for automated array-CGH. Chromosomes (X-axis, 
alternate shading per chromosome) versus the log2 ratios (Y-
axis). At 68°C, dynamic range increased and standard 
deviation of the triplicate spot measurements decreased 
compared with 65°C, therefore 68°C was used in our optimal 
protocol. As can be seen in panel B, the dynamic range and the 
signal-to-noise are adequate to detect and to distinguish 
homozygous and heterozygous loss (chromosome 11p), one 
single-copy number gain (e.g., chromosome 7p), multiple-copy 
numbers gain (chromosome 1q), and unchanged chromosome 
copy numbers (e.g., chromosome 10). Red lines in both panel 
represents the segmentation calls as calculated by CGH-
segmentation. 
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react with oxygen and may influence the buffer’s 
pH during storage. To test the effect of pH on 
the hybridization, six hybridizations with FFPE 
tumor #2 DNA were done, using hybridization 
buffers of pH 6, 7 and 8, as measured in the final 
hybridization buffer. At every pH the CGH 
profile was very similar and highly reproducible. 
As can be seen in table 5, standard deviations of 
the triplicate spot measurements in all six 
hybridizations were very similar. The variances 
are lowest at pH 6 but not very different from 
the variances at pH 7 and 8. For this particular 
tumor, the maximal CGH-segmentation (16) 
value was used as dynamic range (“Max 
CGHseg”, table 5), because the homozygous loss 
on chromosome 11 would have a dispropor-
tional contribution to its value (same tumor as in 
figure 3). These were very similar between 
experiments. Pearson correlation between the 
duplicates shows high correlations for all 
experiments. Therefore, we conclude that aCGH 
is not very sensitive to pH of the buffer between 
pH 6 and 8. 
 Subsequent experiments compared post-
hybridization washing at 65°C or 68°C (step 6 
and 7) both in duplicate on FFPE extracted 
material tumor #2. Figure 3A depicts the average 
profile of two hybridizations washed at 65°C, 
panel B shows the average CGH profile washed 
at 68°C, at both temperatures the CGH profiles 
Table 6: Wash temperature
 
Sample Wash Variance StDev DR Max CGHseg Correlation 
FFPE tumor 2 65°C 0.09 0.04 1.5 0.7 
FFPE tumor 2 65°C 0.08 0.05 1.2 0.6 
0.97 
FFPE tumor 2 68°C 0.09 0.03 1.6 0.7 
FFPE tumor 2 68°C 0.09 0.03 1.7 0.7 
0.99 
 
Variance (Variance), standard deviation (StDev), dynamic range (DR), the highest log2 ratio calculated by CGH-segmentation (Max 
CGHseg), and Pearson correlation (Correlation) of FFPE tumor #2 washed after hybridization at 65°C and 68°C (Wash) in replicate. 
Table 7: Manual and automated hybridization of FFPE tumors
 
Sample Hyb method Variance StDev DR Correlation 
FFPE tumor 3 manual 0.11 0.06 2.0 
FFPE tumor 3 automated 0.10 0.04 1.9 
0.82 
FFPE tumor 4 manual 0.10 0.05 1.4 
FFPE tumor 4 automated 0.08 0.03 1.3 
0.72 
FFPE tumor 5 manual 0.10 0.04 1.5 
FFPE tumor 5 automated 0.08 0.02 1.3 
0.85 
FFPE tumor 6 manual 0.13 0.06 1.9 
FFPE tumor 6 automated 0.08 0.04 1.9 
0.84 
 
Variance (Variance), standard deviation (StDev), dynamic range (DR) and Pearson correlation (Correlation) of four FFPE tumors 
hybridized with our manual and our automated method (Hyb method).
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are very similar. A very small difference could be 
detected in the mean standard deviation of the 
triplicate spot measurements as can be seen in 
table 6, it slightly decreased from 0.04 and 0.05 at 
65°C to both 0.03 at 68°C (p < 0.00001). Also the 
dynamic range kept at similar levels (again the 
highest ratio calculated by CGH-segmentation 
(16) was used because of the homologous loss in 
this tumor in chromosome 11 as depicted in 
figure 3). Although the benefits of changing the 
temperature from 65°C to 68°C were small, we 
decided to wash at 68°C.  
 To validate the optimal automated hybridi-
zation described above, we hybridized four FFPE 
samples (tumor #3, 4, 5 and 6) that were previ-
ously hybridized using our manual method. 
Figure 4 shows the CGH profiles of the FFPE 
tumors (averaged log2 ratios of the manual and 
the automated hybridization), with very similar 
breakpoint locations and copy number estimates 
(16) for each hybridization method. Variance 
and standard deviation of the triplicate spot 
measurements improved slightly but signifi-
cantly (p < 0.00001) for automated compared 
with manual hybridizations. The dynamic ranges 
between pairs of manual and automated hybridi-
zations differed by 5%, 7%, 15%, and 0% respec-
tively, and Pearson correlations were 0.82, 0.72, 
0.85, and 0.84 (table 7). Although the dynamic 
ranges are slightly larger due to higher log2 
ratios at high-level amplifications using the 
manual hybridization method (figure 4), these 
results show that automated and manual CGH 
profiles are quite similar.  
 So far, we performed over one hundred 
automated array-CGH experiments, the oldest 
archival material used was fixed and embedded 
in 1971, all with reproducible and high quality 
results. Figure 3B shows the average profile of 
one archival FFPE tumor hybridized in dupli-
cate, performed with our optimal protocol for 
automated aCGH. As can be seen in figure 3, the 
dynamic range of the hybridizations was ade-
quate to detect and distinguish homozygous and 
heterozygous loss (chromosome 11p), one 
single-copy number gain (e.g., chromosome 7p), 
more then one copy number gain (chromosome 
1q) and unchanged chromosome copy numbers 
(e.g., chromosome 10) in FFPE tumor tissue. 
 
Figure 4 - CGH profiles of four FFPE tumors, hybridized 
manually and automated. 
CGH profiles of four FFPE tumors hybridized using our 
manual and automated methods. Chromosomes (X-axis) 
versus the log2 ratios (Y-axis) averaged over the two methods. 
Breakpoint locations and copy number estimates calculated 
by CGH-segmentation of the manual hybridized tumors 
and of the automated hybridized tumors  , and the average 
CGH profiles (log2 ratios) of the manual and the automated 
hybridized tumor . 
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Conclusion 
 To develop an automated hybridization 
method, we first used the breast cancer cell line 
SKBR3 as a model-genome and subsequently 
optimized and validated the protocol for FFPE 
breast tumors. Reproducible hybridization 
results for FFPE tumor tissue were obtained 
using ULS-labeled unamplified tumor DNA with 
pre-hybridization, hybridized on a hybridization 
station at 37°C for 72 hours with a hybridization 
mixture containing 15% 50 kDa dextran sul-
phate and post-hybridization washing steps 
without using formamide. Pre-hybridization did 
not have a detectable effect on the CGH profile 
of the cell line SKBR3 but did improve CGH 
profiles of FFPE tissue samples. All hybridization 
parameters studied are optimized for the 3.5k 
BAC array-CGH platform but may be different 
for other platforms. This protocol of automated 
array-CGH on archival FFPE ULS-labeled DNA 
outperformed all our manual methods with 
respect to accuracy, reproducibility, easy of 
handling, and speed. 
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Prediction of BRCA1-association in 
hereditary non-BRCA1/2 breast carcinomas 
with array-CGH 
Simon A Joosse, Erik H van Beers, Ivon HG Tielen, Hugo Horlings, Johannes L Peterse, Nicoline Hoogerbrugge, 
Marjolijn Ligtenberg, Lodewyk Wessels, Priscilla Axwijk, Senno Verhoef, Frans Hogervorst and Petra M Nederlof 
While new defects in BRCA1 are still being found, it is unclear whether current breast cancer diagnostics 
misses many BRCA1-associated cases. A reliable test that is able to indicate the involvement of BRCA1 
deficiency in cancer genesis could support decision making in genetic counseling and clinical manage-
ment. To find BRCA1-specific markers and explore the effectiveness of the current diagnostic strategy, 
we designed a classification method, validated it and examined whether we could find BRCA1-like 
breast tumors in a group of patients initially diagnosed as non-BRCA1/2 mutation carriers. A classifier 
was built based on array-CGH profiles of 18 BRCA1-related and 32 control breast tumors, and vali-
dated on independent sets of 16 BRCA1-related and 16 control breast carcinomas. Subsequently, we 
applied the classifier to 48 breast tumors of patients from Hereditary Breast and Ovarian Cancer 
(HBOC) families in whom no germline BRCA1/BRCA2 mutations were identified. The classifier showed 
an accuracy of 91% when applied to the validation sets. In 48 non-BRCA1/2 patients, only two breast 
tumors presented a BRCA1-like CGH profile. Additional evidence for BRCA1 dysfunction was found in 
one of these tumors. We here describe the specific chromosomal aberrations in BRCA1-related breast 
carcinomas. We developed a predictive genetic test for BRCA1-association and show that BRCA1-
related tumors can still be identified in HBOC families after routine DNA diagnostics. 
With kind permission from Springer Science+Business Media: Breast Cancer Res Treat. 2009 Aug; 116(3):479-89. 
© Springer Science+Business Media, LLC 2008 
Background 
 Breast cancer is the most common cancer in 
developed countries and one of the leading 
causes of death in women. One out of nine 
women will be affected by breast cancer (1, 2). 
Up to 25% of familial breast cancer cases are 
explained by mutations in BRCA1 and BRCA2 
(3, 4). Women carrying a mutation in BRCA1/2 
have a lifetime risk of up to 80% of developing 
breast cancer (5-8). Identification of such a 
mutation may not only influence the treatment 
of a patient or carrier (e.g., chemotherapy, 
radiation, bilateral prophylactic mastectomy, or 
salphingooophorectomy (9, 10)) and surveil-
lance, but also allows pre-symptomatic mutation 
screening of family members. 
 Based on family history and age of onset, 
breast cancer patients are eligible for DNA 
screening for pathogenic mutations in BRCA1/2. 
Diagnostics currently include mutation scanning 
and sequencing of gene fragments derived from 
germline DNA, however, it is possible that part 
of the mutations still remains undetected (4, 7, 
11, 12). Additionally, the detection of variants of 
unknown clinical significance complicates 
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counseling and clinical management. Therefore, 
an additional tool that would indicate BRCA1 or 
BRCA2 involvement in breast cancer would be 
an asset to current clinical diagnostics.  
 Numerous studies show specific genetic 
characteristics with which tumors can be 
categorized into subclasses (13). For hereditary 
BRCA1-mutated cancer, previous publications 
from our research group and others show that 
these tumors develop distinct genetic alterations 
on which they can be recognized and distin-
guished from non-hereditary (sporadic) tumors 
(14-17). Various methods using expression 
profiling (14, 15) or comparative genomic 
hybridization (CGH) (16-18) show specific 
genetic alterations for these tumor groups. 
Although analysis of tumor mRNA has led to the 
identification of many different molecular 
portraits, fresh frozen tissue is often not avail-
able, especially when family screening includes 
deceased relatives. On the other hand, formalin-
fixation and embedding in paraffin is the 
common procedure used to handle and archive 
tumor tissue for pathology based diagnosis. We 
have previously shown that paraffin embedded 
tumors can be of adequate quality to perform 
CGH studies (19, 20). The enhanced resolution 
of a microarray, compared with metaphase CGH 
(16), may improve the sensitivity and specificity 
of the detection of BRCA1- or BRCA2-related 
tumors using CGH technology. Additionally, it 
will also provide a better estimate of the location 
of the chromosomal breakpoints of the genetic 
aberrations. 
 To limit the already large number of indi-
viduals eligible for DNA-screening, a pre-
selection procedure to detect individuals with 
the highest risk of carrying a mutation is desir-
able. Prediction models based on family history 
to calculate the risk for carrying a mutation can 
be inadequate predictors, e.g., in small families 
(21). An independent test based on tumor 
characteristics that would indicate involvement 
of BRCA1 could help to select for those patients 
who may be offered more extensive mutation 
analysis. Studies based on clinical assessment 
and pathological reviewing show the limited 
sensitivity and specificity of predicting BRCA1-
status with the currently available markers (12, 
22). Genomic profiling of tumors using com-
parative genomic hybridization could also 
function as a predictive strategy to select patients 
with a high priori risk of a BRCA1 mutation. 
However, this approach has not been applied 
earlier in a diagnostic setting. In general, more 
BRCA1 mutations are being found in HBOC 
(Hereditary Breast and Ovarian Cancer) than in 
HBC (Hereditary Breast Cancer) families, and 
the former group would therefore be more 
suited for our study to identify possible missed 
BRCA1-associated tumors for evaluation of 
current diagnostics. 
Patients and Methods 
Patient selection 
 This study was performed on primary tumor 
samples of three breast cancer groups: (1) 34 
breast tumors from patients with a confirmed 
pathogenic BRCA1 germ-line mutation, mean 
age at diagnosis of 38 years (range: 27– 61); (2) 
48 sporadic breast tumors, mean age at diagnosis 
of 45 years (range: 32–60), no family history of 
breast cancer and selected from the institute’s 
pathology archive matched for p53-status with 
the BRCA1-associated tumor group (Table 1); 
(3) 48 tumors from HBOC families (defined as at 
least two breast and one primary ovarian 
cancer), that were subjected to routine diagnos-
tic testing (4) and had a negative test result for 
mutations in both BRCA1 and BRCA2, with a 
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mean age at diagnosis of 48 years (range: 20–61). 
Patients' characteristics for all three groups are 
described in Supplementary data 1. All sample 
material was formalin-fixed, paraffin-embedded 
(FFPE) tissue and extracted DNA had to be of 
sufficient quality, which was tested as previously 
described (19). All experiments involving human 
tissues were conducted with the permission of 
the institute’s medical ethical advisory board. 
Immunohistochemistry 
 Presence of ER, PR, ERBB2 (HER2/neu), p53 
and KRT5/6 was determined by immunohisto-
chemistry using the antibodies: estrogen recep-
tor AB-14 clone 1D5 + 6F11, titer 1:50 (Neo-
markers); progesterone receptor clone PR-1, titer 
1:400 (Immunologic), c-erbB-2 clone SP3, titer 
1:25 (Neomarkers); p53 clone D0-7, titer 1:8000 
(Dako); and keratin 5/6 clone D5/16 B4, titer 
1:100 (Dako) respectively. If ≥70% of the tumor 
cells expressed ER, PR, p53 or CK5/6, the tumor 
was scored as positive (+) for the corresponding 
staining, in case ≤10% of the cells were stained, 
the tumor was scored as negative (-) and be-
tween 10 and 70% the tumor was scored as ± for 
the corresponding staining. ERBB2 staining was 
scored positive when a 3+ staining was observed, 
otherwise it was scored negative (only one 
sporadic case was IHC 2+, and was called 
negative). 
DNA isolation 
 Tumor DNA was isolated from FFPE tumor 
tissues as follows. 10 x 10 μm slices containing at 
least 70% tumor cells were cleared of paraffin 
(2x 5 min xylene, 2x 30 s 100% ethanol, 30 s 90% 
ethanol, 30 s 70% ethanol, and rinsed with H2O), 
treated with 1 M NaSCN at 37°C overnight, and 
sections of interest (>70% tumor cells) were 
scraped in 200 μl buffer ATL (Qiagen, cat. no. 
51304). 27 μl of proteinase K (15 μg/μl, Roche, 
cat. no. 3115879001) was immediately added, as 
well as at the end of the day, and at the begin-
ning and end of the next day; samples were 
constantly shaken at 37°C during the time of 
digestion. The following day, 40 μl RNase A 
(20 μg/μl, Sigma, cat. no. R5500) was added to 
the sample, vortexed, and incubated for 2 min at 
room temperature. 400 μl of buffer AL (Qiagen, 
cat.no. 51304) was added and incubated for 
10 min at 70°C. 420 μl of 100% ethanol was 
added and vortexed. The sample mixture was 
spun on a spincolumn (Qiagen, cat. no. 51304) 
for 1 min at 8,000 rpm. The column was sequen-
tially washed with 500 µl of the following 
reagents and spun for 1 min at 8,000 rpm: AW1, 
AW2, and twice with 80% ethanol. The column 
was spun dry for 3 min at 14,000 rpm. The 
sample was eluted with 50 μl of AE buffer by 
spinning for 1 min at 8,000 rpm. Reference DNA 
was isolated from lymphocytes from six appar-
Table 1 – Pathological characteristics of the analyzed BRCA1 mutation carriers, sporadic, and HBOC breast carcinomas. 
 
 BRCA1 Sporadic HBOC 
No. analyzed 34 48 48 
ER-positive 5.9% (2/34) 54.3% (25/46) 68.9% (31/45) 
PR-positive 5.9% (2/34) 46.8% (22/47) 50.0% (23/46) 
Her2/neu-positive 2.9% (1/34) 40.0% (17/46) 9.8% (4/41) 
p53-positive 44.1% (15/34) 43.5% (20/46) 9.8% (4/41) 
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ently healthy women and pooled. Lymphocytes 
were purified by adding lysis buffer (155 mM 
NH4Cl, 10 mM KHCO3, 1 mM EDTA) 4x the 
blood volume, followed by centrifugation at 
3,000 rpm for 10 min at 4°C. The supernatant 
was removed and the cell pellet re-suspended in 
lysis buffer 5x the original blood volume. These 
steps were repeated until all erythrocytes were 
removed and the supernatant formed a clear 
solution. 1/10 of the initial blood volume 
DNAzol (Invitrogen, cat. no. 10503-027) was 
added to the cell pellet and mixed by pipetting 
until a clear solution remained. 1/2 of the 
DNAzol volume 100% ethanol was added; DNA 
was removed from the solution, washed in 70% 
ethanol and dissolved in Tris-EDTA buffer. 
DNA was sonicated until the average length was 
300– 800 bp. 
Array-CGH 
 As described previously (20), hybridizations 
were done on microarrays containing 3.5k 
BAC/PAC-derived DNA segments covering the 
whole genome with an average spacing of 1 Mb, 
obtained from the Welcome Trust Sanger 
Institute (UK). The whole library was spotted in 
triplicate on every slide. To prevent slide batch 
spotting bias, samples were hybridized in 
randomized order. Data processing of the 
scanned microarray slide included signal 
intensity measurement with the ImaGene 
software program, followed by median pin-tip 
(c.q. subarray) normalization. Intensity ratios 
(Cy5/Cy3) were log2-transformed and triplicate 
spot measurements were averaged. 
Aberration detection and 
quantification 
 To analyze and visualize the chromosomal 
aberrations, we determined breakpoint locations 
and estimated copy number levels using the 
CGH-segmentation algorithm (23). Based on the 
estimated copy number levels, the frequency of 
gains and losses for all BAC clones was calcu-
lated using the fixed log2-ratio thresholds of 0.15 
and -0.15, respectively. The association of the 
frequency of a clone being ‘gained’, ‘lost’ or 
‘unchanged’ and the two tumor groups was 
calculated by employing 3 x 2 Fisher’s exact (FE) 
test. A small P-value corresponds to a significant 
association between the observed copy number 
changes and the two groups. This procedure was 
employed to compare the whole cohort of 
BRCA1-related tumors to: (1) the whole set of 
sporadic tumors and (2) to particular subgroups 
in order to obtain an indication of the aberra-
tions associated with these subgroups. First, 
subgroups were defined based on IHC-status of 
ER, PR, ERBB2 or p53 of the tumors (KRT5/6 
status was not used to define a subgroup due to 
the small number of KRT5/6 positive tumors). 
IHC status can either be positive or negative 
(IHC-medium (±) samples were assigned to the 
corresponding IHC-positive group). Hence, four 
IHC-negative and four IHC-positive subgroups 
of sporadic tumors were generated. Then the FE 
test was employed to identify two sets of signifi-
cant different aberrations. The first set, denoted 
as ‘BRCA1/IHC-negative’ includes aberrations 
that are significantly associated with the class 
label (BRCA1-related or sporadic) when com-
paring BRCA1-relateted and IHC-negative 
sporadic tumors. The second set, denoted as 
‘BRCA1/IHC-positive’, includes aberrations that 
are significantly associated with the class label 
when comparing BRCA1-related and IHC-
positive sporadic tumors. Since a IHC status 
(e.g., ER) can strongly be associated with the 
class label in a dataset contacting the BRCA1-
related and IHC-positive sporadic subsets, the 
aberrations in the ‘BRCA1/IHC-positive’ can be 
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either BRCA1 associated or IHC associated. 
Since BRCA1-related tumors are mostly ER, PR 
and ERBB2 negative, the aberrations in these 
‘BRCA1/IHC-negative’ sets are mainly BRCA1 
associated. Therefore, an aberration included in 
either of these subgroups is specific for the 
associated IHC-status. An aberration included in 
both sets is likely to be specific for BRCA1-
associated tumors only. 
 
Class prediction: training 
 To build a class predictor based on log2-
ratios derived from array-CGH experiments, the 
shrunken centroids (SC) algorithm was em-
ployed (24) using equal priors, πk = 1/K, where K 
is the number of classes. We predicted, employ-
ing the approach of Dobbin and Simon (25), that 
in order to detect a standardized fold change of 
1.7 (1 copy number gain) amongst 3277 BAC 
clones at an error tolerance of 0.10 for the 
classifier, the minimal sample size for the 
training set had to be 31, equally divided over 
the two classes. The class predictor was built on 
18 BRCA1-related and 32 sporadic breast 
tumors (referred to as the training sets). Since it 
is known that p53- and ER-status are associated 
with specific genomic aberrations in breast 
cancer (26, 27) that could influence the classifi-
cation process, we stratified for p53-status in 
both the training sets, and for ER-status in the 
sporadic training set only. 
 
Class prediction: testing 
 The class predictor was validated on inde-
pendent sets of 16 BRCA1-mutated and 16 
sporadic tumors (referred to as the validation 
sets). Classification of a sample using the SC 
algorithm results in the probability scores 
between 0 and 1 for each class. The sum of the 
two probability scores for any sample is always 1; 
hence, in a two-class problem, the most likely 
class is the class for which the probability 
exceeds 0.5. For legibility we only describe the 
highest probability. 95% reference intervals were 
calculated based on the class-probability distri-
bution in the training sets and employed in the 
validation of the classifier and the classification 
of the HBOC group. Samples predicted outside 
the 95% reference intervals were not assigned to 
a class but scored as ‘‘not classified’’. 
 
Methylation detection 
 Hypermethylation of the BRCA1 promoter 
for all samples (n = 130) was determined using 
Methylation MLPA according to the manufac-
ture’s protocol (MRC-Holland, ME001). DNA 
fragments were analyzed on a 3730 DNA 
Analyzer (AB, USA). 
 
Loss of heterozygosity (LOH) 
 LOH at the BRCA1 locus was determined for 
the HBOC cases (n = 48) using 5 STR markers: 
D17S579, D17S588, D17S1322, D17S1323 and 
THRA1. Primers and the detailed PCR program 
are described in Supplementary data 2. DNA 
fragments were analyzed on a 3730 DNA 
Analyzer (AB, USA). 
 
Results 
 In total, we obtained the array-CGH profiles 
of 34 BRCA1- related, 48 sporadic and 48 HBOC 
breast tumors. In this report we outline the 
chromosomal aberrations and their locations, 
the differences between the tumor groups, and 
the discriminating power of a class predictor 
based on our CGH results. 
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Chromosomal aberrations 
 We observed significant differences in the 
spectrum of aberrations with respect to the 
BRCA1-associated and sporadic breast tumors. 
The upper panels of Fig. 1 depict the frequency 
of gain (green) and loss (red) of the BAC clones 
for the BRCA1-associated and the sporadic 
breast tumors, respectively. The significances of 
the group differences are calculated by Fisher’s 
exact test for each clone and are displayed in the 
bottom panel of Fig. 1. 
 We also found that BRCA1-related tumors 
have more copy number alterations (CNAs) 
compared with the sporadic breast tumors. 
Table 2 summarizes the most prominent aberra-
tions of both tumor groups. These regions 
comprise several adjacent clones (at least 10 Mb 
in size), are aberrant in at least 30% of the tumor 
cases in one group, or show a significant differ-
ence between the tumor groups (average P-value 
for that region of < 0.01, Fisher’s exact test). 
Gain of chromosome 1q and 8q are found in 
almost half of both the tumor groups which have 
been reported previously to be common for 
breast cancer (28-31). In total, the BRCA1-
associated tumors showed 12 regional (> 10 Mb) 
gains and 11 regional losses that were observed 
in > 30% of the tumors. Using the same criteria, 
we observed gain in 2 chromosomal regions and 
5 regional losses in the sporadic breast tumors. 
 
Figure 1 – Frequency plots. The top two panels display the frequency of gain (green) and loss (red) in 34 BRCA1-associated and 48 
sporadic breast carcinomas based on the estimated copy numbers as described in the Methods. The bottom panel shows the signifi-
cance between the two tumor groups computed by Fisher’s exact test for each clone (uncorrected for multiple testing). P-values < 0.01 
are indicated dark blue. 
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BRCA1 and sporadic breast 
tumor class predictor 
  We used Shrunken Centroids (SC) (24) 
to discriminate between germline mutated 
BRCA1 and sporadic tumors. We randomly 
selected 18 BRCA1-associated and 32 sporadic 
tumors for the SC analysis; these tumors are 
referred to as the training set. Employing leave-
one-out cross-validation (LOOCV) on the 
training set, Δ = 1.3 was the parameter setting 
resulting in the smallest number of misclassifica-
tions. The training set yielded 191 discrimina-
tory features (Supplementary data 3) which were 
used in this study for further classification. From 
these 191 features most were abundant in 
regions of chromosome 3q22-27 (gain), 5q12-14 
(loss), 6p23-22 (gain), 12p13 (gain), 12q21-23 
(loss), and 13q31-34 (gain). Based on the 
classification scores of the training samples, 95% 
reference intervals were calculated for both 
groups. The minimum reference interval for the 
BRCA1 class was a BRCA1-like probability of 
0.8; the minimum reference interval for the 
sporadic class was a sporadic-like probability of 
0.7 (i.e., a BRCA1-like probability of 0.3). 
 The remaining samples were used as external 
validation for the class predictor. In the valida-
tion set, 14/16 samples of the BRCA1-related 
group were predicted as BRCA1-like and were 
inside the 95% reference interval, while the 
remaining two cases were outside the interval 
but predicted as BRCA1-like, with a lower 
(< 0.8) probability. One of the 16 sporadic breast 
cancer cases was classified as sporadic-like with a 
probability of 0.62 whereas all others (n = 15) 
classified within the 95% reference intervals. 
These results can be formulated as a total 
sensitivity of 88% and a specificity of 94% (PPP: 
93%, NPP: 88%). Fig. 2a depicts the distribution 
Table 2 – Chromosomal aberrations. Locations and average 
frequencies of the most prominent aberrations in 34 BRCA1-
associated and 48 sporadic breast tumors together with the 
average P-values (FE test) for the significance in aberration 
difference between tumor groups.  
 
 
   BRCA1 Sporadic  
Chromosome Aberration (%) (%) P-value
1q Gain 53 47 0.5186 
3q22-25 Gain 46 4 0.0006 
3q26-29 Gain 43 13 0.0327 
4p16-15 Loss 34 19 0.2466 
5p13-5p12 Loss 19 1 0.0031 
5q11-23 Loss 37 6 0.0017 
5q31-35 Loss 24 4 0.0111 
6p Gain 37 7 0.0010 
6q21-q23 Gain 32 17 0.1493 
7p22-15 Loss 17 0 0.0080 
7q22-36 Gain 37 13 0.0283 
8p23 Loss 31 28 0.5767 
8q Gain 55 40 0.3306 
9p21-13 Loss 35 28 0.7177 
10p15-14 Gain 57 27 0.0129 
10p14-12 Gain 32 11 0.0248 
11p14-13 Gain 30 13 0.1000 
11q22-25 Loss 13 35 0.1523 
12p13-12 Gain 38 12 0.0165 
12q12-14 Loss 20 0 0.0100 
13q Loss 36 32 0.2302 
14q22-23 Loss 45 16 0.0568 
14q32 Loss 49 26 0.0942 
15q11-21 loss 35 13 0.0791 
16q Loss 10 36 0.0312 
17p Loss 24 32 0.5579 
17q22-23 Gain 34 26 0.5522 
20q11-12 Loss 26 0 0.0007 
22q Loss 34 33 0.4091 
Xp22 Loss 31 15 0.1638 
Xq Loss 40 24 0.1715 
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of the classification scores obtained on the 
training and validation sets; the classification 
scores for each individual sample are docu-
mented in Supplementary data 1. 
ER, PR, ERBB2 and p53 specific 
aberrations 
 In our tumor groups, 91% of the BRCA1-
mutated tumors are ER, PR and ERBB2 negative 
(also known as ‘triple negative’), while only 19% 
of the sporadic cases are triple negative (Sup-
plementary data 1). To investigate the relation-
ship between ER, PR, ERBB2 or p53-status with 
chromosomal aberrations and thus the possible 
influence on our class predictor, the BRCA1-
associated tumor group was compared to subsets 
of the sporadic tumors selected by their IHC 
phenotypes as described in the Methods section 
‘‘Aberration detection and quantification’’. 
Chromosomal regions 3q22-3q26, 5p14, 6p22.3 
and 14q22 were significantly more often aber-
rant in BRCA1-associated tumors, independent 
of the sporadic breast tumors’ IHC phenotype 
(Fig. 3 upper four panels, indicated in blue). 
BAC clones within these BRCA1-specific regions 
were also represented in the classifier (Supple-
mentary data 3, Fig. 3 bottom panel). However, 
the largest part of the loss in chromosome 5q, 
that was selected by the SC algorithm, appeared 
to be ER and/or ERBB2 status specific rather 
than BRCA1-specific as calculated by Fisher’s 
exact test (Fig. 3, indicated in orange). 
 To evaluate the performance of the classifier 
features in discriminating BRCA1-related and 
sporadic tumors and the influence of the IHC 
profile, we performed hierarchical cluster 
analysis (complete linkage, Pearson correlation) 
to the array CGH results of the 34 BRCA1-
associated and 48 sporadic breast tumors based 
on the 191 classifier features. The samples were 
separated into two large clusters, one containing 
most of the sporadic breast cancer cases (Fig. 4, 
left branch), and one containing all the BRCA1-
associated tumor samples (Fig. 4, right branch). 
Although, some of the sporadic cases resided 
together with the BRCA1-associated cases, this 
could not be explained by association with the 
ER or ERBB2 status (P = 0.24 and P = 0.25, 
respectively; FE test). Since the basal-like 
phenotype is very common for BRCA1-
associated breast cancer, we investigated whether 
the sporadic tumors clustering together with the 
BRCA1-related tumors were also basal-like by 
 
 
Figure 2 – Classification results. Probability scores for the Training and Validation sets of the BRCA1-associated  and sporadic  
tumor samples (upper panel). Samples predicted as BRCA1-like are plotted right of the 0.5 probability border and samples predicted as 
sporadic are plotted left. Dotted lines indicate the 95% reference intervals for both classes based on the results of their training sets. 
Bottom panel shows the classification of the HBOC group  where 2 tumors were classified as BRCA1-like. Samples outside the classes’ 
95% reference intervals were not assigned to a class. Sample labeled ‘M’ showed methylation of the BRCA1 promoter. 
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performing IHC for KRT5/6 (Supplementary 
data 1). Only two of the five sporadic breast 
tumors expressing KRT5/6 clustered within the 
BRCA1 branch which showed not to be a 
significant correlation (P = 0.23; FE test). 
 Since ER status is highly correlated with the 
class label (BRAC1-related or sporadic) we 
compared the performance of our classifier with 
a classifier that predicts a tumor to be BRCA1-
like when the tumor is ER negative. In the 
validation set, 15/16 samples of the BRCA1-
related tumor group are predicted as BRCA1-
like while seven of the 16 sporadic breast cancer 
cases were classified as sporadic-like. When 
employing the conventional approach in the SC 
classifier of assigning all samples as BRCA1-like 
when the probability of the BRCA1-like class 
exceeds 0.5 (i.e. not using rejection regions) the 
SC classifier has a total error rate of 0/32. The ER 
classifier, when also employing a single ER level 
cut-off, achieves an error rate of 8/32. Assuming 
these proportions are samples from a binomial 
distribution, the 95% confidence intervals for 
these proportions are [0; 0.1089] for the SC 
classifier and [0.1146; 0.4340] for the ER classi-
fier, respectively. Employing the McNemar test 
for matched pairs, we can conclude that the SC 
classifier has a significantly better performance 
on the validation set than the ER classifier 
(P = 0.007). 
 Taken together, these results suggest that 
specific chromosomal aberrations are associated 
with the tumors’ IHC-status (Fig. 3), neverthe-
less, BRCA1-related and sporadic breast tumors 
can be distinguished using the 191 features 
selected by the SC algorithm (Figs. 2, 4). 
 
 
Figure 3 – Influence of IHC-status. The four upper panels depict the significance in differences between the BRCA1-related cohort 
and the sporadic IHC tumor subgroups calculated by Fisher’s exact test. Blue areas are BRCA1-specific aberrations while orange 
aberrations are specific for the corresponding IHC positive-phenotype, computed as described in the Methods. Grey are the non-
significant areas (P>0.01). Lower panel shows the 191 shrunken centroids that are used for the classifier. 
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Application of the classifier on 
non-BRCA1/2 families 
 Forty-eight patients from non-BRCA1/2 
HBOC families were selected and analyzed using 
aCGH. We found 2 samples (HBOC34 and 
HBOC41) to be BRCA1-like (P>0.8), 40 samples 
were predicted as sporadic-like, and 6 samples 
could not be assigned to a class with sufficient 
certainty as they were classified outside the 95% 
reference intervals. Fig. 2b shows the distribu-
tion of the clinical samples in comparison with 
the BRCA1-related and sporadic tumors used to 
build and validate our class predictor. 
 To find evidence for BRCA1 involvement in 
the two BRCA1-like breast cancer cases, we first 
performed LOH analysis of the BRCA1 locus. 
Loss of the wild type BRCA1 tumor suppressor 
gene is considered to be required for BRCA1-
related tumor development. We observed clear 
LOH of BRCA1 in samples HBOC34, HBOC41 
and HBOC08, as well as allelic imbalance (where 
one allele is diminished but still present) in 
HBOC03, HBOC04, HBOC07, HBOC18, 
HBOC29, HBOC042 and HBOC45. Allelic 
imbalance can be caused by trisomy of the locus, 
tumor heterogeneity and limited tumor cell 
percentage. We next performed additional tests 
that were not included in the original routine 
diagnostic setting. As BRCA1 exon 11 was 
analyzed for truncating mutations using the 
Protein Truncation Test (PTT) (32), we now 
sequenced exon 11 in DNA isolated from 
peripheral blood lymphocytes from cases 
HBOC34 and HBOC41 but found no mutations. 
The next test was to investigate somatic inactiva-
tion of BRCA1 by methylation of the BRCA1 
promoter. This was determined for all BRCA1-
associated, sporadic and HBOC samples using 
MLPA-methylation (MRC-Holland, ME001). 
Case HBOC34, which was classified as BRCA1-
like, was the only sample that showed methyla-
tion at the BRCA1 promoter (labeled ‘‘M’’ in 
Fig. 2). This patient also presented with an 
ovarian carcinoma that, like the breast tumor, 
showed methylation at the BRCA1 promoter, 
interestingly, germline DNA of this patient did 
not show methylation at this site. 
Discussion 
 In this study we show that BRCA1-
associated breast tumors possess rearranged 
genomes with specific genomic aberrations that 
 
 
Figure 4 – Hierarchical clustering. Complete hierarchical clustering of 34 BRCA1-related (B1) and 48 sporadic (Sp) breast carcino-
mas based on the log2-ratios of the 191 BAC clones (shrunken centroids) from the classifier. Shown are the IHC-status of ER, PR, 
ERBB2 and p53 of all samples as positive , negative , and intermediate  staining. The dendrogram can be divided in two main 
branches: BRCA1-related (right) and sporadic tumor samples (left). 
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differ significantly from sporadic breast tumors. 
Based on array-CGH data, we identified the 
most significant differences between these two 
tumor groups and built a class predictor with 
88% sensitivity and 94% specificity using the 
Nearest Shrunken Centroids method (24). 
Compared with the BRCA1-associated tumors, 
aberrations are less frequent in the sporadic 
breast tumors. Many of the identified regions 
specific for the BRCA1-related tumors have been 
reported before (16-18, 31, 33, 34). In this study 
we applied the BRCA1 classifier tool on diagnos-
tic cases in order to investigate the performance 
of the familial breast cancer routine mutation 
screening. By doing so, we identified 2 out of 48 
tumors as BRCA1-like. Since all tumors were 
formalin-fixed and paraffin-embedded, investi-
gation of mRNA could be problematic (35), and 
further analyses were performed on genomic 
DNA from the tumor. Since potentially any 
(somatic) inactivation of BRCA1 could result in 
a BRCA1-like phenotype (36, 37), we investi-
gated methylation of the BRCA1 promoter. One 
of the BRCA1-like HBOC cases indeed showed 
methylation and LOH of the BRCA1 gene, 
strongly indicating BRCA1 dysfunction in the 
tumor. Cancer formation due to BRCA1 muta-
tion is generally accompanied by the loss of the 
wild-type allele, i.e. LOH, which was also found 
in the second BRCA1-like HBOC tumor. 
However, no novel or described mutations in the 
BRCA1 gene were identified in this patient after 
sequencing. This particular patient’s family 
history was atypical from that of an average 
BRCA1-involved family (breast and ovarian 
cancer), with incidence of brain cancer, colon 
cancer, and leukaemia. Additionally, the tumor 
was ER and PR positive, which is rare for 
BRCA1-related tumors (38). This unresolved 
BRCA1-like case may be analyzed more in-
tensely when new techniques and knowledge 
become available. Another way to predict the 
involvement of a BRCA1-mutation is to use 
prediction models based on family characteris-
tics. We have calculated Evans’ scores (39) for all 
possible cases to determine the probability to 
find a BRCA1 mutation. Both BRCA1-like 
tumors showed a small probability (20 and 
11.8%), which could explain why no germline 
BRCA1 mutations were found in these families 
but a somatic inactivation of BRCA1 in case 
HBOC34, consistent with a low Evans’ score. 
 In an earlier study we were able to classify 
BRCA1-associated and control tumors using 
chromosomal CGH with an accuracy of 84% 
(16). A control group with a relatively large 
proportion of bilateral tumors was used to 
mimic the situation in high-risk breast cancer 
families. The disadvantage of this approach was 
that it resulted in many ‘false’ positives in the 
control group (specificity of 76%); however, 
many of those were proven to be actual BRCA1-
associated tumors later on (unpublished results). 
We now used automated array-CGH, which is a 
high throughput technique and therefore 
suitable to be performed in specialized diagnos-
tic laboratories. Additionally, the use of a 
microarray in this study localizes the significant 
genomic areas with increased chromosomal 
resolution and may help to develop a test (e.g., 
PCR based) that can be applied in any routine 
diagnostic laboratory. In contrast to our previ-
ous study that contained a relatively large 
number of control cases later proven to be true 
BRCA1-mutated tumors, we now use a random 
control group of sporadic tumors excluding 
family history for breast cancer and bilateral 
breast cancer. Although the differences between 
chromosomal and array-CGH and patient 
selections between our previous and current 
studies are substantial, both loss in 5q and gain 
in 3q were identified as important discrimina-
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tory aberrations, as confirmed by others (17, 33, 
34). 
 While exploring chromosomal aberrations it 
has to be kept in mind that steroid hormone 
receptor status is strongly correlated with the 
genomic profile (26, 27). It has been reported 
that BRCA1-associated tumors are in general 
(>90%) ER, PR, and HER2/neu-negative (38). 
Since we chose to randomly select breast carci-
nomas for our control group, these tumors do 
not all share the triple-negative phenotype of the 
BRCA1-related tumors. Training on triple-
negative breast tumors only could restrict our 
class predictor to triple-negative carcinomas 
while our goal was to build a general classifica-
tion method to classify all non-BRCA1/2 HBOC 
patients. Also, selection for triple-negative 
tumors only would increase the likelihood for 
false positives since a triple-negative population 
is per definition enriched for unidentified 
BRCA1-associated cases. Instead, we investi-
gated the extent to which specific aberrations 
could be associated with ER, PR, ERBB2 and 
p53-status to obtain an indication of their 
possible influence on our class predictor. Loss of 
chromosomal region 5q12-14, which is present 
in our classifier as discriminatory region (Fig. 3), 
was found to be specific for ER-negative tumors. 
Although this would suggest selection for the 
ER-phenotype, no false positives or false nega-
tives were present in the validation sets. The 
result that all ER-negative (and triple-negative) 
sporadic tumors were correctly classified as 
sporadic-like further supports that classification 
is not based on ER-status alone, but is based on 
the combination of the BRCA1-specific regions. 
 Increasing evidence shows that the majority 
of BRCA1-related carcinomas are basal-like 
tumors with respect to morphology and mRNA 
expression level (40). This is also true for the 
BRCA1-specific aberrations as reported here and 
elsewhere (16-18, 33, 34) that show many 
analogies to the breast cancer basal-like subtype 
[(28), this article]. Similarities between these 
hereditary and sporadic breast cancer groups 
could be explained by the effect of the same 
deficient DNA repair pathway (i.e., BRCA1). So 
far, our Fisher’s exact test (Fig. 3), hierarchical 
clustering (Fig. 4), and classification results 
(Fig. 2) all indicate differences between the 
BRCA1-related and the triple-negative (basal-
like) sporadic tumors that lie within the 191 
discriminatory features. 
 In the future, it may be possible to include 
our profiling test in clinical genetic screening 
programs to select the individual in a high-risk 
family with the highest prior probability for 
finding the BRCA1 germline mutation, as an 
alternative or addition to screening of the 
youngest affected case as is currently done. 
Furthermore, it could help in decision making 
and treatment management, also when no 
BRCA1-like profile is found which would be an 
(extra) indication to rule out BRCA1 involve-
ment. Moreover, aCGH classification of a tumor 
with a nucleotide variant of uncertain signifi-
cance may give extra indications for the signifi-
cance of the variant (41). 
Conclusion 
 Based on aCGH data, we were able to 
identify BRCA1-specific aberrations that were 
different from those seen in sporadic breast 
tumors and employed this to build a class 
predictor. Although steroid hormone receptor 
status is strongly associated with genomic 
instability, this class-predictor distinguished 
BRCA1-associated tumors from sporadic breast 
carcinomas with increased accuracy than current 
screening protocols. We conclude that current 
BRCA1 mutation screening seems to identify 
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most hereditary BRCA1-associated breast 
tumors. However, while we could still find 
BRCA1-related breast tumors in a non-BRCA1/2 
tumor group, our array-CGH approach may also 
be used as an additional tool to identify BRCA1-
associated patients or families where the relation 
to BRCA1 is still unclear. 
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Prediction of BRCA2-association in 
hereditary breast carcinomas using array-
CGH 
Simon A Joosse, Kim IM Brandwijk, Peter Devilee, Jelle Wesseling, Frans BL Hogervorst, Senno Verhoef, and 
Petra M Nederlof 
Germline mutations in BRCA1/2 increase the lifetime risk for breast and ovarian cancer dramatically. 
Identification of such mutations is important for optimal treatment decisions and pre-symptomatic 
mutation screening in family members. Although current DNA diagnostics is able to identify many 
different mutations, it remains unclear, how many BRCA2-associated breast cancer cases remain 
unidentified as such. In addition, mutation scanning detects many unclassified variants (UV) for which 
the clinical relevance is uncertain. Therefore, our aim was to develop a test to identify BRCA2-
association in breast tumors based on the genomic signature. A BRCA2-classifier was built using array-
CGH profiles of 28 BRCA2-mutated and 28 sporadic breast tumors. The classifier was validated on an 
independent group of 19 BRCA2-mutated and 19 sporadic breast tumors. Subsequently, we tested 89 
breast tumors from suspected hereditary breast (and ovarian) cancer (HBOC) families, in which either 
no BRCA1/2 mutation or an UV had been found by routine diagnostics. The classifier showed a sensitiv-
ity of 89% and specificity of 84% on the validation set of known BRCA2-mutation carriers and sporadic 
tumor cases. Of the 89 HBOC cases, 17 presented a BRCA2-like profile. In three of these cases, addi-
tional indications for BRCA2-deficiency were found. Chromosomal aberrations that were specific for 
BRCA2-mutated tumors included loss on chromosome arm 13q and 14q, and gain on 17q. Since we 
could separate BRCA1-like, BRCA2-like, and sporadic-like tumors using our current BRCA2- and 
previous BRCA1-classifier, this method of breast tumor classification could be applied as additional test 
for current diagnostics to help clinicians in decision-making and classifying sequence variants of un-
known significance. 
With kind permission from Springer Science+Business Media: Breast Cancer Res Treat. Published online 2010 Jul. 
© Springer Science+Business Media, LLC 2010 
Introduction 
 Individuals that inherit a germline mutation 
in BRCA1 or BRCA2 have a significantly in-
creased lifetime risk of developing breast or 
ovarian cancer. Recent publications review the 
importance to identify BRCA1/2 mutation 
carriers for optimal therapy and non-carriers for 
chemoprevention (1, 2). Defects in homologous 
recombination (impaired BRCA1/2 pathway) 
cause high sensitivity for drugs that induce 
double-strand breaks (e.g., alkylating agents). 
However, successful mutation identification 
impacts not only the patient but also on the 
family members, since it allows for pre-
symptomatic mutation screening. The current 
strategy to identify mutation carriers is first to 
select those patients eligible for mutation 
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screening based on prediction models that use 
age and family history (4). Subsequently, the 
mutation screening is performed; e.g., by 
sequencing of gene fragments in germline DNA, 
protein truncation test (PTT) and denaturing 
gradient gel electrophoresis (DGGE) (5, 6). 
However, it still remains unclear, to what extent 
mutation carriers are identified with the current 
diagnostic tools since many families with a 
history for breast cancer remain unexplained. It 
is known that mutation prediction models are 
highly dependent on the number of family 
members, from which information is available 
(4, 7); this type of information is often limited. 
Another clinically difficult situation is the 
identification of an unclassified variant (UV) in 
coding or non-coding regions in either one of 
the BRCA genes. The pathogenicity of such a 
nucleotide variant is often uncertain as the effect 
on the protein function is unknown. Therefore, 
its clinical significance also remains unclear. 
Although functional assays exist for the proteins 
produced by mutated BRCA1/2 genes, these are 
laborious, difficult to interpret in clinical terms, 
limited to only a number of protein functional-
ities, and not yet routinely applicable in a 
diagnostic setting (8). Therefore, our goal was to 
evaluate profiling of somatic genetic changes in 
breast tumors as a new strategy that can provide 
additional information about the involvement of 
BRCA2 in tumorigenesis. 
 For BRCA1-mutated tumors, several mo-
lecular portraits have been generated using copy 
number alterations (3, 9-12) and gene expression 
patterns (13, 14). It has already been shown that 
such genetic profiling can successfully be applied 
to identify BRCA1-associated cases (3, 15) and to 
provide an additional indication whether an UV 
is pathogenic or not (16). For BRCA2-mutated 
tumors, there is much less evidence for the 
existence of a specific genetic signature, also the 
immunohistochemical phenotype is not that well 
defined (17). Although several studies investi-
gated the differences between BRCA1-mutated, 
BRCA2-mutated and sporadic breast tumors in 
gene expression patterns (13) and copy number 
alterations (11, 12, 18, 19), these signatures have 
not been validated extensively and were not 
evaluated in a clinical setting. The number of 
samples was relatively small and/or the investi-
gated tumor groups were not matched for sex, 
histological grade, tumor type, and estrogen 
receptor (ER) status, which all have been shown 
to have their own individual characteristics at 
the genomic level that could be misinterpreted as 
the signature of interest (20-24). This implies the 
need for a validated BRCA2 signature, which is 
independent of tumor grade and receptor status, 
and which can be used in combination with a 
BRCA1 signature. 
 Because BRCA1 and BRCA2 play important 
roles in DNA repair by homologous recombina-
tion, it is not surprising that breast tumors 
deficient in either one of the encoding genes 
show extensive chromosomal imbalance (3, 9). 
This could be exploited as the basis for molecu-
lar profiling. In this study, we have used array-
CGH to investigate the copy number changes of 
DNA sequences extracted from formalin-fixed, 
paraffin-embedded (FFPE) tissue, which is 
readily available in pathology archives and 
therefore very suitable for diagnostic purposes. 
Additionally, using the same technique as our 
previous classifier, allows the combination of 
tests for both BRCA profiles. 
Materials and methods 
Patient selection 
 Three breast cancer groups were used which 
were selected from the institute’s archive: (1) 47 
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breast carcinomas from women with a con-
firmed pathogenic BRCA2 germline mutation, 
mean age at diagnosis of 46 years (range 26–86), 
referred to as BRCA2-mutated tumors; (2) 47 
sporadic breast tumors from women with 
unknown BRCA2 status, mean age at diagnosis 
of 45 years (range 29–78), no known family 
history for breast cancer and matched to the 
tumor group mentioned above for age, gender, 
ER, PR, ERBB2, and p53 immunohistochemical 
(IHC) status and tumor grade; (3) 89 tumors 
from women that were eligible for, and subjected 
to, routine diagnostic testing according to the 
HBOC criteria (25) but were negative for 
pathogenic BRCA1/2-mutations or carried an 
UV in either BRCA1/2; mean age at diagnosis of 
47 years (range 29–75). This third group in-
cluded 37 HBOC cases from our previous study 
(3), 47 new HBOC cases, and 5 cases carrying an 
UV (Table 1). This third group is referred to as 
non-BRCA1/2 tumors. All experiments involv-
ing human tissues were conducted with the 
permission of the institute’s medical ethical 
advisory board. Individual sample characteristics 
are listed in Supplementary Table 1 including 
which samples were used to built or validate the 
classifier. The 34 CGH profiles of BRCA1-
mutated tumors described in this manuscript are 
from our previous study (3). 
Sample material 
 All sample material was formalin-fixed, 
paraffin-embedded (FFPE) archival tissue from 
invasive ductal carcinomas (IDC). 10 μm 
sections were cut and regions containing at least 
70% tumor cells were scraped. DNA was ex-
tracted by proteinase-K digestion after deparaf-
fination; and quality was tested by a multiplex 
PCR as described elsewhere (3, 26). In total, we 
isolated DNA of 69 BRCA2-mutated, 104 
sporadic and 107 non-BRCA1/2 tumors for this 
study. Only those DNA samples of which PCR 
products of at least 200 bp could be produced, 
were of sufficient quality for array-CGH (data 
not shown). 
Pathological review 
 Presence of ER, PR, HER2, and p53 were 
determined by revision of immunohistochemical 
staining that were previously performed in 
standard clinical procedure with antibodies: 
estrogen receptor AB-14 clone 1D5 + 6F11, titer 
Table 1 – Unclassified variants. Unclassified variants (UV) found in the HBOC tumor group. Listed are the Type and the Effect of 
the UVs. aCGH profiles were classified with both the ‘BRCA1 classifier’ and the ‘BRCA2 classifier’ (Classification). Case PFT2946 was 
diagnosed with two primary tumors. 
 
Case Gene UV Type Effect Classification 
PFT2946 
(2x) 
BRCA2 c.6842-20T>A Intronic variant Different splice prediction 
programs: no effect 
Sporadic-like 
PFT5737 BRCA2 c.9502-12T>G Intronic variant Loss of splice acceptor site, 
deletion of exon 26 
BRCA2-like 
PFT6270 BRCA2 c.1395A>C Silent coding 
variant 
Very likely no effect Sporadic-like 
PFT3045 BRCA1 c.81-9C>G Intronic variant Creation and use of novel 
acceptor site, frame shift 
BRCA1-like 
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1:50 (Neomarkers); progesterone receptor clone 
PR-1, titer 1:400 (Immunologic); c-erbB-2 clone 
SP3, titer 1:25 (Neomarkers); and TP53 clone 
D0-7, titer 1:8,000 (DAKO), respectively. 
 For simplicity, IHC scoring was divided into 
two classes. If ≥1% of the tumor cells expressed 
ER, PR, or p53, the tumor was scored as positive 
(+), otherwise, the tumor was scored as negative 
(-) for the corresponding staining, according to 
Viale et al. (27). HER2 scoring was performed 
according to ASCO/CAP and oncoline guide-
lines (28, 29). A tumor was scored positive for 
HER2 when a 3+ staining was observed. When a 
2+ staining was observed, CISH was performed 
to determine amplification (+ in case of 6 spots 
or more per nucleus) or no amplification (-). A 
1+ or negative IHC staining was scored as 
negative (-). 
 Tumor grade was determined by the modi-
fied Bloom–Richardson–Elston staging system 
(30). 
Array-CGH 
 Sample preparation, labeling, BAC arrays 
preparation, and array processing were done as 
previously described (31). In short, ULS-Cy5 
labeled tumor DNA and ULS-Cy3 labeled 
reference DNA from six apparently healthy 
women were co-hybridized for 72 h on a mi-
croarray containing 3.5k BAC/PAC derived 
DNA segments covering the whole genome with 
an average spacing of 1 Mb spotted in triplicate. 
Hybridization was performed on a Tecan 
HS4800 hybridization station, which uses liquid 
agitation during hybridization. In total we 
performed aCGH with 57 BRCA2-mutated, 82 
sporadic, and 77 non-BRCA1/2 tumors samples. 
The quality of the hybridization was assessed by 
calculating the standard deviations of the log2 
ratios of the triplicate spots. Only aCGH profiles 
with a mean standard deviation < 0.1 were used. 
These microarray data have been deposited in 
NCBI’s Gene Expression Omnibus (32) and are 
accessible through GEO Series accession num-
bers GSE16511 (BRCA2-mutated), GSE9114 
(sporadic), and GSE22481 (non-BRCA1/2). 
Analyses of aCGH profiles 
 We have employed three different methods 
to analyze the aCGH profiles. First, the fre-
quency of the aberrations was calculated and 
plotted in a so called ‘frequency plot’, purely to 
summarize and visualize the percentage of 
(common) aberrations in BRCA2-mutated and 
sporadic tumors. As second method, a classifier 
was built which could discriminate between the 
tumor groups and assign individual tumors to a 
tumor class (group). Finally, the association 
between the individual tumors was examined 
using hierarchical clustering (complete linkage, 
Pearson correlation) based on the features used 
for the classifier. Details are described below. 
Aberration quantification 
 Breakpoint locations and estimated copy 
number level of the chromosomal aberrations 
were determined by the CGH-segmentation 
algorithm described by Picard et al. (33), further 
referred to as the ‘segmentation data’. To 
calculate aberration frequency and the average 
number of aberrations per tumor group, the 
segmentation data was discretized to ‘neutral’, 
‘loss’, ‘gain’, and ‘amplified’ by applying thresh-
olds as described by Chin et al. (34). Thresholds 
for gain/loss and amplification were defined by 
two and eight times the standard deviation of 
50% quantile of the segmented data, respectively 
(34). Significant differences between the tumor 
groups for frequency of aberrations (‘neutral’, 
‘gained’, ‘lost’, or ‘amplified’) was calculated by 
employing a 4 x 2 Fisher’s exact (FE) test (35). P-
values were not directly corrected for multiple 
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testing since this would be too stringent. Instead, 
since adjacent BAC clones are highly correlated, 
a genomic region was called significant when at 
least five adjacent BAC clones were calculated to 
be significant with p < 0.01. Using this approach, 
copy number variations smaller than 5 Mb could 
also be excluded from the results. 
 To calculate the association of the average 
number of aberrations between tumor groups, 2-
tailed t-test was applied. 
Shrunken centroids-based 
classifier 
 To prevent over-fitting of the classifier, the 
approach of Dobbin and Simon (36) was used to 
calculate the required sample size using a 
standardized fold change of 1.7. For an error 
tolerance of < 0.10, more than 15 samples of 
each class were needed. As in our previous study 
(3), we have used the shrunken centroids (SC) 
algorithm (37) to construct the ‘BRCA2 classi-
fier’, however, now based on the segmentation 
data to eliminate technical noise. To train the 
‘BRCA2 classifier’, a fraction of 0.6 of each group 
was randomly selected (28 BRCA2-mutated and 
28 sporadic tumor profiles, total n = 56). The 
classifier was validated with the remaining 
samples of each group (19 BRCA2-mutated and 
19 sporadic tumor profiles, total n = 38). As a 
result, the classification algorithm predicts the 
classes’ likelihoods for each sample. Since the 
sum of the two likelihoods is always ‘‘1’’, we only 
describe the highest class probability (> 0.5). 
Depending on the classes’ highest likelihood, the 
sample will be referred to as BRCA2-like or 
sporadic-like. Next we tested the aCGH profiles 
of 89 non-BRCA1/2 tumors for BRCA2 class 
likelihood, additionally we tested for BRCA1 
likelihood with the ‘BRCA1 classifier’ from our 
previous study (3) to the same cases which uses 
the similar scoring method. 
Additional screening for 
BRCA1/2 defects 
 To identify defects in the BRCA1/2 genes 
that could have been missed by standard diag-
nostics, we performed the following additional 
tests: BRCA2 exon deletion/duplication MLPA 
according to the manufacturer’s protocol (MRC-
Holland, The Netherlands, MLPA kit P090); 
mRNA sequence analysis from peripheral blood 
lymphocytes to determine bi/mono-allelic 
expression of BRCA2, using regions containing a 
single nucleotide polymorphism (SNP); loss of 
heterozygosity (LOH) of the BRCA2 locus in 
tumor DNA using the markers D13S171, 
D13S260, D13S267, and D13S289 and LOH of 
the BRCA1 locus as described before (3); methy-
lation of the BRCA1 and BRCA2 promoters 
using methylation MLPA according to the 
manufacturer’s protocol (MRC-Holland, The 
Netherlands, MS-MLPA kit ME001B). More-
over, we have analyzed multiple family members 
of four families to investigate the presence of a 
common CGH profile by classification. 
Results 
Immunohistochemistry 
 BRCA2-mutated tumors were predomi-
nantly ER positive (83%) with various histologi-
cal tumor grade, while BRCA1-mutated tumors 
were mainly ER negative (94%) and grade III 
(Table 2). This is in concordance with literature 
which reports similar numbers (17). The distri-
bution of tumor grade among non-BRCA1/2 
HBOC tumors was similar to that of BRCA2-
mutated tumors, although, fewer tumors were 
ER positive (Table 2). 
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Chromosomal aberrations: 
BRCA2 versus sporadic 
 Most aberrations found in the BRCA2-
mutated tumors were also present in the spo-
radic tumor group, and with similar frequencies. 
The top two panels of Fig. 1 show the genome-
wide frequency of losses (red), gains (green) and 
high level gains (dark green) in the BRCA2-
mutated and the sporadic control group, respec-
tively. Based on these numbers, 4 x 2 Fisher’s 
exact test was employed to determine significant 
differences between the groups. The middle 
panel depicts p values with significant p-values 
(p < 0.01) indicated in dark blue. Three chromo-
somal aberrations were identified to be more 
associated with BRCA2-mutated tumors: loss of 
chromosome bands 13q12–q14, 14q23–q32 and 
gain of 17q11–q21.31. More associated with 
sporadic tumors were gain of chromosome band 
16p13 and loss of 16q12 (Table 3; Supplemen-
tary Table 2). Based on the calculated break-
points using CGH-segmentation (33), the 
numbers of aberrations in both tumor groups 
were counted. BRCA2-mutated tumors showed 
on average 75.7 ± 11.9 aberrations (range 56–
109) and sporadic tumors showed a comparable 
average of 78.4 ± 12.3 aberrations (range 
50-111), which was not significantly different 
(p = 0.24, two-sided, paired t-test). 
Table 2 – Tumor group characteristics. Immunohistological characteristics of the different tumor groups in this study.  
 
BRCA2-mutated Sporadic Training B2 Training Sp Non-BRCA1/2 BRCA1-mutated  
(n=47) (n=47) (n=28) (n=28) (n=89) (n=34) 
Grade       
I 15 (n= 7) 15 (n=7) 18 (n=5) 14 (n=4) 10 (n=9) 0 (n=0) 
II 36 (n=17) 32 (n=15) 29 (n=8) 29 (n=8) 35 (n=31) 21 (n=7) 
III 49 (n=23) 53 (n=25) 54 (n=15) 57 (n=16) 43 (n=38) 79 (n=27) 
ER       
+ 83 (n=39) 83 (n=39) 82 (n=23) 79 (n=22) 53 (n=47) 6 (n=2) 
- 17 (n=  8) 17 (n=8) 18 (n=5) 21 (n=6) 33 (n=29) 94 (n=32) 
PR       
+ 45 (n=21) 57 (n=27) 54 (n=15) 57 (n=16) 40 (n=36) 6 (n=1) 
- 55 (n=26) 43 (n=20) 46 (n=13) 43 (n=12) 44 (n=39) 97 (n=33) 
ERBB2       
+ 13 (n= 6) 19 (n= 9) 18 (n=5) 21 (n=6) 12 (n=11) 3 (n=1) 
- 87 (n=41) 81 (n=38) 82 (n=23) 79 (n=22) 70 (n=62) 97 (n=33) 
p53       
+ 43 (n=20) 36 (n=17) 86 (n=24) 82 (n=23) 20 (n=18) 44 (n=15) 
- 57 (n=27) 64 (n=30) 14 (n=4) 18 (n=5) 49 (n=44) 56 (n=19) 
BRCA1-mutated tumors are from our previous study (3). Values are expressed as percentage. 
Training B2 = Classifier training group BRCA2-mutated, Training Sp = Classifier training group Sporadic 
 




BRCA2 versus BRCA1 
 Comparison of the CGH profiles of BRCA2- 
with BRCA1-mutated tumors revealed many 
significant different aberrations (Figure 1; 
Supplementary Table 2). The bottom two panels 
of Figure 1 show the genome-wide gains and 
losses of the BRCA1-mutated tumors from our 
previous study (3), and the p-values indicating 
the association of the aberration frequencies 
between the two hereditary breast cancer groups, 
respectively. The full list of aberration frequen-
cies and p-values are documented in Supple-
mentary Table 2. The number of aberrations 
differed significantly between these groups, 
(p = 3.75e-4). BRCA2-mutated tumors showed 
75.7 aberrations on average, compared to 
85.4 ± 11.2 aberrations (range 69-113) in 
BRCA1-mutated breast tumors. 
Figure 1 – Comparison of 
aberration frequency. Frequency 
of gain (green), amplification 
(dark green) and loss (red) over 47 
BRCA2-mutated (A) and 47 
matched sporadic breast 
carcinomas (B) based on the 
estimated copy numbers as 
described in Material and 
Methods. C: significance between 
the two tumor groups computed 
by Fisher’s exact test for each 
clone. P-values < 0.01 are 
indicated in dark blue. The 
bottom two panels show the 
aberration frequencies of 34 
BRCA1-mutated breast carcino-
mas (D) and the significant 
regions between the BRCA2-
mutated and BRCA1-mutated 
tumor groups (E), respectively. P-
values are -log10 transformed. 
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BRCA2 classifier 
 Twenty-eight CGH profiles of the BRCA2-
mutated tumor group and 28 of the sporadic 
tumor group were randomly selected to train the 
‘BRCA2 classifier’. Table 2 shows that the 
distribution of IHC status of the training sets is 
similar to the original groups, and thus also 
comparable with the population. Employing 
leave-one-out cross-validation (LOOCV), 
D = 0.4 led to the lowest misclassification rate. 
Using these 56 profiles, 703 features were 
selected as discriminatory by the SC algorithm 
(clone name and genomic location are given in 
Supplementary Table 3). The features selected by 
the SC algorithm showed a large overlap (67%) 
with the regions selected using the frequencies 
(Table 3). For the training sets, one sample of the 
BRCA2-mutated tumors and one sample of the 
sporadic tumors classified to the opposite class 
(misclassification of 4%). 
 The remaining 38 samples were used to 
validate the classifier. Figure 2 shows the distri-
bution of the classification scores for the training 
as well as for the validation sets. Samples classi-
fied as sporadic-like are plotted left, while 
BRCA2-like samples are plotted right. In the 
validation sets, 17/19 BRCA2-mutated tumors 
(red) and 16/19 sporadic tumors (yellow) were 
correctly classified. Consequently, the sensitivity 
was 89% and specificity 84%, the positive (PPP) 
and negative predictive power (NPP) were 85 
and 89%, respectively. 
 To further evaluate the chromosomal 
regions that were selected for the ‘BRCA2 
classifier’, we performed hierarchical cluster 
analyses on the segmentation data of all the 
samples based on these regions only. Figure 3 
depicts the result of the cluster analyses and 
shows that the samples are divided into three 
large clusters. IHC data of each sample are 
displayed along the cluster tree to explore 
whether samples of both groups clustering 
together would share the same IHC phenotype; 
this was not the case. Clusters B and C contain 
all except two (45/47) of the sporadic cases, 
cluster A contains all but two (45/47) of the 
BRCA2-mutated cases (Figure 3). These results 
indicate that the features selected for classifica-
tion have indeed discriminatory power, regard-
less of the algorithm used and independent of 
IHC phenotype. 
Table 3 – BRCA2 associated chromosomal aberrations. Five chromosomal regions (Chr.) were present in significantly different 
frequencies between the BRCA2-mutated and sporadic breast tumors calculated by Fisher’s exact test. Given are the average 
percentages of gain and loss in both tumor groups of the corresponding chromosomal region and p-value (FE test). 
 
  BRCA2-mutated Sporadic FE test 
Chr. Cytoband Gain Loss Gain Loss p-value 
13 q12-q14 4% 78% 5% 44% 2.1e-3 
14 q23.2-q32.2 2% 62% 9% 22% 5.7e-4 
16 p13 14% 2% 41% 3% 3.7e-3 
16 q12 10% 18% 5% 51% 3.0e-3 
17 q11-q21.31 36% 8% 15% 32% 6.2e-3 
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Clinical application of the 
‘BRCA1/2 classifiers’ 
 To evaluate the ‘BRCA2 classifier’ in clinical 
setting, 89 breast cancer samples from non-
BRCA1/2 HBOC patients were analyzed (Fig-
ure 2, blue circles; Supplementary Table 1). 
Seventeen cases (19%) were classified as BRCA2-
like with a BRCA2-class probability > 0.5, 13/17 
with high probability > 0.8; the remaining 72 
cases (81%) were classified as sporadic-like. One 
of the BRCA2-like cases carried the BRCA2 UV 
c.9502-12T>G. The same cases were also classi-
fied using the ‘BRCA1 classifier’ (3), 11 samples 
were classified as BRCA1-like. Of these 11 
tumors, one carried the BRCA1 UV c.81-9C>G 
and two tumors were also classified as BRCA2-
like. All 17 BRCA2-like cases, 11 BRCA1-like 
cases and cases carrying an UV were studied in 
more detail using additional molecular tests to 
identify possible missed BRCA1/2-associated 
cases (described below and listed in Supplemen-
tary Table 1). 
Unclassified variants 
 
 Routine mutation analysis of germline DNA 
had previously revealed four unclassified 
variants in BRCA2 and one in BRCA1 (Table 1). 
To investigate whether the UVs cause aberrant 
mRNA molecules, mRNA was isolated from 
blood of these patients and analyzed by cDNA 
sequencing. This revealed that BRCA2 UV 
c.9502-12T>G led to the deletion of exon 26. 
Also, BRCA1 UV c.81-9C>G caused a splicing 
defect leading to a truncated protein. These 
results indicate that both unclassified variants 
are pathogenic and result in non-functional 
proteins. This correlates with the CGH profiles 
of these cases that were classified as BRCA2- and 
BRCA1-like, respectively. For the remaining two 
BRCA2 UV cases, no indications were found for 
pathogenicity, also these findings were in 
concordance with the classifier’s prediction, 




Figure 2 – Classification with the ‘BRCA2 classifier’. The top panel shows the probability scores for the training and validation sets 
of the BRCA2-mutated ( n=47) and sporadic ( n=47) tumor samples. Samples predicted to be BRCA2-like are plotted right and 
samples predicted to be sporadic are plotted left. The bottom panel depicts the classification results of the non-BRCA1/2 tumor group 
( n=89), where 17 tumors were classified as BRCA2-like (probability > 0.5). 
CHAPTER 5    
 98 
Mutation analysis 
 The BRCA2 gene was investigated for whole-
exon deletions or duplications using the P090 
MLPA kit (MRC-Holland). None of the investi-
gated cases showed such aberration. 
Loss of heterozygosity (LOH) 
 We investigated LOH at four microsatellite 
markers flanking the BRCA2 gene in the 
BRCA2-like cases. Most of the samples (75%) 
showed LOH or allelic imbalance (AI) for at least 
one informative (i.e., heterozygous) marker. The 
BRCA1 locus was investigated using five mi-
crosatellite markers. This region showed LOH or 
AI in 67% of the investigated cases (Supplemen-
tary Table 1). 
Promoter methylation 
 Methylation of the BRCA1 and BRCA2 
promoter were investigated using the ME001 
methylation MLPA kit (MRC Holland). None of 
the HBOC cases were found to be positive for 
methylation of the BRCA2 promoter, only one 
BRCA1-like case showed methylation of the 
BRCA1 promoter. 
Allele-specific expression 
 Some mutations might be hidden and hard 
to find (e.g., intronic). In BRCA1/2 mutation 
carriers, often mRNA expression of only the 
wild-type gene can be detected in blood. There-
fore, we explored whether single allele expres-
Figure 3 – Hierarchical clustering. Complete hierarchical 
clustering of 47 BRCA2-mutated  and 47 sporadic  breast 
carcinomas based on the segmentation data of the same 704 
BAC clones (shrunken centroids) that were used for the 
classifier. Shown are the IHC status (from left to right) of p53, 
ERBB2, PR and ER of all samples: IHC positive , negative , 
and intermediate  staining. The dendrogram can be divided 
into three main branches: one cluster of mainly BRCA2-
mutated tumors (A, 47 samples) and two clusters of mainly 
sporadic tumor samples (B, 29 samples, and C, 18 samples).  
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sion of BRCA2 could be identified, indicative of 
a defective gene. mRNA regions containing a 
SNP that was detected by routine diagnostics 
were sequenced to identify the ratio of expressed 
alleles. Eleven of the BRCA2-like cases were 
found to be heterozygous for a coding SNP. Only 
cases PFT6363 and PFT6386 appeared to express 
one allele of BRCA2, which may suggest that 
these patients carry a defective copy of BRCA2 in 
their germline DNA. 
Discussion 
 We investigated the chromosomal aberra-
tions of BRCA2-mutated breast tumors by array-
CGH to identify their molecular signature. We 
found that these tumors can be distinguished 
from sporadic tumors with an accuracy of 86.5%. 
To our knowledge, such accuracy has not been 
shown before using an array-CGH classifier. 
This signature can be used to give additional 
indications about the involvement of BRCA2 in 
the tumorigenesis of a specific breast tumor case 
where the role of BRCA2 is still unclear (i.e., UV) 
or in patients in whom no mutation has been 
found (yet), but where a hereditary factor is 
suspected. In combination with our previous 
‘BRCA1 classifier’, classification suggesting the 
involvement of either BRCA1 or 
 BRCA2 could lead to extended diagnostics, 
may help clinicians in their decision making, and 
can lead to adjusted therapy that exploits 
BRCA1/2 deficiency. 
Classifier and clinical 
application 
 Using the shrunken centroids algorithm, we 
built a classifier with BRCA2-mutated and 
sporadic tumors resulting in a high accuracy 
(86.5%). For the misclassified samples, it cannot 
be excluded that some of the patients in the 
sporadic group in fact harbor a BRCA2 germline 
mutation, as they were not tested for this. Based 
on the population frequency, this percentage will 
most likely not exceed 1% of all breast cancer 
cases. Furthermore, negative misclassification 
could be the result of a low tumor cell percent-
age, tumor heterogeneity, or an actual sporadic 
tumor in a germline BRCA2 mutation family. 
Applying the ‘BRCA2 classifier’ to non-
BRCA1/2 and BRCA1/2 UV cases, we found 17 
tumors to be BRCA2-like. In three of these 17 
cases, we have found indications for dysfunc-
tional BRCA2. Although we also found LOH/AI 
of BRCA2 in 9 tumors of the remaining 14 cases, 
we were unable to infer a BRCA2 defect directly 
linked to tumorigenesis. Also methylation of the 
BRCA2 promoter was not found, however, this is 
in agreement with reports suggesting that 
BRCA2 promoter methylation does not occur 
frequently in breast cancer (38, 39). It should be 
noted here that based on the validation results, 
16% of the samples could also be false positive. 
This means that of the 89 BRCA2-like cases, 14 
may be false-positive sporadic tumors. Neverthe-
less, although these 14 BRCA2-like cases remain 
unsolved and could be considered false positive, 
these patients might benefit from the same 
treatment as true BRCA2 mutation carriers, as 
they present similar genomic characteristics and 
might therefore also suffer from similar defective 
pathways (e.g., impaired homologous recombi-
nation, discussed below). Further investigation 
to support this hypothesis is needed. Applying 
the ‘BRCA1 classifier’ to the 89 non-BRCA1/2 
cases, 11 were classified as BRCA1-like, which 
also include the two BRCA1-like cases from our 
previous study (3). One of the new cases was 
found to carry the BRCA1 UV c.81-9C>G, which 
led to a splicing defect. Together with LOH, this 
UV caused BRCA1 deficiency. 
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BRCA1 and BRCA2 
Several studies have investigated BRCA1/2-
mutated tumors for chromosomal aberrations in 
comparison with control tumors. Most of the 
aberrations we have found have also been 
reported by others. Supplementary Table 4 
describes the aberrations found on chromo-
somes by Tirkkonen et al. (9), van Beers et al. 
(11), Jonsson et al. (12), Stefansson et al. (19) 
and us. As has been shown by others (9, 11, 12, 
19), comparison of the aCGH profiles of 
BRCA2- with BRCA1-mutated tumors shows a 
number of differences of which also many (if not 
most) can be related to ER status and histological 
grade (20-24). Since our technique makes use of 
the CGH profile of the whole genome, the 
chromosomal aberrations associated with grade 
and receptor status would greatly bias the 
groups’ signatures. Therefore, we have generated 
two separate classifiers based on BRCA1/2 
mutation status, to prevent interference of these 
characteristics that are not of interest. To 
overcome this problem, a comparison between 
these hereditary tumor groups using ER status 
and histological grade equal samples should be 
made. Due to the sparse occurrence of ‘triple-
negative’, grade 3, BRCA2-mutated tumors, or 
ER-positive BRCA1-mutated tumors, such 
comparisons have not been performed yet. 
Interestingly, (only) two of the 89 non-BRCA1/2 
cases classified as BRCA1-like and BRCA2-like, 
indicating that these profiles present both 
BRCA1- and BRCA2-specific aberrations. 
Whether this ‘double BRCA’ classification 
reflects a truly shared biological basis for heredi-
tary tumors as suggested by Stefansson et al. 
(19), or the imperfectness of both classifiers is 
currently not clear yet. Since both classifiers are 
binomial and ‘force’ each sample into one class, 
these ‘double positives’ currently require a third 
method of classification or a pre-selection (e.g., 
based on grade or ER status). In addition, an 
additional family member could be screened. 
Since our method is validated on archival 
material, also tumor material from relatives from 
earlier generations could be investigated. In 
general, material from 1980 and onwards can be 
used (data not shown). Of one of these double 
positives, we could analyze additional family 
members (Supplementary Table 1, family 
number 2128). This one was classified as 
BRCA2-like, indicating that it is very likely that 
this family is affected by a hereditary defect in 
the BRCA2 pathway. 
Homologous recombination 
deficiency (HRD) 
A common genetic profile might reflect a 
common defect in DNA repair mechanisms also 
in the absence of a germline mutation as the 
defect may be somatic. DNA double-strand 
breaks (DSB) caused by DNA-damaging agents 
(such as alkylating chemotherapy) or the 
inhibition of DNA repair mechanisms (e.g., 
PARP inhibitors), can be lethal for cells that are 
deficient in homologous recombination. Ho-
mologous recombination is the only error-free 
repair mechanism for DNA double-strand 
breaks, and thus, identification of HRD tumors 
may lead to specifically targeting these tumors 
with alkylating agents or PARP inhibitors. 
Although both BRCA1/2 genes are involved in 
homologous recombination, the histology of the 
BRCA1- and BRCA2-mutated tumors is quite 
different, as are their CGH profiles. The function 
of BRCA2 in DNA repair is probably restricted 
to HR only (40), while BRCA1 has many more 
functions and is involved in other DNA repair 
mechanisms as well, i.e., HR and NHEJ (non-
homologous end joining) (41, 42). This may 
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explain the limited number of chromosomal 
breaks in BRCA2-mutated tumors where other 
repair mechanisms, e.g., NHEJ, may still be 
functional. The accumulating DNA breaks in 
BRCA1-mutated tumors may be explained by 
the fact that more DNA repair mechanisms are 
affected by the absence of BRCA1 (43). Recent 
studies in our institute have employed both 
classifiers as marker for HRD in sporadic 
tumors. It was shown that a BRCA1- or BRCA2-
like CGH profile correlates with a higher 
response rate to adjuvant and neoadjuvant 
alkylating chemotherapy ((44), Lips et al. Breast 
Cancer Research 2011). 
Future perspectives 
Based on the identification of the BRCA1- and 
BRCA2-specific chromosomal aberrations, these 
regions can now be combined for the develop-
ment of a simple, stable and less expensive assay, 
such as a PCR-based test. Such a test would be a 
powerful additional tool in current diagnostics 
routine to identify hereditary breast cancer. 
Conclusion 
Using archival material, we have built a classifi-
cation method that is able to distinguish BRCA2-
mutated from sporadic breast tumors based on 
their chromosomal aberrations with an accuracy 
of 86.5%. We conclude that, although current 
DNA diagnostics detects most BRCA2-mutated 
cases, our aCGH classifier can identify BRCA2-
related cases in addition to those identified by 
current diagnostics. As such, we suggest that this 
new approach, together with our previous 
BRCA1 classifier, may be used as an additional 
tool to identify BRCA1/2-associated tumors, 
either of hereditary or sporadic origin. 
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Genomic signature of BRCA1 deficiency in 
sporadic basal-like breast tumors 
Simon A Joosse, Kim IM Brandwijk, Lennart Mulder, Jelle Wesseling, Juliane Hannemann and Petra M Nederlof 
About 10–20% of all breast carcinomas show a basal-like phenotype, while ~90% of breast tumors from 
BRCA1-mutation carriers are of this subtype. There is growing evidence that BRCA1-mutated tumors 
are not just a specific subset of the basal-like tumors, but that (the majority of) basal-like tumors show a 
dysfunctional BRCA1 pathway. This has major treatment implications, because emerging regimens 
specifically targeting DNA repair mechanisms would then be most effective against these tumors. To 
further understand the involvement of BRCA1 deficiency in sporadic basal-like tumors, we investigated 
41 basal-like tumors for BRCA1 mRNA expression by quantitative real-time polymerase chain reaction, 
BRCA1 promoter methylation, their genomic profile by array-CGH, and gene expression levels by whole 
genome expression arrays. Array-CGH results were compared to those of 34 proven BRCA1-mutated 
tumors. Basal-like tumors were subdivided into two equal groups: deficient and proficient in BRCA1 
gene expression. The chromosomal makeup of BRCA1 deficient sporadic basal-like tumors was similar 
to that of BRCA1-mutated tumors. BRCA1 proficient sporadic basal-like tumors were more similar to 
nonbasal-like tumors. Only half of the basal-like breast tumors are actually deficient in BRCA1 expres-
sion. Gain of chromosome arm 3q is a marker for BRCA1 deficiency in hereditary and sporadic breast 
tumors. 
Genes, Chromosomes and Cancer. 2011 Feb; 50:71-81. © 2010 Wiley-Liss, Inc. 
Introduction 
 Breast cancer is the most frequently occur-
ring cancer among women in the western world. 
It is a heterogeneous disease, consisting of 
several tumor subtypes. Identification and 
characterization of these subtypes are important 
to understand the pathogenesis of the disease 
and obtain better treatment options in the 
future. One of the breast cancer subtypes is 
called ‘‘basal-like’’ and describes an aggressive 
tumor group with poor prognosis. Basal-like 
breast tumors are characterized by the expres-
sion of markers often found in normal 
basal/myoepithelial cells (1) and the absence of 
the expression of estrogen receptor (ER), 
progesterone receptor (PR), and ERBB2 
(HER2/neu) (2, 3). Because of the lack of 
expression of these receptors, this group is often 
referred to as "triple-negative". Among the 
sporadic breast cancers, the basal-like phenotype 
represents ~15% of the invasive tumors (3, 4). 
However, among the hereditary BRCA1-mutated 
breast tumors, this subtype accounts for 80–90% 
of cases (5, 6). Gene-expression profiles of 
BRCA1-mutated breast tumors show many 
similarities to those of sporadic basal-like tumors 
(7), and it has been shown that BRCA1 mRNA 
expression is lower in most basal-like tumors 
compared to matched controls (8). This indi-
cates that loss of function of BRCA1 is important 
in basal-like tumors. 
 Sporadic basal-like tumors can loose BRCA1 
by various mechanisms, such as gene mutation 
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or promoter hypermethylation. Although in 
~10% of the basal-like breast tumors a BRCA1 
mutation can be found (9), screening for gene 
mutations is generally not allowed in sporadic 
cancer cases where the patient did not give any 
informed consent. Furthermore, investigating 
promoter hypermethylation is not part of 
routine diagnostics for sporadic breast cancer, 
although it can be found in a substantial propor-
tion of breast cancer patients (8, 10, 11). We 
therefore explored whether we could identify a 
general marker for BRCA1 deficiency in this 
study. 
 Because BRCA1 is involved in DNA repair 
by homologous recombination, loss of function 
will result in accumulation of DNA damage and 
chromosomal instability. As we and other 
researchers have shown, BRCA1-mutated 
tumors develop a distinct pattern of chromoso-
mal aberrations (12-17). Some of these aberra-
tions are similar to those of sporadic basal-like 
tumors (18, 19). However, the use of different 
detection techniques, control groups, and study 
designs in these studies makes direct and 
quantitative comparison between the sporadic 
basal-like and BRCA1-mutated tumors difficult, 
if not impossible. Thus far, the similarity be-
tween these two groups concerning copy num-
ber alterations remains elusive. 
 It would be of clinical and biological rele-
vance to determine whether all or a fraction of 
the sporadic basal-like tumors are similar to the 
hereditary BRCA1-mutated tumors. The exact 
location of associated chromosomal aberrations 
and gene expression changes would result in a 
better understanding of tumorigenesis due to 
BRCA1 deficiency in hereditary and sporadic 
basal-like tumors and may finally lead to the 
identification of common therapeutic targets. It 
has already been shown that breast cancer 
patients diagnosed with a BRCA1-mutation are 
more sensitive to DNA damage-based chemo-
therapy than sporadic tumors (20). Additionally, 
evidence for poly(ADP-ribose) polymerase 
(PARP) inhibitors efficiently targeting BRCA1 
deficiency is emerging quickly (21). In this study, 
we show the correlation between copy number 
alterations of basal-like sporadic breast carcino-
mas and their BRCA1 mRNA expression levels. 
 
Materials and methods 
Tumor specimens 
 This study includes two groups of breast 
cancer cases that were all negative for ER, PR, 
and ERBB2 expression by immunohistochemis-
try (IHC) and scored as histological grade III. 
The first group consists of 41 sporadic basal-like 
breast tumors of invasive ductal carcinoma 
(IDC) type, defined as being sporadic as having 
no family history for any type of cancer, with a 
mean age at diagnosis of 48 years (range, 26–82), 
from which gene expression and histopathologi-
cal data were available from an earlier study 
from our institute (2). The second group in-
cludes 34 breast carcinomas (IDC) from patients 
with a confirmed pathogenic BRCA1 germ-line 
mutation and with a mean age at diagnosis of 38 
years (range, 27–61). mRNA, and therefore gene 
expression data, was not available.  
 As an additional control, BRCA1 gene-
expression levels were measured in 83 unselected 
luminal sporadic tumors (IDC) by qRT–PCR, 
taken from an unrelated study from our institute 
(22), and included individuals with a mean age 
at diagnosis of 46 years (range, 27–78). Molecu-
lar breast cancer subtypes were determined by 
the subtype single sample predictor developed by 
Hu et al. (23) for both the basal-like and luminal 
tumor groups. 
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 As a control group for chromosomal aberra-
tions, array-CGH profiles from 23 sporadic, 
histological grade III, and carcinomas (IDC) 
were used. These tumors expressed either one or 
a combination of ER, PR, and ERBB2 (Support-
ing Information Table 1) and with a mean age at 
diagnosis of 45 years (range, 32–60). This group 
is further referred to as the nonbasal-like 
tumors. 
 All experiments involving human tissues 
were conducted with the permission of the 
institute’s medical ethical advisory board. 
 
Pathological review 
 The presence of ER, PR, and ERBB2 were 
determined by revision of immunohistochemical 
staining that was previously performed using a 
standard clinical procedure with antibodies: ER 
AB-14 clone 1D5 + 6F11, titer 1:50 (Neomark-
ers); PR clone PR-1, titer 1:400 (Immmu-
nologic); and c-erbB-2 clone SP3, titer 1:25 
(Neomarkers), respectively. For simplicity, IHC 
scoring was divided into two classes. If ≥1% of 
the tumor cells expressed ER or PR, the tumor 
was scored as positive (+); otherwise, the tumor 
was scored as negative (-) for the corresponding 
staining, according to Viale et al. (24). ERBB2 
scoring was performed according to ASCO/CAP 
and oncoline guidelines (25, 26). A tumor was 
scored positive for ERBB2 when a 3+ staining 
was observed. When a 2+ staining was observed, 
CISH was performed to determine amplification 
(+ in case of six spots or more per nucleus) or no 
amplification (-). A 1+ or negative IHC staining 
was scored as negative (-). Tumor grade was 
determined using the modified Bloom–
Richardson–Elston staging system (27). 
Table 1 – Median number of aberrations per tumor group.
 
Tumor group Average Range StDev t-test p-value 

























B1 vs BL 
B1 vs BLb1-low 
B1 vs BLb1-high 
B1 vs C 
BLb1-low vs BLb1-high 
BLb1-low vs C 


















BLb1-low vs BLb1-high 4.6E-4 









BLb1-low vs BLb1-high 0.86 









BLb1-low vs BLb1-high 0.47 
 
P-values are calculated between tumor groups using 2-tailed t-tests. Number of aberrations in basal-likeB1-low and basal-likeB1-high 
tumors were also separately analyzed for losses, gains, and amplifications. B1=BRCA1-mutated, BL=Basal-like, C=non-basal-like, 
StDev=Standard Deviation. 
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DNA isolation and array-CGH 
 All sample material used for array-CGH 
experiments was formalin-fixed, paraffin-
embedded tissue from the hospital’s pathological 
archive, collected between 1985 and 2001. DNA 
was extracted by proteinase-K digestion after 
deparaffinization, and quality was tested using a 
multiplex PCR as previously described (13, 28). 
Tumor and reference DNA were labeled with 
Cy5 and Cy3, respectively, co-hybridized to a 
microarray containing 3.5k BAC/PAC-derived 
DNA segments covering the whole genome with 
an average spacing of 1 Mb and processed as 
already described (29). Microarray data were 
deposited in NCBIs Gene Expression Omnibus 
and are accessible through GEO Series accession 
number GSE22401 (basal-like), GSE9021 
(BRCA1-mutated), and GSE9114 (nonbasal-
like). 
Aberration detection and 
quantification 
 To analyze and visualize chromosomal 
aberrations, we determined breakpoint locations 
and estimated copy number levels using the 
CGH-segmentation algorithm by Picard et al. 
(30). These data are referred to as the "segmenta-
tion data". To call the copy number level of 
aberrations, profile-dependent cutoffs were used 
that were based on the SD of the middle 50% 
quantile of the segmented data as described by 
Chin et al. (31). The association of the frequency 
of a clone being at a neutral, lost, gained, or 
highly gained copy number between different 
tumor groups was calculated by using a 2 x 4 
Fisher’s exact (FE) test (32). Because adjacent 
BAC clones are expected to be highly correlated, 
a genomic region was called significant when at 
least five adjacent BAC clones were calculated to 
be significant with p < 0.01. Using this approach, 
identifying a region of 5 Mb by chance is < 0.01 
(Benjamini), and copy number variations 
smaller than 5 Mb were also excluded from the 
analyses. 
Methylation MLPA 
 Methylation of the BRCA1 promoter was 
investigated using a methylation-specific MLPA 
kit according to the manufacturer’s protocol 
(ME001B, MRC-Holland, The Netherlands). 
This kit includes probes against the gene pro-
moters of APC, ATM, BRCA1, BRCA2, CASP8, 
CD44, CDH13, CDKN1B, CDKN2A, CDKN2B, 
CHFR, DAPK1, ESR1, FHIT, GSTP1, HIC1, 
IGSF4, MLH1, PTEN, RARB, RASSF1, TIMP3, 
TP73, and VHL and includes 15 reference 
probes. Basal-like tumors that show BRCA1 
promoter methylation were classified as BRCA1-
deficient. The BRCA1 mRNA expression levels 
of these samples were used to calculate the 95% 
reference range. Next, the reference range was 
applied to BRCA1 mRNA expression levels of 
basal-like samples without BRCA1 promoter 
methylation. Samples with expression levels 
inside the reference range were included into the 
BRCA1-deficient group, and samples outside the 
95% reference range were classified as BRCA1-
proficient. 
Quantitative RT–PCR 
 Expression levels of BRCA1 were assessed by 
quantitative real-time polymerase chain reaction 
(qRT-PCR) as a method independent of the 
microarray data to prevent array-based bias in 
the 41 basal-like and 83 luminal breast tumors. 
The TaqMan Gene Expression Assay for BRCA1 
(#Hs01556193_m1, Applied Biosystems, Foster 
City, CA) was used for this purpose. The reac-
tions were performed according to the manufac-
turer’s protocol with 10 ng cDNA (2 ng/μl) for 
each sample, resulting in an amplification 
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product of 59 nucleotides. Expression levels of 
β-actin and GAPDH were measured as endoge-
nous controls, and cDNA from MCF-7 cells in 
different dilutions was used to obtain a standard 
curve. qRT-PCR runs were performed on the 
7500 Fast System, and analyses were conducted 
using 7500 Fast Real-Time PCR Software version 
1.3.1. Expression levels were calculated by the 
relative standard curve method. 
Results 
BRCA1 expression in basal-like 
tumors 
 To investigate whether basal-like tumors 
could be subdivided into groups based on their 
level of BRCA1 expression, BRCA1-deficient 
tumors were identified by measuring BRCA1 
promoter methylation. Fourteen of the basal-like 
tumors (34%) showed BRCA1 promoter methy-
lation. Promoter methylation usually results in 
silencing of the gene. Indeed, all cases with 
methylated BRCA1 promoter showed low-
BRCA1 mRNA expression compared to the 
remaining samples (p < 5.0e-5, two-sided t-test). 
We defined the basal-like tumors with methy-
lated BRCA1 promoter as the basal-like 
‘‘BRCA1-low" group, which is subsequently 
referred to as the basal-likeB1-low group. Using 
95% reference range on their BRCA1 expression 
levels, we determined which of the basal-like 
samples without BRCA1 promoter methylation 
could be included in the basal-likeB1-low group. 
All samples outside the 95% reference range 
were classified as basal-like ‘‘BRCA1-high’’ and 
are subsequently referred to as the basal-likeB1-
high group. As can be seen in Supporting Infor-
mation Fig. 2, a binominal distribution could be 
used to describe the methylation results (methy-
lated and unmethylated), because no continuous 
correlation was observed between levels of 
methylation and mRNA expression. Twenty-one 
samples (51%) were included in the basal-
likeB1-low group, and 20 samples (49%) were 
included in the basal-likeB1-high group (Fig. 1). 
 Expression of BRCA1 mRNA in the com-
plete basal-like tumor cohort was significantly 
lower compared to the 83 sporadic luminal 
tumors (p = 1.4e-4, two-sided t-test) (Fig. 1). 
Median relative expression of BRCA1 was 0.24 
and 0.69 in basal-like and luminal breast tumors, 
respectively. For the basal-likeB1-low group, the 
median expression level was 0.17, while it was 
0.66 for the basal-likeB1-high group, which is 
comparable to that of the luminal tumors 
(p = 0.47, two-sided t-test) (Fig. 1 and Support-
 
 
Figure 1 – BRCA1 mRNA expression. Box plots showing 
relative BRCA1 mRNA expression in sporadic basal-like breast 
tumors (left, n=41), luminal breast tumors (middle, n=83), 
and the same basal-like breast tumor cohort separated on the 
basis of BRCA1 deficiency as described in Methods. 
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ing Information Table 1). These results indicate 
that approximately half of the basal-like breast 
tumors express BRCA1 at levels similar to 
luminal tumors and half express BRCA1 at a 
significantly lower level, if at all. 
RASSF1 gene promoter methy-
lation and BRCA1 expression 
 Although promoter methylation of BRCA1 
was abundant in sporadic basal-like tumors, we 
could not detect it in nonbasal-like tumors 
(n = 23). Additionally, in a larger series 
(n > 150), we have seen that methylation of the 
BRCA1 promoter in sporadic nonbasal-like 
tumors was rare (3%, unpublished data). Besides 
BRCA1, 23 other tumor suppressor genes were 
simultaneously investigated for promoter 
methylation including RASSF1. Methylation of 
the RASSF1 promoter is reported to be less 
abundant in BRCA1-associated breast cancer 
(33). As shown in Supporting Information 
Table 1, a trend can be observed in our data set, 
such that the RASSF1 promoter was more often 
methylated in basal-likeB1-high tumors compared 
to basal-likeB1-low tumors (p = 0.034, two-sided 
t-test, uncorrected for multiple testing). These 
data were similar to the methylation patterns of 
BRCA1-mutated tumors, in which methylation 
of the promoter of RASSF1 was also absent; 
nonbasal-like tumors on the other hand often 
showed methylation of the RASSF1 promoter 
(73%, unpublished data, n > 150). These results 
indicated that BRCA1 expression could be 
correlated with methylation of the RASSF1 
promoter. Methylation states of all individual 
basal-like tumor samples are listed in Supporting 
Information Table 1. 
Figure 2 – Clustering of array-CGH 
profiles. Unsupervised hierarchical 
clustering (complete linkage) of BRCA1-
mutated , basal-likeB1-low , basal-likeB1-
high , and nonbasal-like  tumors. While 
the BRCA1-deficient cases cluster together 
in cluster I , the BRCA1-proficient cases 
are located in clusters II-III . Shown is 
the heat map of the CGH segmentation 
data, where green is positive log2(ratio) 
and red negative. Here, gain on chromo-
some 3q has been highlighted, which has 
been found in BRCA1-deficient, and not 
BRCA1-proficient tumors, as a significant 
difference in later analyses. Blue circles 
indicate samples with methylation of the 
BRCA1 promoter . 
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Level of chromosomal imbal-
ance is associated with level of 
BRCA1 expression 
 Histological high-grade tumors show 
extensive chromosomal imbalance (34). To 
determine whether there was a difference in the 
level of chromosomal imbalance among BRCA1-
mutated, basal-likeB1-low, basal-likeB1-high, and 
grade III nonbasal-like control tumors, the 
number of aberrations (i.e., calculated segments 
outside the profile-dependent thresholds) was 
counted (Table 1 and Supporting Information 
Fig. 3). Although all investigated tumors were 
histological grade III, the basal-likeB1-high group 
showed significantly less aberrations compared 
to the BRCA1-mutated and basal-likeB1-low 
groups (p < 0.01), but there was no significant 
difference when these tumors were compared to 
the nonbasal-like control tumors (p = 0.33). The 
average number of aberrations of the BRCA1-
mutated and basal-likeB1-low tumor groups was 
very similar (p = 0.39, Table 1). The difference in 
the number of aberrations was mainly caused by 
more losses found in basal-likeB1-low tumors 
(Table 1). These results imply that the level of 
chromosomal imbalance is not dependent on 
histological grade, but on BRCA1 status. 
Copy number alterations in 
hereditary and sporadic breast 
tumors 
 To investigate the correlation among the 
genetic signatures (aberrations) of the different 
 
 
Figure 3 – Aberration frequencies. Frequency plots of basal-like (A), BRCA1-mutated (B), basal-likeB1-low (E) and basal-likeB1-high (F) 
tumors, showing the amount of gain (green) and loss (red) along the whole genome. Fisher’s exact test was used to determine the most 
significant regions between BRCA1-mutated and basal-like tumors (C), basal-likeB1-low and basal-likeB1-high tumors (D), BRCA1-
mutated and basal-likeB1-low tumors (G), and BRCA1-mutated and basal-likeB1-high tumors (H). P-values are minus log10 transformed 
and depicted as light blue (p>0.01) or dark blue (p<0.01). 
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tumor groups, unsupervised hierarchical 
clustering (complete linkage correlation) was 
performed on the whole-genome segmentation 
data of sporadic basal-like, BRCA1-mutated, and 
control tumors. Figure 2 shows that basal-
likeB1-low tumors cluster with BRCA1-mutated 
tumors, while many basal-likeB1-high tumors 
cluster separately from the BRCA1-deficient 
tumors along with grade III nonbasal-like 
tumors. This indicates that similar aberrations 
are present in BRCA1-deficient tumors that are 
independent of the cause of the deficiency (i.e., 
mutation or methylation). Additionally, tumors 
proficient in BRCA1 develop a different signa-
ture of aberrations. 
 Next, supervised analyses were performed 
based on the frequency of copy-number altera-
tions. We published previously that BRCA1-
mutated tumors show a different spectrum of 
aberrations compared to the general population 
of sporadic breast cancer (13). In the present 
study, we also show that the spectrum of aberra-
tions was very different when only compared to 
grade III nonbasal-like sporadic tumors (Sup-
porting Information Fig. 1). Interestingly, the 
sporadic basal-like tumors were much more 
similar to the BRCA1-mutated breast tumors 
(Figs. 3A–3C). Panels A and B of Figure 3 
display the genome-wide frequency of gain 
(green) and loss (red) in basal-like and BRCA1-
mutated breast tumors, respectively. Most 
tumors in both groups showed the common 
breast cancer aberrations, namely, gain of 
chromosome arms 1q and 8q and loss of 8p. 
Moreover, previously identified aberrations 
specific for BRCA1-associated, ER negative, or 
basal-like tumors were also found, as repre-
sented by gains of regions in chromosome arms 
3q, 6p, 10p, 12p, and 21q and losses of regions in 
3p and 5q (see Supporting Information 2 for a 
detailed whole-genome description and exact 
locations). Figure 3C shows p-values calculated 
by Fisher's exact test based on the number of 
different aberrations in both groups. Several 
genomic regions (e.g., located on 3q, 5q, 14q and 
19q, see Supporting Information Table 2 for full 
list) were identified with significantly different 
frequencies between BRCA1-mutated and basal-
like tumors (p < 0.01, indicated in dark blue). To 
determine whether these aberrations were 
correlated with BRCA1 expression, the following 
two comparisons were performed. 
 First, an aberration frequency comparison 
was made between basal-likeB1-low and basal-
likeB1-high tumors, which revealed several signifi-
cantly different genomic regions (Fig. 3D and 
Supporting Information Table 2). In basal-
likeB1-low tumors, 3p24-p22.3, 3q13-q26.2, 13q22, 
16p12-p11, and 16q22-q24 were more often 
gained, and 9q, 9q31.3-q33.1, 10q23.1-q23.31, 
and 12q23.3 were more often lost, compared to 
basal-likeB1-high tumors. 
 Second, the basal-like tumor subgroups were 
compared to BRCA1-mutated tumors using a 
similar frequency analysis as outlined earlier. 
Figures 3E and 3F depict the aberration frequen-
cies in the basal-like subgroups, whereas Figures 
3G and 3H show the corresponding p-values 
calculated by Fisher's exact test (see also Sup-
porting Information Table 2). Basal-likeB1-low 
breast tumors were most similar to BRCA1-
mutated tumors, and only two small genomic 
regions at 2p24-25 and 14q24 presented with a 
significantly different frequency (P < 0.01 at ≥ 5 
adjacent BAC clones). Basal-likeB1-high tumors 
showed many more aberrations with signifi-
cantly different frequencies (Fig. 3H and Sup-
porting Information Table 2), which included 
3p21-p26, 3q11-26, 5q11-q33, 6q12-21, 10q21-
q23, 12q13.13-q14.1, 12q21.2-q24.22, 14q11-q12, 
14q23-q24, 16p12-p11, 16q22-q24, and 17p. 
 These results indicate that basal-like tumors 
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are quite similar to BRCA1-mutated tumors. 
However, differences among these groups are 
still present, which were only identified in basal-
likeB1-high tumors. Basal-likeB1-low tumors are 
almost identical to BRCA1-mutated tumors. 
H2B gene regulation is associ-
ated with BRCA1 expression 
 Gene-expression data from Kreike and 
colleagues (2) were investigated to determine 
whether BRCA1 mRNA expression relates to 
different gene-expression patterns in basal-like 
tumors. Differentially expressed genes in basal-
likeB1-low tumors could reveal biological processes 
associated with BRCA1 deficiency. Additionally, 
the analysis of gene-expression patterns in basal-
likeB1-high tumors could elucidate differences 
within basal-like breast cancer. 
 To evaluate the statistical significance of 
gene-expression patterns between basal-likeB1-low 
and basal-likeB1-high tumors, the significance 
analysis of microarrays method (35) was used for 
all the 5830 significant genes. For a false discov-
ery rate of 5%, delta was 0.488. Fifty-seven 
unique genes were found to be significantly 
downregulated in basal-likeB1-low tumors when 
compared with basal-likeB1-high tumors (Support-
ing Information 3) and none was upregulated. 
DAVID (36) was used to perform functional 
annotation clustering. From the significant 
genes, 7 (12.5%) were selected to be at the most 
significant cluster, Histone H2B (p = 5.5e-9, 
Benjamini), and consisted of the genes H2BFS, 
HIST1H2BB, HIST1H2BD, HIST1H2BJ, 
HIST1H2BM, HIST1H2BO, and HIST1H2BE. 
Discussion 
 Breast carcinomas that are negative for ER, 
PR, and ERBB2, and of a basal-like subtype, are a 
distinct breast cancer subgroup associated with 
poor prognosis. Literature concerning the 
relationship between BRCA1-pathway deficiency 
and basal-like breast cancer has been increasing 
rapidly in the last few years (37-40). Because of 
their BRCA1 deficiency, it is not surprising that 
basal-like and BRCA1-mutated breast tumors are 
similar in many aspects (20). It is of high clinical 
and biological interest to identify the similarities 
between these groups, which could lead to the 
identification of common therapeutic targets. 
BRCA1 expression in basal-like 
tumors 
 Turner et al. (8) showed that basal-like 
breast tumors express less BRCA1 mRNA 
compared to controls. Although slightly differ-
ent definitions for basal-like and control cases 
were used, we can confirm these results and see a 
similar picture when comparing basal-like with 
luminal breast tumors (Fig. 1). 
 In our study, many basal-like breast tumor 
samples showed methylation of the BRCA1 
promoter (34%), which was significantly corre-
lated with BRCA1 gene downregulation. Al-
though our methylation results accord with the 
findings of other studies, which showed that 
BRCA1 promoter methylation is found in 32% of 
basal-like samples (10, 41), Turner et al. (8) 
detected a lower rate of 12% of ductal basal-like 
carcinomas exhibiting BRCA1 promoter methy-
lation. This difference might also be the result of 
the use of slightly different definitions for basal-
like tumors. Besides promoter methylation, gene 
mutation can be the cause of loss of function and 
lowered gene expression. A recent study has 
shown that BRCA1 is mutated in about 10% of 
sporadic basal-like breast tumors. It is therefore 
suggested that young women with early-onset 
triple-negative breast cancer are candidates for 
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mutation screening, regardless of family history 
of breast or ovarian cancer (9). Unfortunately, a 
limitation in our study was that permission for 
mutation screening was not granted for the 
sporadic tumors, because most samples where 
archived 10–20 years ago, and no indication of a 
hereditary mutation was present. From the 
remaining (non-methylated) samples, an 
additional 17% of cases also showed a down-
regulated BRCA1 expression, which may actually 
be due to a real BRCA1 mutation. Separating 
basal-likeB1-low cases based on methylation status, 
however, did not change any of our results (data 
not shown). 
 Forty-nine percent of all basal-like samples 
showed a BRCA1 expression comparable to that 
of luminal tumors (Fig. 1). 
BRCA1 proficiency 
 Although basal-like tumors are similar to 
BRCA1-mutated breast tumors in regard to gene 
expression profiles (7), our study, involving 
unsupervised analyses of genomic aberrations, 
showed that some basal-like tumors cluster away 
from BRCA1-mutated tumors and cluster 
together with nonbasal-like tumors (Fig. 2). 
These tumors belong primarily to the BRCA1 
expressing group (basal-likeB1-high). Analyses of 
aberration frequencies in basal-likeB1-high tumors 
show a different pattern compared to BRCA1-
mutated tumors. A significant difference in-
volved a gain of chromosome arm 3q, an 
aberration very abundant in BRCA1-mutated 
and basal-likeB1-low breast tumors, but almost 
always absent in basal-likeB1-high and nonbasal-
like breast tumors. Significant differences among 
the tumor groups were found not only for the 
frequency of specific aberrations, but also for the 
total number of aberrations. It can be presumed 
that the number of chromosomal aberrations 
(i.e., level of genomic imbalance) is associated 
with the deficiency in a specific DNA repair 
pathway within a defined tumor population. 
Basal-likeB1-high and control nonbasal-like tumors 
showed significantly fewer aberrations compared 
to basal-likeB1-low and BRCA1-mutated breast 
tumors, indicating a difference in the handling 
of DNA repair. Frequent RASSF1 promoter 
methylation in basal-likeB1-high cases makes this 
group additionally more similar to nonbasal-like 
breast tumors where methylation of RASSF1 
promoter is common. RASSF1 promoter methy-
lation in basal-likeB1-low and BRCA1-mutated 
breast tumors is rare, as noted by other research-
ers (33). Taken together, our results indicate that 
basal-likeB1-high tumors are very similar to 
nonbasal-ike grade III breast tumors and less 
similar to proven BRCA1-deficient breast 
tumors. 
BRCA1 deficiency 
 Our results indicate that basal-like breast 
tumors with BRCA1 deficiency (basal-likeB1-low 
tumors) show many similarities to hereditary 
BRCA1-mutated breast tumors in regard to 
genomic aberrations using direct comparisons. 
Unsupervised clustering and supervised analyses 
showed that the well-known BRCA1-specific 
aberrations located along 3p (loss), 3q (gain), 5q 
(loss), and 12q (loss) are shared between the two 
groups. Furthermore, the total number of 
aberrations and rare methylation of the RASSF1 
promoter is similar. When mRNA expression 
profiles of basal-likeB1-low and basal-likeB1-high 
tumors were compared, only a few differences 
were found. The most prominent gene cluster 
that was downregulated in basal-likeB1-low tumors 
was histone H2B. Downregulation of histone 
gene expression has been shown to occur in 
response to DNA double-strand breaks (42). We 
postulate that, due to lack of functional BRCA1, 
accumulation of doublestrand breaks is high in 
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basal-likeB1-low tumors, which keeps histone H2B 
downregulated. Because basal-likeB1-high tumors 
show fewer aberrations and higher BRCA1 gene 
expression levels, histone H2B is normally 
regulated in these tumors. However, because p53 
deficiency alleviates H2B downregulation (42) 
and p53 is frequently mutated in basal-like and 
BRCA1-mutated breast cancer (43, 44), the 
correlation is counter intuitive, and the biologi-
cal relevance of this observation needs to be 
further investigated. Nevertheless, these results 
indicate that the loss of BRCA1 causes only 
minor and indirect gene expression changes in 
basal-like tumors and might explain why basal-
like tumors always cluster together in gene-
expression studies while greater heterogeneity is 
found among basal-like tumors in CGH studies. 
 
Chromosome arm 3q as a 
BRCA1 deficiency marker 
 Several studies have investigated chromoso-
mal aberrations in both sporadic basal-like (18, 
19) and BRCA1-mutated tumors  (12-14, 16, 17, 
45). These studies show gain along 3q and 10p 
and loss along 5q as the most common aberra-
tions in both groups [see also (46) Supporting 
Information Table 4]. This has led to the pre-
sumption that these tumor groups are similar in 
terms of chromosomal aberrations (40). How-
ever, in-depth analysis of these studies also 
reveals many discrepancies. It should be noted 
that the different study designs limit interstudy 
comparisons and hamper localization of the 
exact chromosomal boundaries of the aberra-
tions that are shared by the tumor groups. In our 
study, we showed that only half of the basal-like 
tumors are very similar to BRCA1-mutated 
tumors. The genomic instability and specific 
aberrations that develop in basal-like tumors are 
strongly associated with BRCA1 mRNA expres-
sion. Our cluster analyses even suggest that the 
genomic signature as a consequence of (the lack 
of) BRCA1 expression could be as prominent as 
the dominant ER signature, because the basal-
likeB1-high tumors (ER-negative) cluster together 
with ER-positive, grade III, sporadic tumors 
instead of residing with tumors having equal ER, 
PR, and ERBB2 status. 
 In previous studies, we and other researchers 
have identified gain of chromosome arm 3q to 
be an important marker of BRCA1-mutated 
tumors when compared with sporadic tumors 
(12, 13, 17). In the study presented here, we 
showed that gain of 3q is not only present in 
hereditary tumors but also present as most 
significant and in the highest frequency in 
sporadic basal-like BRCA1-deficient tumors 
compared to basal-like sporadic tumors express-
ing BRCA1. Our results indicate that gain of 3q 
(smallest common region of gain: 3q24) could 
serve as a potential marker of BRCA1 deficiency. 
 
Conclusion 
 We conclude that only half of the basal-like 
breast tumors are actually deficient in BRCA1 
expression. Lack of BRCA1 leads to a large 
amount of aberrations and accumulation of 
DNA damage, but not to many direct differences 
in gene-expression profiles. Gain of chromo-
some arm 3q is a marker for BRCA1 deficiency 
in hereditary and sporadic breast tumors. Future 
research should include prescreening of basal-
like tumors for gain of 3q to initiate additional 
BRCA1 diagnostics (i.e., mutation and promoter 
methylation screening) and to prove the clinical 
relevance of the similarity between BRCA1-
mutated and basal-likeB1-low breast tumors. 
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Germline mutations in BRCA1 and BRCA2 explain approximately 25% of all familial breast cancers. 
Despite intense efforts to find additional high-risk breast cancer genes (BRCAx) using linkage analysis, 
none have been reported thus far. Here we explore the hypothesis that BRCAx breast tumors from 
genetically related patients share a somatic genetic etiology that might be revealed by array comparative 
genomic hybridization (aCGH) profiling. As BRCA1 and BRCA2 tumors can be identified on the basis 
of specific genomic profiles, the same may be true for a subset of BRCAx families. Analyses used aCGH 
to compare 58 non-BRCA1/2 familial breast tumors (designated BRCAx) to sporadic (non-familiar) 
controls, BRCA1 and BRCA2 tumors. The selection criteria for BRCAx families included at least three 
cases of breast cancer diagnosed before the age of 60 in the family, and the absence of ovarian or male 
breast cancer. Hierarchical cluster analysis was performed to determine sub-groups within the BRCAx 
tumor class and family heterogeneity. Analysis of aCGH profiles of BRCAx tumors indicated that they 
constitute a heterogeneous class, but are distinct from both sporadic and BRCA1/2 tumors. The BRCAx 
class could be divided into sub-groups. One subgroup was characterized by a gain of chromosome 22. 
Tumors from family members were classified within the same sub-group in agreement with the hypothe-
sis that tumors from the same family would harbor a similar genetic background. This approach 
provides a method to target a sub-group of BRCAx families for further linkage analysis studies. 
With kind permission from Springer Science+Business Media: Breast Cancer Res Treat. 2011 Nov; 130(2):425-36. 
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Introduction 
 According to the World Health Organiza-
tion, breast cancer is the most common cancer 
in women worldwide, representing 16% of all 
female cancers (1). It is estimated that 10% of all 
breast cancer occurrence is familial and that 
known susceptibility genes account for only 
about 25% of familial breast cancer cases. Some 
families are explained by alterations in the high-
penetrance breast cancer predisposition genes 
BRCA1 (2) and BRCA2 (3, 4), fewer by moder-
ate-penetrance genes like CHEK2 (5), ATM (6), 
BRIP1 (7), and PALB2 (8), while an unknown 
fraction is expected to be more truly polygenic, 
meaning that susceptibility is conferred by the 
joint action of several low-risk loci, each with a 
small effect on breast cancer risk (9-11). Other 
genes (PTEN (12), STK11 (13), CDH1 (14), TP53 
(15-18)) are associated with syndromes in which 
the incidence of breast cancer is elevated, but the 
actual risk is difficult to estimate (19). 
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 Although clear progress in our understand-
ing of the genetic susceptibility to breast cancer 
has occurred during the past 15 years, genetic 
studies have failed to identify additional high-
risk breast cancer genes. The majority (75%) of 
families with multiple breast cancer cases do not 
segregate mutations in the known breast cancer 
genes. It is presently not known how many 
breast cancer susceptibility genes exist, how 
many will fall into the class of rare high-risk 
(e.g., BRCAx) or common low-risk susceptibility 
genes, and if and how these factors interact with 
each other to cause susceptibility (a polygenic 
model). Thus, the remainder of familial risk 
might be attributable to an unknown number of 
genes (both recessive and dominant), combina-
tions thereof (10, 20-25), or to common variants 
of genes each conferring a low risk (9, 26, 27). 
Linkage analysis, mutational screening of 
candidate genes, and association studies have 
been the most common methods used in the 
search for new genetic predisposition factors. 
Ponder et al. (28) have argued that linkage is 
appropriate to detect BRCA-like genes (rare and 
highly penetrant), but not common low-risk 
variants, while the reverse is true for association 
studies (28, 29). A linkage study of 149 BRCAx 
families, including several from the present 
study, failed to identify significant LOD scores 
that might signal a new breast cancer susceptibil-
ity gene (30), suggesting that perhaps more than 
one risk-conferring locus was involved. Support-
ing the latter notion, population-based epidemi-
ological studies have shown that most of the 
excess familial clustering of breast cancer is 
distributed across many families, each with a 
small number of cases, rather than in a few very 
extensive families (31, 32). 
 Array comparative genomic hybridization 
(aCGH) was developed to investigate copy 
number changes on a genome-wide scale using 
one single experiment (33). However, the 
sensitivity of aCGH to tumor-derived DNA 
samples is limited by several factors, related to 
sample quality (e.g., contamination with non-
tumor cells such as lymphocytes and stromal 
cells, intratumoral heterogeneity) or technical 
parameters such as array resolution. DNA copy 
number may also be measured using SNP arrays 
(34), which measure the loss of heterozygosity 
(LOH) in addition to copy numbers. Since it can 
be applied to formalin-fixed paraffin-embedded 
(FFPE) material, aCGH is a valuable tool when 
fresh tissue is not available, which is often the 
case when family screening includes deceased 
relatives. 
 Considering the direct connection between 
genetic alterations and oncogenic pathways (35-
41), we hypothesized that families with similar 
aCGH profiles may harbor mutations in the 
same susceptibility gene(s). Consequently, 
specific aCGH aberrations recurrent among 
family members or even different families may 
be indicators of a shared genetic defect. Indeed, 
we have been able to demonstrate that breast 
tumors with a known gene-defect in BRCA1 or 
BRCA2 display distinctive aCGH profiles, which 
allowed us to develop predictive genetic tests for 
BRCA1-mutation (41) and BRCA2-mutation 
(42) carriers. Motivated by our previous results 
from the BRCA1/2 classifiers, we compared 
aCGH profiles derived from BRCAx (n = 58) 
tumors with those of the sporadic control 
(n = 49), BRCA1-mutated (n = 28) and BRCA2-
mutated (n = 28) tumors. Although breast 
tumors of the BRCAx type constitute a hetero-
geneous class displaying widespread genomic 
instability (38, 39), we identified one distinct 
sub-group of tumors from the BRCAx class 
which harbor similar genomic profiles. 
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Materials and methods 
Patients and tumor specimens 
 Genomic tumor DNA of sufficient quality 
for automated aCGH (43) was isolated from 58 
FFPE primary tissue blocks (30) belonging to 27 
different families. Our criteria for classifying the 
samples as BRCAx tumors were as follows: at 
least three cases of breast cancer in the family, 
diagnosed before the age of 60, from which 
genotype could be determined (n = 216) or 
inferred (n = 20); families with cases of ovarian 
cancer or male breast cancer were excluded, and 
occurrences of other types of cancer were 
ignored (30). 
 Forty-nine sporadic control tumors were 
selected from the institute’s archival tissue bank 
without any indication of familial risk for breast 
or ovarian cancer, and no history of visiting a 
clinical genetics center for breast cancer. These 
control cases were all sporadic invasive ductal 
breast carcinomas (IDC) from our previous 
study (41). Out of the 27 families contributing 
together 58 BRCAx tumor DNAs of sufficient 
quality, ten families contributed each a single 
aCGH profile, eight families two, five families 
three, three families four, and one family five 
aCGH profiles. Immunohistochemistry (ER, PR, 
ERBB2, p53) was performed as described before 
(44). 
 The 58 BRCAx tumors were also screened 
for CHEK2 1100delC germline mutation, as 
described by Oldenburg et al. (45). 
 For comparison, this study further included 
28 aCGH profiles of BRCA1-mutated tumors 
and 28 aCGH profiles of BRCA2-mutated 
tumors, from our previous studies (41, 42). A 
single batch of normal reference genomic DNA 
was used in the array hybridizations (for its 
preparation see next section). 
Array-CGH 
 Tumor DNA was extracted from ten FFPE 
sections, each of 10 μm thickness, as previously 
described (46). Reference DNA was prepared 
from whole blood of a reference panel composed 
of six healthy females and sonicated to an 
average fragment length comparable to that of 
the FFPE tumor DNA (600 bp). The control and 
tumor DNA were labeled with ULS-Cy3 and 
ULS-Cy5, respectively, and employed in ~1 Mb 
genome-wide aCGH using bacterial artificial 
chromosome (BAC) probes. Automated hybridi-
zations were performed for 72 h, followed by 
automated washing and drying as described 
before (46). Arrays were scanned with an Agilent 
DNA microarray scanner (Model G2505B, Serial 
number US22502518). Signal intensities were 
determined with ImaGene Scan Control soft-
ware (Version 6.0.1) and raw data processing 
involved median pintip (c.q. sub-array) and 
average signal normalization; for performing 
unsupervised hierarchical clustering (complete 
linkage clustering using Pearson correlation as 
distance metric selection) log2 ratios derived 
from aCGH profiles were used in Matlab 
software (version 7.0.1, The Mathworks, Natick 
MA, USA) . 
 The microarray data have been deposited in 
NCBIs Gene Expression omnibus and are 
accessible through GEO Series (accession 
number GSE18626). 
Statistical methods 
 Raw aCGH data consisted of log2 intensity 
ratios for each of the 3,248 BAC probes situated 
at an average spacing of 1 Mb across all 22 
autosomes and chromosome X. These ratios 
were segmented with an algorithm developed by 
Picard et al. (47). Copy number alterations 
(CNAs) were interpreted as gains or losses and 
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defined as segmented ratios greater than 0.2 or 
smaller than -0.2, respectively. Differential 
aCGH profiles between tumor classes (BRCAx, 
sporadic controls, BRCA1, and BRCA2) were 
defined by two-sided Fisher’s exact testing. 
 In order to build a class predictor based on 
log2 ratios derived from aCGH experiments, we 
employed Prediction Analysis of Microarrays 
(PAM), which uses nearest shrunken centroids 
algorithm, as described by Tibshirany et al. (48). 
We used PAM 2.0 adapted to an Excel frontend, 
which is freely accessible from Stanford Univer-
sity (http://www-stat.stanford.edu/~tibs/PAM). 
Results 
Genomic aberrations of BRCAx 
breast tumors compared to 
sporadic controls, BRCA1- and 
BRCA2-mutated breast tumors 
 Array-CGH profiles were produced for 58 
BRCAx breast tumors. All aCGH data were 
segmented as before (46, 47), and outlier fre-
quencies were given as a fraction of each tumor 
class (58 BRCAx, 49 sporadic controls, 28 
BRCA1, and 28 BRCA2 tumors) presenting a 
gain or loss for each of the 3,248 BAC probes 
measured (Fig. 1). BRCAx tumors were com-
pared to the sporadic control (Fig. 1a), BRCA1-
mutated (Fig. 1b), and BRCA2-mutated (Fig. 1c) 
breast tumors. The frequency of aberrations in 
the aCGH profiles of BRCAx tumors is depicted 
in black, whereas for the other class they are 
compared with the frequency depicted in yellow. 
Significant differential gains and losses (present 
at a higher frequency in one of the classes 
compared) are marked in each of the three 
Figure 1 - Significant differential 
aberrations in BRCAx tumors. 
 A) The comparison between 58 
BRCAx (black trace) and 48 control 
(yellow trace) tumor CGH profiles is 
shown. The x-axis represents all 3,248 
probes on all 23 chromosomes (1 
through X). Centromeres are indicated 
by vertical black lines. The frequencies 
of aberrations (|log2ratio|>0.2) are 
plotted on the y-axis. Vertical green 
bars correspond to significant 
differential gains as determined by a 
two-sided Fisher exact test. All 
depicted bars show p-values below 
0.05; longer bars indicate higher 
significance, with a minimum p-value 
of 0.0001. Similarly, red bars indicate 
significance for differential losses. B) 
The comparison between BRCAx and 
BRCA1 tumors is shown. C) The 
comparison between BRCAx and 
BRCA2 tumors is shown. 
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individual panels of Fig. 1 with green and red 
vertical bars, respectively. Chromosomal loca-
tions (including cytogenetic banding) for most 
significant class differences (p < 0.01, Fisher’s 
exact test) between BRCAx and the other three 
tumor classes investigated are presented in 
Supplementary Table 1 (shaded boxes). While in 
Fig. 1 all significant differential regions are 
marked, the table only lists regions that consist 
of at least three adjacent BAC probes with the 
same pattern of significance. 
 Differential gains between BRCAx and 
sporadic control tumors (Fig. 1a) were promi-
nent on chromosome arms 2q, 8p, 11p, 12q, and 
19p, and along the entire chromosome 22. 
Differential losses were prominent on chromo-
some arms 1p, 4q, and 13q. Despite these 
differences, there was also an abundant overall 
similarity between aCGH profiles of BRCAx and 
sporadic breast tumors. For example, frequent 
aberrations observed in both classes were a gain 
of chromosome arms 1q and 8q, as well as a loss 
of chromosome arms 8p and 11q. 
 Differential gains between the aCGH profiles 
of BRCAx and BRCA1-mutated tumors (Fig. 1b) 
were prominent on chromosome arms 2q, 11q, 
12q, and 19p, and differential losses were 
prominent on chromosome arms 6q and 16q. 
Some of the regions that were earlier identified 
with metaphase CGH (35) as being highly 
specific to BRCA1-mutated tumors are also 
visible, such as 3q (gains) and 5q (losses), as well 
as 3p (losses) which is less pronounced in our 
data set. Aberrations in these three regions were 
more frequent in BRCA1-mutated tumors than 
in BRCAx tumors. 
 Comparison of the frequency of aberrations 
between BRCAx and BRCA2-mutated tumors 
(Fig. 1c) also indicates significant differential 
regions. Differential gains include chromosome 
arms 2q, terminal regions of 7q, 11q, and 12q, as 
well as the entire chromosome 22. Differential 
losses are visible on chromosome arm 6q. In 
regions like 10q or 13p losses are more frequent 
in BRCA2 tumors. 
 To summarize, despite the fact that BRCAx 
tumors are heterogeneous in their aCGH 
profiles, they present 11 cytogenetic regions with 
recurrent gains (2q37, 7q36, 8p11, 10q22, 11p15-
11q13, 12q13, 19p13, 19q13, 20p11, 22q13, and 
Xp22) and one cytogenetic region with specific 
recurrent losses (21q21), which differ from 
sporadic controls, BRCA1- and BRCA2-mutated 
breast tumors. These regions are indicated in 
Supplementary Table 1 (shaded boxes). There 
were few regions like 2q, 11p, 12q, 19p, and 19q, 
which appeared as gains in more than 30% of 
BRCAx tumors and were not found in the other 
three tumor classes. 
 BRCAx tumors have on average 30% (1063 
vs. 816) more aberrant clones (gain or loss) than 
sporadic tumors. This difference was statistically 
significant in a two-sided, unpaired t-test 
(p = 0.003). We next investigated the genomic 
locations of the aberrations in BRCAx tumors, 
and aimed to determine whether any of the 
aberrations which appeared recurrent in this 
class were truly specific (different from controls, 
BRCA1- or BRCA2-mutated tumors). 
BRCAx tumor profile 
heterogeneity 
 The heterogeneity among BRCAx tumors 
could not be seen in Fig. 1, as these graphs 
presented average data for the four tumor 
classes. Therefore, in addition to frequency plots, 
we visualized the genomic profiles of each 
chromosome per tumor per tumor class using 
heatmap diagrams (Fig. 2) after performing 
hierarchical clustering (Pearson complete 
correlation) of the samples. This allowed 
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evaluation of within tumor class heterogeneity 
and direct genome-wide comparison of BRCAx 
tumors with sporadic control, BRCA1-, and 
BRCA2-mutated tumors. We used this approach 
to investigate all 22 autosomes and chromosome 
X. For the majority of chromosomes there were 
no major differences between the heatmap 
diagrams of BRCAx and the other tumor classes, 
 
 
Figure 2. Heatmap diagrams (derived from log2 ratios) for different chromosomes illustrating that BRCAx tumors are distinct from 
BRCA1, BRCA2, and sporadic control tumors. Diagrams for chromosomes 8, 14, 17, 21, and 22, are shown in panels a, b, c and d, 
respectively. Samples are sorted vertically. This vertical sorting is performed individually per panel (class), based on sample-to-sample 
complete Pearson correlation clustering of DNA copy number state (CGH level). Horizontal axes are not plotted to genomic scale but 
jump from BAC to BAC clone at the library density of approximately 1 Mb resolution. Color scales were set to saturate at -1 and 1 for 
relative DNA copy numbers (red–black–green). Gains are represented in green and losses in red. 
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and there were obvious similarities between 
BRCAx sub-groups and at least one sub-group 
from the other tumor classes. Interestingly, for a 
number of chromosomes, the genomic profiles 
derived from BRCAx tumors showed distinct 
patterns in at least some tumor sub-groups, in 
contrast to all other three tumor classes. Four of 
the most prominent examples to illustrate these 
differences for chromosomes 8, 17, 21, and 22 
are presented in Fig. 2a–d, respectively. Heatmap 
diagrams for all the other chromosomes are 
provided as supplementary material (Supple-
mentary Figure 1). 
 For all tumor classes, chromosome 8 is 
characterized by frequent loss (red) of chromo-
some arm 8p and gain (green) of arm 8q (Fig. 
2a). In contrast, a subset of BRCAx tumors 
showed no change, gain or loss of the entire 
chromosome (middle part of BRCAx panel). 
 For chromosome 17, there was a common 
pattern shared by all four classes, characterized 
by loss of chromosome arm 17p and gain of arm 
17q. However, a large subset of BRCAx tumors 
displayed gain of the complete chromosome 
(Fig. 2b, upper half of the BRCAx panel), while a 
relatively small subset of BRCAx tumors pre-
sented loss of the entire chromosome (Fig. 2b, 
middle part of the BRCAx panel). 
 The majority of BRCAx tumors showed 
chromosome arm 21p loss and gain of arm 21q, 
but the reverse pattern can be discerned in a 
minor fraction as well (Fig. 2c, upper part of the 
BRCAx panel). All other tumor classes showed 
more scattered patches of gains and losses 
(Fig. 2c). 
Chromosome 22 gain in a sub-
group of BRCAx tumors 
 The profiles of BRCAx tumors for chromo-
some 22 were approximately equally distributed 
in two major classes: those with gain and those 
with loss of the entire chromosome. Neverthe-
less, a minority of tumors with more complex 
rearrangements were also present. While the 
class with loss of chromosome 22 is similar to 
the pattern observed in BRCA1-, BRCA2-
mutated and sporadic control tumors, the class 
with chromosome 22 gain is specific for BRCAx 
tumors (Fig. 2d, bottom part of the BRCAx 
panel). 
 Given the very distinct pattern of chromo-
some 22, we further asked whether the BRCAx 
sub-groups identified based on chromosome 22 
profiles were family related and whether tumors 
from the same family fall into the same sub-
class. It was our hypothesis that BRCAx sub-
groups that harbor a common predisposing gene 
might exist. In this case one would expect that 
the same genomic aberrations will be displayed 
by the tumor profiles of sub-group members and 
that family members would belong to the same 
sub-group. To test this hypothesis, we evaluated 
chromosome 22 profiles of all families for which 
we had three or more tumor cases analyzed. The 
most interesting were cases with a gain of 
chromosome 22, as that pattern seems specific 
for BRCAx tumors only. 
 Among the 27 families included in our 
BRCAx series, seven families contributed three 
or more aCGH profiles to our dataset, forming a 
total of 25 tumor profiles. When visualized by 
Unsupervised Hierarchical Clustering (Fig. 3), 
three of these families presented a gain of 
chromosome 22 in all tumors (RUL39 n = 4, 
RUL79 n = 5, RUL154 n = 3) and one family in 
two of the three tumors analyzed (RUL70 n = 3). 
From the remaining three families, one showed a 
loss of chromosome 22 in all tumors (RUL153 
n = 4) and the other two families in two of the 
three tumors analyzed (RUL148 n = 3, RUL75 
n = 3). Subsequently, the median ratio for all 
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BAC probes was calculated for tumors of the 
four 22-gain families (yellow trace in Fig. 4a), 
and compared to the median ratio of the remain-
ing three BRCAx families with 22-loss (red trace 
in Fig. 4a) and to the median ratio of the spo-
radic cases (black trace in Fig. 4a). The 22-gain 
BRCAx subgroup had a median ratio signifi-
cantly higher than that of the 22-loss BRCAx 
sub-group, which showed a median ratio similar 
to that of sporadic tumors, as expected from the 
heatmap diagrams (Fig. 2d). 
 We then considered the 22-gain group as a 
potential BRCAx sub-group, and aimed to 
determine whether other chromosome-specific 
patterns could also be identified. First, we 
selected all BAC probes that showed a large 
difference in median ratios between the 22-loss 
and the 22-gain groups. If we selected an (arbi-
trary) ratio difference ≥ 0.3, a total of n = 157 
BAC probes were selected, which were distrib-
uted over several chromosomes (Fig. 4b). 
Interestingly, the sporadic group (black trace in 
Fig. 4b) showed a median ratio similar to that of 
the BRCAx 22-loss group (red trace in Fig. 4b) 
for nearly all BAC probes. 
 We further employed the nearest shrunken 
centroid algorithm (PAM analysis) (48) in order 
to build a class predictor, which could discrimi-
nate between the 22-loss and 22-gain groups. 
The classifier was built on ten breast tumors with 
22-loss and 15 breast tumors with 22-gain 
(referred to as the training sets), including all 
3,248 log2 measurements for all BAC probes on 
the array. A classifier consisting of 405 BAC 
probes was obtained, which was able to correctly 
assign 14/15 tumors from the 22-gain training 
set, and 9/10 tumors from the 22-loss training 
set (Supplementary Fig. 2). The first three 
chromosomes that contributed the most in the 
classifier were 13, 4, and 22 (see Supplementary 
Table 2), which contributed 12, 8, and 7% of the 
 
Figure 3. Unsupervised Hierarchical Clustering for chromo-
some 22 of aCGH profiles derived from 25 tumors belonging to 
seven families from the BRCAx series. Each family contributed 
more than three aCGH profiles. Members of the same family 
are framed in rectangles of the same color. Color scales were 
set to saturate at -1 and 1 for relative DNA copy numbers 
(red–black–green). Gains are represented in green and losses 
in red. 
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total number of BAC probes in the classifier, 
respectively. Chromosome 22 was represented 
by 27 BAC probes, which represented 52% of all 
the BAC probes of chromosome 22 on the array. 
 Among the remaining 33 BRCAx cases, 19 
were classified as 22-gain-like (Supplementary 
Fig. 3). Not all cases showed the characteristic 
22-gain; actually, 4/19 showed 22-loss, but all 
showed the characteristic loss of chromo-
some 13. 
 Most sporadic tumors showed a loss of 
chromosome 22 when visualized by Unsuper-
vised Hierarchical Clustering (Fig. 2d), and 
resembled the BRCAx 22-loss group when the 
median ratios were calculated for this chromo-
some (Fig. 4a). These observations were also 
consistent with the results of the PAM classifier: 
47/49 sporadic control tumors were classified as 
22-loss-like (Supplementary Fig. 4). 
 Figure 5 presents the Unsupervised Hierar-
chical Clustering of the aCGH profiles derived 
from BRCAx and sporadic control tumors. All 
3,248 log2 ratios for all 22 autosomes and 
chromosome X were used for the clustering. The 
dendrogram indicates that the ‘within class’ 
heterogeneities are comparable between sporadic 
and BRCAx tumors, and that there are neither 
major branch points nor obvious immunophe-
notypes across the four immunohistochemical 
markers ER, PR, ERBB2, and p53, suggesting an 
obvious stratification of BRCAx subphenotypes. 
On the other hand, it also seems clear that 
 
Figure 4. Differential median ratios 
derived from the BAC probe 
measurements of 22-loss (red trace), 
22-gain (yellow trace), and sporadic 
control tumors (black trace). The 
absolute difference between 22-loss 
and 22-gain BRCAx sub-groups was 
arbitrarily selected ≥ 0.3.  
A) Chromosome 22 
B) All chromosomes 
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BRCAx and sporadic control tumor profiles did 
not cluster at random, suggesting a possible role 
for an underlying class-specific biology. Both 
BRCAx and sporadic tumors clustered in nine 
sub-clusters, five of which (clusters 1, 2, 5, 6, and 
9) contained only BRCAx tumors. Two other 
clusters (clusters 4 and 7) contained only 
sporadic tumors, another (cluster 3) contained 
24 sporadic tumors and one BRCAx tumor, and 
in another cluster (cluster 8) three sporadic 
tumors were mixed with four BRCAx tumors. 
 The BRCAx tumors cluster in different 
branches: clusters 1 and 2 in a separate branch 
from cluster 5. PAM analysis was performed to 
determine which BACs makeup the differences 
between these main branches. In total, 207 BACs 
were selected on basis of the PAM analysis to be 
able to separate these two groups. These BACs 
are located on different chromosomes and do 
not seem to cluster in specific regions (Supple-
mentary Figure 5). 
Morphology and immunohisto-
chemistry (IHC) of the 22-gain 
BRCAx subgroup 
 The majority (83%, 48/58) of the BRCAx 
tumors was invasive ductal carcinomas (IDC), 
and 16% (9/58) were lobular carcinoma (LC) or 
lobular carcinoma in situ (LCIS). From the 22-
gain group, 73% (11/15) were IDC, which was 
not significantly different from the total group. 
Twenty-nine percent (17/58) of the BRCAx 
tumors were ER- and 16% (9/58) were triple 
negative (ER-/PR-/ERBB2-). In the 22-gain 
group, 20% of the BRCAx tumors were ER-, but 
none were triple negative. In total, 40% (6/15) of 
the 22-gain BRCAx tumors were p53+, but this 
fraction was lower in the remaining BRCAx 
cases (19%, 7/36). 
Discussion 
 A number of linkage studies during the past 
15 years have attempted to identify new high-
risk breast cancer susceptibility gene(s), collec-
tively called BRCAx. No major gene has been 
identified, apart from PALB2 (8), BRIP1 (7), and 
RAD51C (49), which are responsible for a small 
percentage of hereditary breast cancers. BRCAx 
families are primarily defined by the exclusion of 
a role for the known breast cancer susceptibility 
genes BRCA1 and BRCA2, either by direct 
genetic testing, or through phenotypic (clinical) 
criteria such as the presence of ovarian cancer or 
male breast cancer cases. Shortly after the 
identification of BRCA1 (2), it was noted that 
breast cancer families with a case of male breast 
cancer did not show linkage to the BRCA1-locus 
(50). A linkage search in these families readily 
detected a linkage signal on 13q12, the BRCA2 
locus (3). However, a feature that positively 
selects families that are due to an as yet un-
known and rare high-risk gene is lacking. It is 
very likely, therefore, that a group of ‘‘non-
BRCA1/2 breast cancer families’’ is attributable 
to multiple genetic defects. It is not known how 
many additional breast cancer susceptibility 
genes exist, how many will fall into the class of 
 
Figure 5. Unsupervised Hierarchical Clustering of the aCGH 
profiles derived from BRCAx and control tumors. Clustering 
was performed in Matlab using log2 ratios for each of the 3248 
probes from chromosome 1 to chromosome X. Vertical distances 
represent the similarity distance calculated acrossall 3,248 
probes. BRCAx are labeled in blue, and sporadic tumors are
labeled in yellow. Immunohistochemical staining scores are 
given as no staining (gray), positive staining (black), or missing 
data (hatched). 
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rare high-risk (i.e., BRCA1-like) or common 
low-risk susceptibility alleles, and if and how 
these factors interact with each other to cause 
susceptibility (polygenic model) (51). However, 
given that some of the larger linkage studies have 
failed to yield a significant linkage signal, it 
appears that even if a high-risk gene is found, it 
will not explain more than approximately 20% of 
the families. The power of linkage analysis would 
increase dramatically if we could select a sub-
group of patients that would increase the 
proportion of families with this high-risk gene to 
over 50%. Herein, we explored whether aCGH 
profiles of breast tumors from patients of 
BRCAx families could resolve the heterogeneous 
genetic background of these patients. This was 
prompted by the fact that breast tumors from 
patients carrying BRCA1 (41) and BRCA2 (42) 
mutations displayed characteristic aCGH 
patterns. 
 In the present study, we used aCGH to 
analyze a series of 58 BRCAx tumors from 
selected families from a nationwide collection 
(30). These families had three or more members 
with breast cancer diagnosed before the age of 
60, and no ovarian or male breast cancer. These 
criteria are therefore more stringent compared 
with earlier BRCAx reports, which did not 
exclude ovarian cancer (38, 39, 52), included 
samples with less than 60% tumor cells (39), and 
included families (6 of 18) with just two cases of 
breast cancer (53). Moreover, these studies were 
performed in patients from geographically 
distinct regions, which could increase the genetic 
heterogeneity, caused for example by local 
founder mutations. The above-mentioned 
differences may affect risk factor stratification 
and limit comparison with our study. We also 
included two or more tumors from the same 
family to evaluate the assumption that aCGH 
patterns of tumors from family members 
resemble each other more strongly than those 
from different families, since they probably share 
the same genetic predisposition. 
 As expected, we observed a high degree of 
heterogeneity among the 58 BRCAx aCGH 
profiles, in accordance with the failure to 
identify predisposing genes in previous linkage 
analysis in these families (25). We next examined 
family-specific recurrent aCGH aberrations in 
families contributing at least three available 
aCGH profiles. 
 We made two major observations: (1) 
BRCAx tumors show large heterogeneity in their 
genomic profiles, but overall they differ from 
both BRCA1/2 and sporadic tumors; (2) one 
distinct BRCAx sub-group (with chromosome 
22-gain) can be identified on the basis of the 
genomic profiles. This sub-group (consisting of 
4 families) is different from BRCA1/2-mutated 
and sporadic tumors, and shows an overrepre-
sentation of tumors from the same family. 
BRCAx tumor characteristic 
aberrations 
 Chromosome 22-gain among BRCAx 
tumors seems unique since we have not observed 
this high frequency gain in either sporadic, 
BRCA1- or BRCA2-mutated breast tumors 
(Fig. 2d). It will be interesting to determine 
whether 22-gain is a cause or consequence in a 
substantial proportion of BRCAx tumors. In 
BRCA1-mutated tumors, no loss of the BRCA1 
locus can be observed by aCGH in the majority 
of cases, although LOH analysis indicates that 
the wild-type allele is lost, probably due to 
mitotic recombination. Therefore, the predispos-
ing gene does not necessarily need to be on 
chromosome 22. 
 Using a 1 Mb resolution BAC platform, 
Melchor et al. (54) compared 31 non-BRCA1/2 
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tumors with 19 BRCA1-, 24 BRCA2-mutated, 
and 19 sporadic breast tumors by aCGH. They 
distinguished common aberrations across all 
breast cancer groups (such as gains of 1q and 
16p, and losses of 8p and 16q), which are 
concordant with our results. In addition, they 
report a set of altered regions that discriminate 
between tumor classes, but are not specific for 
only one tumor class. The most frequent altera-
tions per tumor class are also visible in our 
frequency plots (e.g., loss of chromosome arm 5q 
in BRCA1-mutated tumors or loss of 13q in 
BRCA2-mutated tumors). In contrast to our 
results, in their study population BRCA1/2-
mutated tumors showed a higher genomic 
instability than BRCAx and sporadic cases. It is 
conceivable that the differences are partially 
attributable to their different tumor selection 
criteria, ethnicity, or both. 
 In a recent SNP-based linkage study, Rosa-
Rosa et al. (55) found a single family (FAM153) 
with suggestive linkage signals in two different 
chromosomes (11q13 and 14q21). Despite the 
fact that mutational screening on candidate 
genes in 11q13 did not indicate any deleterious 
mutations, data from microsatellite markers 
(STR) confirmed 11q13 as a candidate region to 
contain a breast cancer susceptibility gene. This 
family is also included in the present study with 
four tumors analyzed, all classified in the 22-loss 
sub-group. We identified the 11q13 region as 
being specifically altered in BRCAx tumors, as it 
contains differential gains in BRCAx tumors 
compared to other tumor classes. 
BRCAx tumor heterogeneity 
 An elusive but crucial aspect of BRCAx 
families is whether or not different risk factors 
were co-selected for by the clinical criteria used. 
Besides BRCA1 and BRCA2, one other breast 
cancer gene variant was tested in these familial 
tumors, namely, CHEK2-1100delC. We ob-
served both intra- and inter-familial heterogene-
ity for CHEK2 carrier status in BRCAx families 
and concluded that CHEK2 is not the determin-
ing factor in these cancers. Among the 15 
individuals belonging to the 22-gain sub-group, 
only one was carrying the CHEK2-1100delC 
mutation. 
 The Unsupervised Hierarchical Clustering of 
the aCGH profiles derived from BRCAx and 
sporadic control tumors (Fig. 5) indicates 
comparable ‘‘within class’’ heterogeneities 
between sporadic and BRCAx tumors, without 
stratification of BRCAx aCGH profiles across the 
four immunohistochemical markers analyzed 
(ER, PR, ERBB2, and p53). On the other hand, 
tumors from both classes do not cluster at 
random, supporting the idea to further stratify 
BRCAx tumors based on ‘‘aCGH phenotypes’’. 
While our results are promising, the number of 
tumors analyzed is still relatively small. Accord-
ingly, we could identify only four families with 
tumors that had the 22-gain aCGH-pattern. 
Given the limited linkage information of each of 
these families, this number was too small to 
perform meaningful linkage analyses, even 
under homogeneity (data not shown). We are 
presently validating the 22-gain aCGH-pattern 
in an independent set of cases, concomitantly 
collecting DNA for linkage analysis, with the aim 
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Materials and methods 
Sample material: formalin-
fixed, paraffin-embedded 
 In most pathology laboratories worldwide, 
formalin-fixed, paraffin-embedded (FFPE) 
samples are the only tissue specimens available 
for routine diagnostics. To have access to a vast 
amount of material, and to be able to implement 
our results in routine diagnostics in the future, 
we have limited ourselves to the use of FFPE 
material in the studies described in this thesis. 
However, it was the experience in our research 
laboratory from earlier studies that DNA 
extracted from FFPE tissue is not always suitable 
for array CGH analysis. Time and money could 
be used more efficiently if the sample quality can 
be assessed prior to array CGH experiments. 
This has motivated us to develop a multiplex 
PCR to determine the maximum length of DNA 
able to be amplified as a measure of DNA 
quality. Short DNA fragments due to degrada-
tion, or DNA strands that are unable to form 
single strands due to crosslinks, may cause 
unspecific binding and thus hamper hybridiza-
tion efficiency which results in unreliable array 
data. Chapter 2 describes the development of a 
multiplex PCR that is able to test the possibility 
of producing DNA fragments of 100, 200, 300, 
or 400 bp long. We postulated that the longer the 
fragments are that can be produced, the better 
the sample quality is (1). For this test, we have 
chosen the gene GAPDH as genomic target 
because of its importance in cancer cell survival. 
GAPDH plays a central role in glycolysis-
dependent energy supply, and because cancer 
cells metabolize glucose mainly through the 
glycolytic pathway and depend far less on 
oxidative phosphorylation, tumor cells are 
highly dependent on GAPDH for survival and 
proliferation. Therefore, it is very unlikely that 
GAPDH will be lost in breast tumors, making it a 
reliable target for investigation. Indeed, we have 
not observed a successful aCGH experiment 
using DNA from which no PCR product could 
be produced post hoc. 
 The multiplex PCR has been very helpful 
during our studies, especially when investigating 
breast cancer families (see for example Chap-
ter 7). Registration of families carrying a germ-
line predisposition for breast cancer already 
covers several generations on many occasions in 
our hospital. In such cases where tumor tissue 
has been archived, the material can be very old 
and the DNA degredated beyond usage. Here, 
our multiplex PCR has given us insight in which 
samples could still be investigated by array CGH. 
In the past decades, fixation time, usage of 
buffered formalin, and storage conditions have 
been improved and standardized. We have seen 
in our studies that this has led to better conser-
vation of sample material as DNA isolated from 
newer material (after 1990) is of better quality 
compared to older material (before 1990) in our 
hospital. Also other laboratories have been using 
our DNA quality test (2-5). And although array 
CGH technology has improved much in the 
latest couple of years to even combined SNP 
genotyping and copy number alteration analysis, 
sample quality is hard to control, which under-
scores selection of samples prior to analysis for 
even these more advanced microarray platforms 
(4, 5). 
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Array CGH: hybridization 
 In cancer research, array CGH has become a 
valuable tool for the detection of chromosome 
copy number alterations. Challenges of this 
technique were to obtain high signal-to-noise 
ratios to detect single copy number changes, and 
to obtain highly reproducible results with a 
minimal variance for FFPE material. In the past, 
we performed the hybridization procedure and 
washing of the arrays manually, which often led 
to capricious results. Chapter 3 describes the 
standardization of an array CGH protocol for 
FFPE material, making use of a hybridization 
station. Deployment of a hybridization station 
allowed us to hybridize with a more viscose 
hybridization mixture, because we were no 
longer limited in the force of mixing by a 
rocking table as with the manual procedure 
described in chapter 2. A higher viscosity 
facilitated by doubling dextran sulphate concen-
tration increased the effective concentration of 
labeled DNA and thereby increased the signal-
intensities. Additionally, automation of the 
hybridization and washing steps of the arrays 
resulted in highly reproducible results and less 
overall variance in the CGH profiles. Another 
major improvement in our protocol was the 
elimination of formamide, which is commonly 
used in large amounts in most microarray wash 
protocols but is very toxic. Last, although DNA 
from FFPE tissue is generally more problematic 
than fresh material, our automated protocol has 
proven to be very successful in the use of FFPE 
material (6). 
 Further improvements in the technology 
could be made. In an unpublished study, we 
have looked at the dispersion of labeled DNA 
over the microarray during hybridization in a 
hybridization station. For this, we have injected 
hybridization buffer into the hybridization 
chamber with only the last few microliters 
containing labeled DNA. After hybridization 
and scanning, labeled DNA was found to have 
hybridized over the first half of the slide only 
(Figure 1). These results suggested that not every 
DNA fragment will meet its target and signal-
intensities can theoretically be increased even 
more by applying a different mixing mechanism. 
The hybridization station described in this thesis 
uses agitating membranes, pushing the hybridi-
zation buffer back and forward, to facilitate 
mixing. Improvement in hybridization efficiency 
can be made by applying a continuous flow of 
the hybridization buffer over the whole slide. 
Nonetheless, our protocol has proven to be very 
efficient as it has been applied in many success-
ful studies in our hospital as in studies by others 
[this thesis and e.g., (7-15)]. 
 
Array CGH: the platform 
 When performing CGH studies, one should 
be aware that this technique is unable to detect 
copy-neutral abnormalities in the genome. Only 
by using more complex techniques (e.g., paired-
end mapping and next generation sequencing), 
DNA translocations, inversions and loss of 
heterozygosity (LOH) can be visualized on a 
genome wide scale in high throughput fashion 
(16, 17). Compared to the platform described in 
this thesis, other techniques and platforms with 
higher resolution plus the ability of genotyping 
(i.e., SNP arrays) were available at the time we 
performed our experiments but were proven not 
to be suited for FFPE tissue. Advances in the 
field of high-resolution copy number analysis 
now allow for the use of FFPE material, but were 
made after the initiation of our studies (18). SNP 
arrays make use of single nucleotide polymor-
phisms (SNP) that allow for the detection of 
copy numbers and LOH. 
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 The BAC (bacterial artificial chromosome) 
array platform we used had several advantages 
over the other existing platforms. First, our 
arrays were printed "in-house", which was an 
enormous financial advantage. Second, the 
probes called BAC clones cover several hundreds 
of kbp each, allowing the binding of sufficient 
labeled DNA to produce clear signals for detec-
tion (high signal-to-noise ratio). Lastly, every 
probe was printed three times on a single array, 
thereby increasing the accuracy of every ge-
nomic measurement. The increased signal and 
triplicate measurements were required to 
produce very reliable results from FFPE mate-
rial, which is a difficult source of DNA. Still, the 
relatively low resolution of the BAC array 
compared to other CGH platforms and the 
difficulty in array CGH to detect low copy 
number changes raised the question whether 
small, but also low, copy number aberrations are 
correctly called by the BAC array platform. To 
test this, we investigated whether we could 
properly detect a 2-fold gain of just 600 kbp 
(ESR1 amplification) in a related study (19). For 
this, an in silico experiment was performed using 
array CGH data generated from a subject with 
four X chromosomes versus reference DNA with 
two X chromosomes (4X/2X) and array CGH 
data generated from reference versus reference 
DNA (2X/2X). Next, log2ratio values from 
 
 
Figure 1 - Scans of two microarrays, displaying the dispersion of labeled material during the hybridization procedure. Material was 
injected into the hybridization chamber on the left side. 
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random segments of the X chromosomes, 
corresponding to the same number of probes 
spanning the 600 kbp region, were swapped 
from the 4X/2X data into the 2X/2X data. By 
doing so, we modeled a 2-fold gain of 600 kbp in 
the 2X/2X data. This procedure was repeated 100 
times and the fraction that a gain was correctly 
called was calculated. We could identify the 
segment as gain in 71 out of 100 times, showing 
that the BAC array can detect 2-fold gains of 
small regions most of the time. Nonetheless, the 
genomic coverage of the BAC array is low and 
small aberrations between BAC arrays will be 
missed. Whether hereditary breast cancer shows 
such small aberrations and the detection of them 
would be of prognostic value are still unknown 
and have to be tested.  
Other molecular techniques 
 A widely used microarray technique to study 
the behavior of cancer cells is gene expression 
profiling (GEP) (20). This technique has been 
proven to be very useful in the classification of 
molecular breast cancer subtypes (21) and 
prognostic signatures (22-24). However, the 
biggest disadvantage of this approach to study 
cancer is the requirement of messenger RNA, 
which is an unstable molecule and quickly 
degrades. Freshly frozen tumor material is 
needed to extract intact mRNA, which is not 
available in such large amounts as FFPE mate-
rial. Although mRNA can be extracted from 
selected FFPE samples, the overall success rate of 
obtaining informative mRNA is much lower as 
for DNA (25). Because the studies in this thesis 
describe the investigations of hereditary breast 
cancer covering several generations of patients 
from breast cancer families, obtaining informa-
tive mRNA of a statistically sufficient number of 
samples would be extremely difficult. Therefore, 
DNA is a very suitable platform to study in our 
situation. Although DNA copy numbers carry a 
different form of information compared to 
mRNA gene expression patterns, it has been 
shown for classification problems that breast 
cancer can also be subtyped with array CGH as 
well as with GEP (26, 27). 
 Currently, the most elegant technique to 
determine chromosomal aberrations and 
simultaneously detect mutations and loss of 
heterozygosity (LOH) on a genome wide scale is 
next generation sequencing (NGS). It outper-
forms array CGH in resolution to the single 
nucleotide and is not limited by predefined 
probes. Compared with array CGH, the disad-
vantages of NGS are still the high costs and the 
computer power it requires to map sequence 
reads and calculate copy number variations. For 
diagnostic purposes, NGS will not replace CGH 
where such detailed knowledge about the 
complete genome is not required. For example, 
in pre-implantation genetic diagnostics only 
specific genomic aberrations are being investi-
gated like monosomy for chromosome 18 and 21 
or trisomy for chromosome 22. I anticipate that 
also for the diagnostic application for which we 
have used array CGH, finally not NGS but array 
CGH or a PCR based technique will still be used. 
For exploratory studies, NGS will most likely 
develop to become the standard of investigating 
chromosomal aberrations. 
BRCA status prediction 
in breast cancer 
BRCA1 status prediction in 
hereditary breast cancer 
 Routine diagnostics uses a diversity of 
techniques to identify as many BRCA1 muta-
CHAPTER 8  
 
 147 
tions as possible in women in whom the suspi-
cion of breast cancer susceptibility is high. Still, 
novel defects are being found and it is not 
known to what extent BRCA1-associated breast 
cancer patients are missed with current diagnos-
tics (see Chapter 1). Therefore, we developed an 
array CGH based test that can discriminate 
between BRCA1-associated and sporadic breast 
tumors with high accuracy (28). Chapter 4 
describes the construction and validation of an 
array CGH based BRCA1 classifier. Using this 
classifier, we tested a group of 48 non-BRCA1/2 
patients of whom two cases were found to be 
BRCA1-like. Additional analysis did not reveal a 
novel BRCA1 mutation within theses cases; 
however, we could identify LOH of the BRCA1 
locus in both tumors (suggesting possible loss of 
function) and hypermethylation of the promoter 
of BRCA1 in one case. Additional analysis of the 
latter patient also revealed BRCA1 promoter 
methylation in the patent's ovarian tumor. 
Although recent studies have shown that 
hypermethylation can be inherited (29), it is 
questionable whether hypermethylation in this 
case is a germline epimutation. Although we did 
not investigate mRNA transcription, DNA 
extracted from blood did not show methylation 
of the BRCA1 promoter. 
 Several points need to be addressed regard-
ing the methodology of this study. First of all, 
the control group was a group of randomly 
picked sporadic tumors, only stratified on p53 
status by immunohistochemistry. It has been 
proposed that, similar to a previous study by our 
group (30), breast tumors from non-BRCA1/2 
patients should be used as a control group, 
because that will be the group on which the 
classifier will be employed most. However, this 
latter study reported on many false positive cases 
in their validation group that prove to be real 
BRCA1-mutated cases later on. Therefore, such 
control group could contain many unidentified 
BRCA1-mutated cases, weakening the classifier's 
power. Another possibility as control group 
would have been breast tumors, matched for 
hormone receptors, age and grade. Such a group 
would mainly consist of triple-negative (basal-
like) breast tumors and would most likely result 
in a poor classifier, because approximately half 
of the basal-like breast tumors do not express 
BRCA1 and harbor a CGH profile that is similar 
to BRCA1-mutated breast tumors (Chapter 6). 
Therefore, training of a BRCA1 classifier using 
basal-like tumors as control group requires at 
least twice as many cases as initially calculated to 
achieve similar power. Nevertheless, we have 
shown that by enriching for IHC status and 
comparing with our initial results, the BRCA1-
specific genomic aberrations were not correlated 
to IHC status (Chapter 4). 
 Second, instead of using fixed thresholds for 
the identification of gains and losses, it would 
have been more appropriate to have used CGH 
profile and cell percentage dependent thresholds 
to compensate for technical variation as de-
scribed elsewhere (35). The fixed thresholds 
were too stringent and lowered the frequency of 
all aberrations. Although re-analyses of the 
BRCA1-mutated breast tumors using variable 
thresholds showed higher frequencies of the 
aberrations, no differences were observed in the 
results in respect to the comparison of BRCA1-
mutated and sporadic breast tumors (36, 37). 
Compared to other studies, many of the promi-
nent aberrations in BRCA1-mutated breast 
tumors have also been identified by others 
(Table 1). Aberrations commonly identified to 
be specific in BRCA1-mutated breast cancer are 
gain on chromosome 3q and 10p and loss on 
chromosome 5q. Differences between studies 
can be explained by the different techniques 
used to detect and call aberrations and the 
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choice of control samples to which the BRCA1-
mutated cases were compared. 
 Although the classifier requires validation in 
a larger cohort, its usefulness was demonstrated 
in several subsequent studies. Van den Ouwe-
land and colleagues showed that a novel rear-
rangement in BRCA1, deletion of exon 1a-2, was 
a pathogenic BRCA1 mutation (38). In this 
study, breast tumors from several families were 
investigated by array CGH and tested for 
similarity to our BRCA1 specific CGH profile. 
Tumors from exon 1a-2 deletion carriers were 
classified as being associated with deficient 
BRCA1, whereas one tumor from a family 
member that was diagnosed not to carry the 
deletion was classified as sporadic breast cancer. 
This study shows that deletion of exon 1a-2 in 
the BRCA1 gene is not uncommon in the Dutch 
population, indicating that techniques such as 
MLPA are necessary to detect these mutations. 
Table 1 - Prominent chromosomal aberrations in BRCA1-mutated breast tumors from five different studies (28, 31-34), summa-
rized per chromosome arm (Chr. arm). 
 
Chr. arm Tirkkonen (n=21) Van Beers (n=36) Jönsson (n=14) Stefansson (n=11) Joosse  (n=34) 
2q 2q loss (40%)     
3p  3p gain (33%)    
3q  3q gain (67%) 3q gain (>75%)  3q gain 
4p 4p loss (64%)  4p loss (>75%) 4p loss  
4q 4q loss (81%)   4q loss  
5p     5p loss 
5q 5q loss (86%) 5q loss (72%) 5q loss (>75%) 5q loss 5q loss 
6p 6p gain (40%)    6p gain 
7p     7p loss 
7q   7q gain (>75%)  7q gain 
8p  8p no gain    
9p  9p gain (33%)    
10p 10p gain (30%) 10p gain (50%) 10p gain (>75%) 10p gain 10p gain 
12p     12p gain 
12q 12q loss (40%)    12q loss 
13q 13q loss (55%) 13q gain (25%)    
15q   15q loss (>75%)   
16p  16p no gain    
16q    16q gain 16q no loss 
17p   17p loss (>75%)   
17q 17q gain (45%)     
18p  18p gain (28%)    
20q     20q loss 
Xp    Xp loss  
Xq    Xq loss  
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In a study by Tischkowitz and colleagues, the 
pathogenicity of the missense variant M1775K 
was assessed by a combination of functional, 
crystallographic, biophysical, molecular and 
evolutionary techniques, and classical genetic 
segregation analysis (39). These techniques 
included array CGH profiling of breast tumors 
from carriers of the M1775K variant. Our 
BRCA1 classifier classified the breast tumors 
from M1755K carriers as BRCA1-like and thus 
provided another line of evidence of the patho-
genic effect of the missense variant. Further-
more, in one of our following publications we 
studied the CGH profile of the breast tumor 
from a subject carrying the intronic BRCA1 UV 
c.81-9-C>G (36). The tumor was classified as 
BRCA1-associated and as further analyses 
indicated, this variant results in a frame shift, 
thus having a pathogenic effect. 
 The above described results demonstrate 
that the BRCA1 classifier can be helpful to 
clinical diagnostics in providing indications of 
BRCA1-association in non-BRCA1/2 breast 
cancer patients, but can also aid the diagnosis of 
unclassified variants in providing additional 
indications for the pathogenicity of the variant. 
BRCA2 status prediction in 
hereditary breast cancer 
 Similar to BRCA1 mutation screening, it is 
unknown how many BRCA2-associated breast 
cancer patients are missed in current routine 
diagnostics. Furthermore, identification of 
unclassified variants of BRCA2 can complicate 
clinical management. An additional tool, 
indicating the involvement of mutated BRCA2 in 
cancer formation could therefore be very helpful 
in hereditary breast cancer diagnostics. Inspired 
by the success of detecting a CGH profile specific 
for BRCA1-mutated breast tumors, we investi-
gated the chromosomal aberrations of BRCA2-
mutated breast tumors. Chapter 5 describes the 
identification of chromosomal aberrations 
specific for BRCA2-mutated breast tumors when 
compared to sporadic and BRCA1-mutated 
breast tumors. Table 2 describes the most 
prominent aberrations present in BRCA2-
mutated breast tumors found in our and four 
other studies. Commonly identified were loss on 
chromosome 13q and gain on chromosome 17q, 
but also many discrepancies are present between 
the different studies. Based on the array CGH 
data, we developed and validated an array CGH 
BRCA2 classifier using breast tumors from 
proven BRCA2-mutation carriers and sporadic 
breast tumors from women without any family 
history for cancer.  By testing a large group of 89 
breast cases from non-BRCA1/2 patients, we 
could identify 17 cases to have a BRCA2-like 
CGH profile (36). Additional evidence for 
pathogenic mutations and non-functional 
BRCA2 protein was found in several cases; 
however, many of the BRCA2-like samples 
remained unexplained. During validation, we 
observed that the BRCA2 classifier is not very 
accurate in discriminating between BRCA2-
mutated and sporadic breast tumors; this could 
be due to several reasons. First, the control 
group of the BRCA2 classifier might contain 
BRCA2-associated breast tumors and thereby 
diluting the aberrations of interest; however, this 
is highly unlikely given the prevalence of 
BRCA2-mutations in the population (see 
Chapter 1). Second, BRCA2-associated breast 
tumors might exhibit a similar pattern of 
chromosomal aberrations as sporadic breast 
cancer. Dysfunctional BRCA2 might not lead to 
unique chromosomal aberrations or BRCA2 
might also become dysfunctional in sporadic 
breast cancer leading to similar aberrations. 
Third, technical limitations might be responsible 
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for not identifying BRCA2 specific aberrations, 
i.e., the microarray resolution was too low or the 
studied cohorts were too small. Last and proba-
bly the most likely reason, because BRCA2-
related breast tumors are also pathologically a 
heterogeneous group (40), the diversity among 
the CGH profiles might be biologically driven. It 
is unclear at which time point a BRCA2 deficient 
cell transforms to a tumor cell and what its cell 
of origin is. The heterogeneity among the 
differentiation of BRCA2-mutated tumors 
suggests different cells of origin, i.e., luminal 
progenitor cells in diverse stages of differentia-
tion (41). As such, BRCA2-mutated tumors 
follow different paths of development, leading to 
different genomic profiles (42). To be able to 
find BRCA2 specific characteristics in such a 
heterogeneous group, larger cohorts are required 
and subgroups might have to be defined. 
BRCA1 status prediction in 
sporadic breast cancer 
 We have seen that BRCA1-mutated tumors 
harbor chromosomal aberrations that distin-
guish them from sporadic tumors (28). The 
result of classifying a tumor with BRCA1 pro-
moter hypermethylation as BRCA1-like sug-
gested that the classifier selects for BRCA1 
deficiency, instead of BRCA1 mutation status 
(Chapter 4). BRCA deficiency in sporadic breast 
cancer is also referred to as "BRCAness", and 
holds important implications for the clinical 
management of these cancers (42). The increas-
ing evidence following our initial study that 
sporadic basal-like breast tumors are similar to 
hereditary BRCA1-mutated breast tumors due to 
BRCA1 deficiency (43), motivated us to investi-
gate these two breast tumor subgroups in more 
Table 2 - Prominent chromosomal aberrations in BRCA2-mutated breast tumors from five different studies (31-34, 36), summarized 
per chromosome arm (Chr. arm). 
 
 Chr. arm Tirkkonen (n=15) Van Beers (n=25) Jönsson (n=12) Stefansson (n=18) Joosse (n=47) 
1p 1p loss (45%)   1p loss  
3p 3p loss (55%)   3p loss/gain  
3q  3q gain (56%)    
6q 6q loss (60%)   6q loss  
8p    8p loss  
8q    8q gain  
11q 11q loss (65%)  11q loss (>75%) 11q loss  
13q 13q loss (73%)   13q loss 13q loss (78%) 
14q    14q loss 14q loss (62%) 
16p     16p no gain 
16q 16q no loss   16q loss 16q no loss 
17p    17p loss  
17q 17q gain (85%)  17q gain (>75%) 17q gain 17q gain (36%) 
20q 20q gain (60%)  20q gain (>75%)   
Xp    Xp loss  
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detail for similarities by array CGH. As sus-
pected, BRCA1 related aberrations were not 
unique to hereditary BRCA1-mutated breast 
cancer but could also be found in a subset of 
sporadic basal-like tumors where BRCA1 
expression has been lost (37). Chapter 6 de-
scribes that BRCA1 deficiency in hereditary as 
well as in sporadic breast cancer exhibits a 
common genomic profile. To define BRCA1 
deficiency, we assessed BRCA1 mRNA expres-
sion by qRT-PCR in tumor cases with methy-
lated BRCA1 promoter. Subsequent cases with 
BRCA1 qRT-PCR values within the 95% confi-
dence intervals of the methylated cases were 
considered also to be BRCA1 deficient. More 
appropriate would have been to calculate the 95 
percentile using bootstrapping on the BRCA1 
qRT-PCR values of the methylated samples and 
use that as a cutoff for BRCA1 deficiency and 
proficiency (44). Bootstrapping 1000 iterations 
resulted in a median 95 percentile of 0.3475 
(unpublished results), and would have been 
more appropriate to report in the original 
manuscript. Nevertheless, this cutoff approaches 
the cutoff described in Chapter 6 and all the 
subsequent results would remain identical. The 
results of this study show that BRCA1 deficient 
sporadic basal-like tumors harbor a similar CGH 
profile as hereditary BRCA1-mutated and 
display the characteristic gain on chromosome 
3q and 10p and the loss on chromosome 5q. 
These findings might allow for the identification 
of BRCA1 deficiency in (sporadic) breast cancer, 
leading to targeted therapy in the future for such 
cases. 
 Testing the sporadic basal-like breast cancer 
cases with our BRCA1 classifier did not result in 
a clear classification of BRCA1 deficient and 
proficient tumor cases as would have been 
expected (unpublished results). If our BRCA1 
classifier would be accurate in identifying true 
BRCA1-related cases, it should be able to 
distinguish tumors that are not expressing 
BRCA1 from those that are. Instead, many of the 
BRCA1 proficient cases as defined by qRT-PCR 
were classified as BRCA1-like breast tumors. 
These results indicate that our BRCA1 classifier 
is suffering from underlying biologically driven 
noise and that the specificity is different than 
reported. Due to the choice of unmatched 
control samples, the classification might be 
based on triple-negative/basal-like characteris-
tics rather than BRCA1 deficiency. A more 
appropriate control group for the construction 
of a BRCA1 classifier might had been triple-
negative, basal-like breast tumors, expressing 
BRCA1. 
BRCAness and homologous 
recombination deficiency 
 Both BRCA1 and BRCA2 are involved in 
homologous recombination to maintain chro-
mosomal integrity. Lack of one of these genes 
would sensitize tumors to both DNA double-
strand breaks (DSB) inducing chemotherapy and 
PARP inhibitors (45). Therefore, it was proposed 
to use the BRCA1 and BRCA2 specific CGH 
profiles described in this thesis as markers for 
homologous recombination deficiency (HRD) 
and to study BRCAness in sporadic breast 
cancer. Lips and colleagues have studied the 
response on neoadjuvant chemotherapy in 163 
breast cancer patients in relation to the outcome 
of the classifiers (10). Although no association 
was detected between BRCA1 classification and 
therapy response in triple negative tumors, 
luminal BRCA2-like samples seem to respond 
significantly better to neoadjuvant chemother-
apy than those classified as sporadic like. The 
results of this study indicate that our BRCA2 
classifier has strong predictive value for neoad-
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juvant chemotherapy in ER positive breast 
tumors. In another study, Vollebergh and 
colleagues investigated a cohort of tumors from 
breast cancer patients that were randomly 
assigned to adjuvant high-dose platinum-based 
chemotherapy or conventional anthracycline-
based chemotherapy (46). The tumors were 
tested with our BRCA1 classifier as a synonym 
for HRD. Patients that received high-dose 
chemotherapy and of which the tumors were 
related to BRCA1 by array CGH lived longer 
than all other patients, suggesting more benefit 
from DSB-inducing agents. These results 
indicate that an interesting window of opportu-
nity lies in the identification of BRCA status to 
guide therapy in the future. 
Clinical application 
 The classifiers described in this thesis might 
function as additional diagnostic tools to screen 
for BRCA related breast cancer. It can serve as 
indicator for the association with BRCA in 
unclassified variants but also suggest BRCA 
deficiency in sporadic breast cancer cases (28, 
36). However, the application of array CGH 
requires a specialized laboratory, expensive 
equipment, and is labor-intensive. Therefore, we 
have developed a PCR based method to test for 
BRCA1-association which can be performed in 
most diagnostic laboratories. From our array 
CGH based BRCA1 classifier, the most impor-
tant chromosomal aberrations have been 
selected for which a multiplex ligation-
dependent probe amplification (MLPA) assay 
was designed  (47). This assay is able to classify 
BRCA1-mutated and sporadic breast cancer with 
a sensitivity and specificity of 85% and 87%, 
respectively, and could successfully identify 
BRCA1 deficient breast tumors with BRCA1 
hypermethylated promoter. Next, we studied 46 
breast cancer patients with triple-negative 
disease that received high-dose platinum-based 
(HDPB) chemotherapy or conventional chemo-
therapy. Classifying these 46 cases with our 
MLPA or array CGH BRCA1 classifier clearly 
showed that patients with BRCA1 like breast 
cancer had more benefit from HDPB than 
conventional chemotherapy (Figure 2). These 
data suggest that BRCA1 deficient breast tumors 
can be identified by their chromosomal aberra-
tions and that these patients might benefit from 
other therapy than conventional chemotherapy. 
It might therefore be suggested to screen every 
triple negative hereditary and sporadic breast 
tumor for BRCA1 deficiency using our BRCA1 
classifier. 
BRCA status unknown 
BRCAX 
 A major part of the breast (and ovarian) 
cancer families, which are tested for mutations 
in the BRCA1 and BRCA2 genes, are presented 
with a negative test result; the genetics behind 
their predisposition for breast and ovarian 
cancer remains unknown (Chapter 1). Although 
familial breast cancer is still similarly treated as 
sporadic breast cancer, targeted therapy might 
become available in the future and identifying 
the genetic defects responsible for cancer 
formation would then be of vital importance. 
Therefore, much effort has been undertaken to 
search for undiscovered high-risk breast cancer 
susceptibility genes. Because linkage analysis has 
so far not been able to identify new high-risk 
genes, it is suggested that more than one risk-
conferring locus is involved. To be able to 
identify these loci, genetically homogeneous 
groups have to be selected first. Using array 
CGH, we have seen that certain genetic muta-
tions are correlated with specific chromosomal 
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aberrations (Chapter 4 and 5). It might there-
fore be possible that non-BRCA1/2 families that 
have the same genetic defect also present similar 
chromosomal aberrations. Chapter 7 describes 
the array CGH study performed on tumors of 
non-BRCA1/2 breast cancer families (referred to 
as BRCAX tumors) in order to find clusters of 
families with similar genetic profiles and to 
identify their key genetic characteristics. 
 First, the array CGH profiles of the BRCAX 
tumors were compared with those of sporadic 
breast tumors that were taken from an earlier 
study (28). Although several clear differences 
could be distinguished between the two cohorts 
in respect to aberration frequency, it should be 
noted that the particular control group was used 
because of its accessibility and was not matched 
in any way with the BRCAX tumors. This might 
explain why the differences that have been found 
between the groups and those found in a similar 
study by Gronwald and colleagues (48) are not 
alike. In addition, because the studied groups are 
not matched, the results are not independent 
from other factors and those aberrations found 
to be prominent in BRCAX tumors but not in 
the control tumors may not be called "BRCAX-
specific" and can not solely be correlated to a 
single hereditary factor. 
 Next, several of the CGH profiles of BRCA1- 
and BRCA2-mutated breast tumors from two of 
our earlier studies (28, 36) were compared with 
those of the BRCAX tumors. Here, as also true 
for the control tumor comparison, several issues 
of the methodology have to be dealt with. To be 
 
Figure 2 - Survival curves of 
patients with triple-negative 
breast cancer, treated with 
high-dose platinum-based 
chemotherapy (blue) or 
conventional chemotherapy 
(red), separated based on 
BRCA1 classification using 
our original array CGH 
(upper two panels, n=64) or 
MLPA classifier (lower two 
panels, n=40) (47).  
RFS: relapse free survival. 
Cum Survival: cumulative 
survival.  
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able to call gains and losses in the CGH profiles, 
fixed threshold of 0.2 and -0.2 on the copy 
number alteration segment values are applied 
(Chapter 7). By this, variance between samples 
due to tumor cell percentage is not taken into 
account. Furthermore, no differentiation has 
been made between gain and amplification of 
genomic regions. It might have been more 
appropriate to have used CGH profile and tumor 
cell percentage dependent thresholds as de-
scribed elsewhere (35). Subsequently, the 
correlations of the number of gain/no-gain and 
loss/no-loss between the different cohorts were 
studied using 2 x 2 Fisher's exact tests. By 
investigating only two possible observations per 
measurement (e.g., gain versus no-gain), one 
assumes that a different state of the measure-
ment is non existent; however, this is not true in 
respect to chromosomal aberrations. From a 
biological point of few, a more adequate model 
would have been to transfer the continuous data 
of copy number measurements into the follow-
ing discrete parts: lost (< 2 copies), neutral 
(2 copies), gained (> 2 copies), and amplified 
(high-level gain) (35). By this, a 4x2 table 
containing categorical data (a contingency table) 
is formed and should be analyzed appropriately 
(i.e., 4 x 2 Fisher's exact test or 4 x 2 Chi2 test). 
 Another point that should be addressed is 
the comparison between the BRCAX and 
sporadic breast cancer groups by the average 
numbers of 'aberrant clones' (log2ratio meas-
urements exceeding the fixed gain/loss thresh-
olds). Such a comparison does not provide any 
biological information and might only reflect the 
level of technical noise (although other and 
better analyses are available for such compari-
sons). More relevant comparisons would have 
been the number of chromosomal aberrations, 
the sizes, and the type of CGH profiles (see 
Chapter 1) which are all missing in the study 
described in Chapter 7. 
 The more relevant analyses of this study 
were the comparisons of the BRCAX cases 
among each other. The main finding was that a 
part of the BRCAX samples showed gain of 
chromosome 22 while another part showed loss 
of chromosome 22, which was also commonly 
seen in sporadic breast cancer. This suggests that 
the studied BRCAX samples consisted of at least 
two subgroups. Interestingly, the chromosome 
22 aberrations were consistent among the family 
members within the same BRCAX families, 
indicating that gain of chromosome 22 is a 
BRCAX subgroup specific aberration. Following 
on this finding, a classifier was built based on the 
samples that had gain of chromosome 22 
(n = 10) and those with loss of chromosome 22 
(n = 15). The classifier was built using the 
nearest shrunken centroid algorithm (49); 
however, it lacked power for reliable classifica-
tion. For an error tolerance of < 0.10, more than 
15 samples of each class would have been needed 
(50). This could explain why in subsequent 
testing of other BRCAX cases, samples with loss 
of chromosome 22 were classified within the 
"22-gain" class. An alternative explanation is that 
gain of chromosome 22 might not be a specific 
aberration for a subgroup of BRCAX. Therefore, 
it should be investigated in larger series of 
BRCAX cases, whether gain of chromosome 22 
is a relevant marker and is not related to other 
factors such as TP53 mutation status. Because of 
the limited linkage information of each of the 
"22-gain" families, a meaningful linkage analysis 
could not be performed. 
 In conclusion, because of the high heteroge-
neity among BRCAX tumors, much larger 
cohorts are needed in order to identify geneti-
cally similar subgroups to perform linkage 
analyses on. 
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BRCA status related 
biology 
Co-occurrence of mutated TP53 
and BRCA1 
 It has been shown in mouse models that the 
development of mammary tumors is highly 
accelerated when both Brca1 and Trp53 have 
been knocked out. Because Brca1-/- mice are 
embryonic lethal but lethality can be partially 
rescued by Trp53 knockout, it is suggested that 
loss of Trp53 is required to alleviate the cell-
lethal effects of loss of Brca1. This has raised the 
question whether TP53 loss of function is also 
required in BRCA1-mutated human breast 
cancer. We therefore have sequenced TP53 of 
BRCA1-mutated and sporadic breast tumors 
from our study described in Chapter 4, and 
found that indeed most BRCA1-mutated tumors 
have a pathogenic TP53 mutation (51). In 
respect to immunohistochemistry (IHC), it has 
been shown that BRCA1-associated breast 
tumors are more frequently p53 positive com-
pared to sporadic breast tumors. However, our 
study shows that BRCA1-mutated tumors, 
negative for p53, are carriers of TP53 truncation 
mutations. These results indicate that loss of 
TP53 is required in BRCA1-mutated tumors. 
Although it has been shown that TP53 mutations 
can be found more often in basal-like breast 
cancer compared to luminal breast cancer (15), it 
would be interesting to investigate whether 
sporadic basal-like breast tumors deficient in 
BRCA1 expression harbor a TP53 mutation 
more frequently compared to BRCA1 proficient 
basal-like breast tumors. 
  The above findings also open new therapeu-
tic possibilities by targeting the BRCA1 and p53 
deficiency combination. Recent research has 
proposed inhibitors against Cdc7 kinase as a 
highly specific anti-cancer drug in triple-
negative breast cancers (52). Inhibition of Cdc7 
activates a p53-dependent checkpoint, resulting 
in cell cycle arrest to avoid lethal S phase entry in 
normal cells. Lack of p53 results in abrogation of 
the Cdc7-inhibion checkpoint, which is followed 
by lethal S-G2-M phase progression (52). 
 For the training of our BRCA1 classifier 
described in Chapter 4, we have compared 
BRCA1-mutated with sporadic breast tumors, 
stratified for IHC based p53 status. As men-
tioned, mutated TP53 is common in BRCA1-
mutated breast tumors, even among the p53 IHC 
negative cases, making IHC a difficult indicator 
to interpret for TP53 status. If we assume that 
the IHC based p53 status reflects the TP53 
mutation status in sporadic breast tumors well, it 
might be possible that our study was not strati-
fied for TP53 status after all because only 43.5% 
was positive for p53. Specifically, it is known that 
TP53 status is associated with loss of chromo-
some 5q (53, 54); indeed, loss of chromosome 5q 
was abundantly present in BRCA1-mutated 
breast tumors and therefore part of the BRCA1 
classifier (Chapter 4). Although TP53 mutation 
is a characteristic of BRCA1-mutated tumors, 
and thus also loss of chromosome 5q is, it has to 
be taken into account that a higher BRCA1-like 
score might be given to any TP53 mutated breast 
tumor per se. Although further investigation has 
to be performed, these results suggest that the 
CGH profile described specifically for BRCA1-
mutated breast cancer in Chapter 4, probably 
includes several chromosomal aberrations that 
are not only specific for BRCA1-mutated status 
but also for other characteristics like ER negative 
status or TP53 mutation that are both correlated 
with loss on chromosome 5q (53). 
 
CHAPTER 8    
 156 
Secondary BRCA2 mutation 
 Tumors that are deficient in BRCA1/2 have a 
decreased capability to repair DNA and are 
therefore sensitive to chemotherapeutic agents 
causing DNA cross-link such as cisplatin or 
carboplatin and are susceptible to synthetic 
lethality from PARP inhibitors (55, 56). How-
ever, BRCA1/2 mutation carriers frequently 
develop recurrent disease that is resistant to 
platinum agents. It has been shown in BRCA-
mutated ovarian cancer that BRCA function can 
be restored by a secondary somatic mutation in 
the tumor, leading to chemotherapy resistance 
(57-60). So far, little is known about the occur-
rence of secondary mutations in BRCA in breast 
cancer. To date, cell line HCC1428 is the only 
cell line providing evidence of secondary 
mutations occurring in vivo in breast cancer 
(57). HCC1428 was isolated from a woman 
heterozygous for 6174delT mutation in BRCA2 
after she had undergone chemotherapy. The 
Figure 3 - Array CGH 
profiles of breast cancer cell 
line HCC1428 by Kao et al. 
and Neve et al. (61 6,2) 
(upper two panels). 
Frequency plot of array 
CGH profiles of 52 proven 
BRCA2-mutated breast 
tumors (36). Gain of 
genomic material is 
depicted in green; loss of 
genomic material is 
depicted in red. 
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BRCA2 gene in HCC1428 has a 2135 bp internal 
deletion that spans the original 6174delT 
mutation, leading to expression of functional 
BRCA2 transcripts. Consequently, HCC1428 is 
resistant to cisplatin but could be sensitized 
again by BRCA2 depletion. 
 From a biological perspective, it would be 
most interesting to investigate the genomic 
profile of BRCA-mutated breast tumors that 
have developed a second mutation to restore 
BRCA function. Because of natural selection 
during the development of a tumor, certain 
chromosomal aberrations in breast cancer are 
recurrently found that (indirectly) provide 
growth advantage. As gain on chromosome 3q 
and 10p and loss on chromosome 5q are charac-
teristic for BRCA1-mutated breast tumors and 
probably necessary for tumor survival, it can be 
speculated that upon restoration of BRCA1 
function, some of these aberrations might 
become redundant to even obnoxious. Further 
selection on the tumor could then change its 
genomic make-up. Studying BRCA-associated 
breast tumors with secondary mutations might 
give further insight on how selection based 
development of chromosomal aberrations takes 
place and which role BRCA1/2 plays in these 
selection processes. 
 To test the hypothesis that the genomic 
makeup changes after a second mutation, I have 
investigated the CGH profile of the BRCA2 
double mutated cell line HCC1428, published by 
Kao and colleagues and Neve and colleagues (61, 
62). Figure 3 shows the CGH profiles of cell line 
HCC1428 of both publications (upper two 
panels) and the frequency plot the CGH profiles 
of 52 BRCA2-mutated breast tumor specimens 
from our earlier study (bottom panel) (36). 
Although the cell line shows many similarities 
with BRCA2-mutated tumors in respect to 
chromosomal aberrations, our CGH BRCA2 
classifier classifies the cell line as sporadic-like. 
This suggests that HCC1428 is not similar to 
BRCA2-mutated tumors as expected. In this 
specific case however, it is not certain whether 
the difference is due to the secondary mutation, 
the preservation of the cells in culture for a long 
period of time, or that the primary tumor never 
resembled the general BRCA2-associated CGH 
profile in the first place. 
Conclusion and future 
perspectives 
 Several methods exist to predict the associa-
tion of BRCA1 or BRCA2 in the development of 
cancer. In this aspect, microarray technology is a 
useful technique that is able to characterize 
breast cancer at the molecular level, linking these 
characteristics to BRCA1 or BRCA2. The results 
of our classification studies and the results found 
by others indicate that 4-12% BRCA related 
cases, which have not been found by routine 
BRCA mutation screening, can be identified due 
to the investigation of the tumor's chromosomal 
aberrations (28, 36, 63). Although further 
validation in larger cohorts is required, predic-
tion of BRCA-association based on chromoso-
mal aberrations shows to be a promising tech-
nique. Using the predictive markers described in 
this thesis to develop a MLPA based assay is a 
logical next step to assist mutation screening in 
high-risk breast cancer patients, or to provide 
another link between BRCA unclassified variants 
and breast cancer. In addition to hereditary 
breast cancer diagnostics, linking BRCA status to 
sporadic breast cancer might lead to targeted 
therapeutic options for these patients in the 
future. Because BRCA1 and BRCA2 are required 
for DNA repair by homologous recombination, 
our BRCA classifiers might also be useful in the 
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identification of homologous recombination 
deficient tumors and help to guide anti-breast 
cancer therapy. 
 Future perspectives regarding the investiga-
tion of BRCA status specific chromosomal 
aberrations would include optimization of a 
control group for BRCA1 deficient breast cancer. 
Such a control group would consist of BRCA1 
proficient basal-like breast cancer. Furthermore, 
because of the heterogeneity in BRCA2-mutated 
breast cancer, larger cohorts are required for the 
identification of possible subgroups and their 
specific aberrations. The same is applicable in 
the search for BRCAX subgroups where larger 
cohorts are required. For the detection of 
chromosomal aberrations, array CGH has been a 
valuable tool but newer tools such as SNP arrays 
and next generation sequencing are currently 
available and provide more detailed and accurate 
data.  
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Chapter 1  
 One of the strongest risk factors for develop-
ing breast cancer is a family history of the 
disease. Although in many families the cause of 
the high breast cancer incidence can not be 
identified, most of the DNA mutations that are 
found reside within the genes BRCA1 and 
BRCA2. A pathogenic mutation in one of these 
genes increases the risk for developing breast or 
ovarian cancer substantially and it is therefore of 
high clinical importance to recognize the 
mutation. The gold standard to determine 
mutations is direct sequencing of genomic DNA. 
Because the prevalence of a mutation in BRCA1 
or BRCA2 is in general low, pre-selection is 
performed based on family characteristics to 
determine the eligibility for genetic testing. Still, 
of all the breast cancer families that are eventu-
ally screened, it is estimated that approximately 
15% of the BRCA1 and BRCA2 carriers are 
missed with standard DNA diagnostics. New 
techniques are being applied that are based on 
molecular characteristics of the tumor to identify 
the underlying genetic defects. Because BRCA1 
and BRCA2 are both involved in DNA repair by 
homologous recombination, defects in one of 
these genes will be followed by chromosomal 
instability. Copy number alterations can be 
investigated by array comparative genomic 
hybridization (aCGH) which is the main tech-
nique used for studies described in this thesis. 
 
Chapter 2 
 Usually, tumor material is formalin-fixed 
and paraffin-embedded (FFPE) after it has been 
surgically removed. This way, the malignant 
tumor can be preserved and even after long 
periods of time examined with newly developed 
techniques. However, fixation time and storage 
duration can affect the quality of the DNA 
negatively and the material might not always be 
suitable for array CGH. We have therefore 
designed a multiplex PCR that is able to produce 
amplification fragments of 100, 200, 300, and 
400 bp depending on the quality of the DNA. 
Sample material, which allowed the amplifica-
tion of at least the 100 and 200 bp fragments, 
showed to be suitable for array CGH. 
 
Chapter 3 
 To standardize array CGH, and therefore be 
able to obtain reproducible results, we have 
developed an automated hybridization protocol 
optimized for FFPE material using a hybridiza-
tion station. By studying the different hybridiza-
tion durations, temperatures, washing condi-
tions, and hybridization mixture contents, we 
were able to minimize noise, maximize the 
dynamic range, and obtain very reproducible 
array CGH data. 
 
Chapter 4 
  To find markers specific for BRCA1-mutated 
breast cancer, we designed a classification 
method based on array CGH data. Chromoso-
mal aberrations of 18 BRCA1-mutated and 32 
sporadic breast tumors were obtained by array 
CGH and the two groups were compared. Gains 
on chromosome 3q and 6p and losses on chro-
mosome 5p, 5q, 7p, 12q, and 20q were identified 
to be characteristic for BRCA1-mutated tumors. 
Based on the tumor group specific characteris-
tics, a classifier was designed and 16 BRCA1-
mutated and 16 sporadic breast tumors were 
tested in order to validate the classifier, resulting 
in a sensitivity and specificity of 88% and 94%, 
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respectively. Next, array CGH profiles of 48 non-
BRCA1/2 tumors were tested using our classifier. 
We identified two cases to be BRCA1 like, of 
which we could identify BRCA1 deficiency 




 In order to find markers specific for BRCA2-
mutated breast cancer, array CGH profiles of 28 
BRCA2-mutated and 28 sporadic breast tumors 
were obtained. Chromosomal aberrations were 
compared and a classifier was constructed. 
Chromosomal regions that were characteristic 
for BRCA2-mutated breast tumors were gain on 
chromosome 17q and loss on chromosome 13q 
and 14q. Validation of the classifier was per-
formed using 19 breast tumors of each of the two 
groups and resulted in a sensitivity and specific-
ity of 89% and 84%, respectively. We tested the 
array CGH profiles of 89 non-BRCA1/2 breast 
tumor cases and found 17 cases to be BRCA2 
like. Using additional analyses, clear indications 
were found that three of the BRCA2 like cases 
were indeed BRCA2 deficient. 
 
Chapter 6 
 In order to investigate possible similarities 
between hereditary and sporadic BRCA1 
deficient breast tumors, array CGH was per-
formed on BRCA1-mutated and sporadic basal-
like breast tumors. Within the sporadic basal-
like tumor group, approximately half of the 
tumors were deficient for BRCA1 gene expres-
sion and presented array CGH profiles that were 
similar to that of true BRCA1-mutated breast 
tumors. Sporadic basal-like tumors proficient for 
BRCA1 gene expression exhibited array CGH 
profiles that were not similar to BRCA1-mutated 
breast cancer but rather resided to non-basal-




 In more than half of the breast cancer 
families that are screened for mutations in 
BRCA1 or BRCA2, no mutation is found. These 
non-BRCA1/2 breast cancer patients form a 
large heterogeneous group. To be able to find 
breast cancer susceptibility genes through 
linking analysis, more homogenous groups are 
required. We have therefore investigated 58 
tumors from non-BRCA1/2 (BRCAX) families 
and obtained the array CGH profiles of the 
genomic make-up of the tumors. The array CGH 
profiles of the BRCAX tumors were dissimilar to 
those of BRCA1- or BRCA2-mutated breast 
cancer. Within the families, a subgroup was 
identified that is characterized by gain of chro-
mosome 22 that might be an interesting marker 
for further studies. 
 
Chapter 8 
 In the last chapter of this thesis, the work 
that is presented here is discussed in more detail 
and compared to current literature; in addition, 
follow up studies are handled. After publication 
of our array CGH BRCA1 and BRCA2 classifi-
ers, several studies applied our technique to 
indicate the pathogenicity of unclassified 
variants. Moreover, the classifiers have been 
used in order to find homologous recombination 
deficient tumors, that would respond differently 
on certain chemotherapy compared to tumors, 









 Eén van de grootste risico factoren voor het 
ontwikkelen van borstkanker is een belaste 
familie geschiedenis. Een reden voor hoge borst-
kanker incidentie kan in de meeste families niet 
geïdentificeerd worden, echter, de DNA muta-
ties die gevonden worden bevinden zich meestal 
in de BRCA1 en BRCA2 genen. Een pathogene 
mutatie in één van deze genen verhoogt het 
risico voor het ontwikkelen van borst- en 
ovariumkanker aanzienlijk; het is daarom 
klinisch van groot belang de mutatie te vinden. 
De gouden standaard voor het bepalen van 
mutaties is het sequensen van genomisch DNA. 
Omdat de incidentie van een BRCA1 of BRCA2 
mutatie in het algemeen erg laag is, wordt een 
voorselectie uitgevoerd, die gebaseerd is op 
familiekarakteristieken, om te bepalen wie in 
aanmerking komt voor genetische bepaling. 
Echter, geschat wordt dat ongeveer 15% van de 
mutatie draagsters gemist wordt met de huidige 
DNA diagnostiek. Steeds meer nieuwe tech-
nieken, die gebaseerd zijn op moleculaire 
karakteristieken van de tumor, worden toegepast 
voor het vinden van de genetische defecten. 
Omdat BRCA1 en BRCA2 beiden betrokken zijn 
in het DNA reparatie mechanisme door middel 
van homologe recombinatie, zullen defecten in 
deze genen tot chromosomale instabiliteit leiden. 
Veranderingen in chromosoom kopie nummer 
kunnen onderzocht worden met behulp van 
array comparative genomic hybridization 
(aCGH), dit is de meest gebruikte techniek  in de 
studies beschreven in dit proefschrift.  
 
Hoofdstuk 2 
 Nadat een tumor chirurgisch is verwijderd, 
wordt het weefsel gefixeerd in formaline en 
ingebed in paraffine. Op deze manier kan 
weefsel behouden blijven en ook nog na lange 
tijd onderzocht worden. Echter, fixatietijd en de 
duur dat het weefsel bewaard is gebleven, 
kunnen een negatief effect hebben op de 
kwaliteit van het DNA wat dan niet meer 
geschikt is voor array CGH. We hebben een 
multiplex PCR ontwikkeld waarmee DNA 
fragmenten van 100, 200, 300 en 400 bp 
geamplificeerd kunnen worden, afhankelijk van 
de kwaliteit van het DNA. Monsters waaruit 
DNA fragmenten van tenminste 100 en 200 bp 
geproduceerd konden worden, waren geschikt 
voor array CGH. 
 
Hoofdstuk 3 
 Om array CGH te standaardiseren en 
reproduceerbare resultaten te verkrijgen, hebben 
we een hybridisatie protocol ontwikkeld voor 
een geautomatiseerd hybridisatie station en 
geoptimaliseerd voor paraffine materiaal. Voor 
dit protocol hebben we verschillende tijdsduren 
van hybridisatie, temperaturen, was condities en 
hybridisatie mixen getest, waardoor we de ruis 
wisten te minimaliseren, het dynamische bereik 




  Om specifieke markers te vinden voor 
BRCA1 gemuteerde borstkanker, hebben we een 
classificatie methode ontwikkeld die gebaseerd is 
op array CGH data. Chromosomale afwijkingen 
van 18 BRCA1 gemuteerde en 32 sporadische 
borsttumoren werden verkregen met behulp van 
array CGH en met elkaar vergeleken. Toename 
van DNA op chromosoom 3q en 6p en verlies op 
chromosoom 5p, 5q, 7p, 12q en 20q werden 
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geïdentificeerd als karakteristiek voor BRCA1 
gemuteerde tumoren. Een classificatie methode 
werd ontwikkeld gebaseerd op de tumor groep 
specifieke karakteristieken en gevalideerd met 
behulp van 16 BRCA1 mutant en 16 sporadische 
borsttumoren. De classificatie methode 
resulteerde in een sensitiviteit van 88% en een 
specificiteit van 94%. Vervolgens zijn 48 array 
CGH profielen van niet-BRCA1/2 borsttumoren 
getest met onze classificatie methode. Twee zijn 
geclassificeerd in de BRCA1 klas, waarvan in één 
geval BRCA1 deficiëntie door middel van 
promotor hypermethylatie gevonden is. 
 
Hoofdstuk 5 
 Om markers te vinden die specifiek zijn voor 
BRCA2 gemuteerde borsttumoren, werden array 
CGH profielen verkregen van 28 BRCA2 
gemuteerde en 28 sporadische borsttumoren. 
Chromosomale aberraties werden vergeleken en 
een classificatie methode werd ontwikkeld. 
Chromosomale afwijkingen die karakteriserend 
zijn voor BRCA2 gemuteerde tumoren zijn: 
toename op chromosoom 17q en verlies op 13q 
en 14q. Validatie van de classificatie methode 
werd uitgevoerd met 19 borsttumoren van elke 
tumor groep en resulteerde in een sensitiviteit 
van 89% en een specificiteit van 84%. Vervolgens 
zijn 89 niet BRCA1/2 tumor gevallen getest, 
waarvan 17 zijn geclassificeerd in de BRCA2 
groep. BRCA2 deficiëntie werd gevonden in drie 
gevallen met behulp van extra analysen. 
 
Hoofdstuk 6 
 Array CGH profielen van BRCA1 
gemuteerde en van basaal-achtige sporadische 
borsttumoren zijn vergeleken om mogelijke 
overeenkomsten te vinden. Ongeveer de helft 
van de sporadische groep is deficiënt in BRCA1 
gen expressie en toonde een vergelijkbaar CGH 
profiel met BRCA1 gemuteerde tumoren. 
Sporadische basaal-achtige tumoren die BRCA1 
gen expressie vertoonde, waren niet 
vergelijkbaar met BRCA1 gemuteerde tumoren 
maar groepeerde samen met niet basaal-achtige 




 In meer dan de helft van de borstkanker 
families wordt geen mutatie gevonden in BRCA1 
of BRCA2. De niet-BRCA1/2 borstkanker 
patiënten vormen een grote heterogene groep. 
Om meer borstkanker susceptibiliteitsgenen te 
vinden door middel van koppelings-analysen, 
zijn meer homologe groepen nodig. Daarom 
hebben we van 58 tumoren uit niet-BRCA1/2 
(BRCAX) families de array CGH profielen 
verkregen. Deze profielen zijn anders dan die 
van BRCA1 of BRCA2 gemuteerde borst-
tumoren. Een subgroep kon geïdentificeerd 
worden in de BRCAX families, die gekarak-
teriseerd was met toename van kopie nummer 
van chromosoom 22. 
 
Hoofdstuk 8 
 In het laatste hoofdstuk wordt het werk dat 
in dit proefschrift vermeld is, in meer detail 
bediscussieerd en vergeleken met andere gepub-
liceerde studies. Ook worden follow-up studies 
behandeld. Na de publicatie van onze BRCA1 en 
BRCA2 classificatie methoden hebben 
verschillende onderzoeksgroepen onze tech-
nieken toegepast voor het bepalen van de 
pathogeniteit van ongeclassificeerde varianten in 
BRCA1/2. Tevens zijn onze classificatie 
methoden gebruikt voor het vinden van 
homologe recombinatie deficiënte tumoren, die 
anders zouden reageren op bepaalde 
chemotherapie dan tumoren waar het homologe 
















































aldehyde dehydrogenase 1 family, 
member A1 
adenomatous polyposis coli  
ataxia telangiectasia mutated  
bacterical artificial chromosome 
BRCA1 associated RING domain 1 
breast conserving surgery 
base excision repair 
breast cancer information core 
base pair 
breast cancer, early onset 
BRCA1 C terminus (domain) 
checkpoint kinase 2 




chromogenic in situ hybridization 
copy number alteration 
cancer stem cell 
c-terminal RAD51 binding motive 
ductal carcinoma in situ 





degree of labeling 
double-strand break 
deleted in split hand/foot protein 1 
ethylenediaminetetraacetic acid 
epidermal growth factor receptor  
estrogen receptor 
human epidermal growth factor 
receptor 2 










































sensitive gel eletrophoresis 






gene expression profiling 
gene expression omnibus 








invasive ductal carcinoma 
insulin-like growth factor 
immunohistochemistry 
invasive lobular carcinoma 
intervening sequence 
kilo base pairs 
keratin 
lobular carcinoma 
lobular carcinoma in situ 
logarithm of odds 
loss of heterozygosity 
leave-one-out cross-validation 
Leiden University Medical Center 
mega base pairs 
multiplex ligation dependent 
probe amplification 
magnetic resonance imaging 
v-myc myelocytomatosis viral 
oncogene homolog 
 











































National Center for Biotechnology 
Information 
next generation sequencing 
non-homologous end-joining 
Netherlands Cancer Institute 
nuclear localization signals 
negative predictive power 
oligonucleotide binding 
partner and localizer of BRCA2  
prediciton analysis of microarrays 
poly ADP ribose polymerase 
prophylactic bilateral mastectomy 
prophylatic bilateral salpingo-
oophorectomy 
polymerase chain reaction 
positive predictive power 
progesteron receptor 
phosphatase and tensin homolog  
protein truncation test 
RAD51 homolog 
receptor-associated protein 80 







sodium dodecyl sulfate 
single nucleotide polymorphism 
single-strand break 
saline-sodium citrate 
serine/threonine kinase 11  
short tandem repeat 
tris/borate/EDTA 
two-dimensional gene scanning 
tumor protein 53 
tumor/node/metestasis 
universal linkage system 
unclassified variant 
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